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Gain-of-function and dominant-negative effects of distinct p53 mutations in 
lung tumours 
Frances Kathryn Turrell 
Lung cancer is the most common cause of cancer-related mortality worldwide with 
current treatments providing limited therapeutic benefit in most cases. TP53 (Trp53, p53) 
mutations occur in approximately 50% of lung adenocarcinoma cases and are 
associated with poor prognosis and so novel therapies that target these p53 mutant lung 
tumours are urgently needed. Despite the high frequency of p53 mutations in lung 
tumours, the impact these mutations have on response to therapy remains unclear in this 
cancer type. The aim of my project is to characterise the gain-of-function and dominant-
negative effects of p53 mutations in lung tumours and to identify ways of therapeutically 
targeting these p53 mutant tumours based on dependencies and susceptibilities that our 
analysis uncovers. 
 
To characterise the gain-of-function and dominant-negative effects of p53 mutations I 
compared p53 mutant murine lung tumour cells that endogenously express either a 
contact (R270H, equivalent to R273H in humans) or conformational (R172H, equivalent 
to R175H in humans) p53 mutant protein and p53 null lung tumour cell lines; both in the 
presence and absence of wild-type p53. Interestingly, transcriptional and functional 
analysis uncovered metabolic gain-of-functions that are specific to the type of p53 
mutation. Upregulation of mevalonate pathway expression was observed only in R270H 
lung tumours and consequently R172H and R270H lung tumours displayed distinct 
sensitivities to simvastatin, a mevalonate pathway inhibitor widely used in the clinic. 
Furthermore, the transcriptional signature underlying this sensitivity to simvastatin was 
also present in human lung tumours with contact p53 mutations, indicating that these 
findings may be clinically relevant. 
 
On the other hand, our analysis of the potential dominant-negative effects of the p53 
mutants on wild-type p53 demonstrated that wild-type p53 was able to induce typical p53 
target genes to a similar level in p53 null and mutant cells. Furthermore, wild-type p53 
restoration resulted in comparable tumour suppressive responses in p53 mutant and null 
tumours and thus, p53-restoration therapy will likely be of benefit to patients with p53 
mutations in lung cancer. Hence, I have demonstrated that lung tumours harbouring 
contact and conformational p53 mutations display common and distinct therapeutic 
susceptibilities.  
 i 
Preface 
 
Declaration of originality 
 
This dissertation is the result of my own work and includes nothing which is the 
outcome of work done in collaboration except where indicated in the text. 
 
I confirm that no part of this dissertation has been submitted for any other degree or 
qualification. 
 
 
Statement of length 
 
This dissertation does not exceed 60,000 words in length. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ii 
Publications 
 
Turrell FK, Kerr EM, Gao M, Thorpe H, Doherty G, Cridge J, Shorthouse D, Speed 
A, Samarajiwa S, Hall BA, Meryl Griffiths M and Martins CP (2017). Lung tumors with 
distinct p53 mutations respond similarly to p53-targeted therapy but exhibit genotype-
specific statin sensitivity. Genes and Development 2017 Aug 8.  
 
Kerr EM, Gaude E, Turrell FK, Frezza C, Martins CP. Mutant Kras copy number 
defines metabolic reprogramming and therapeutic susceptibilities. Nature. 2016 
March 03; (531):110–113 (work not included in the thesis). 
 
Talks and poster presentations 
 
F. K. Turrell, E. M. Kerr, M. Gao, H. Thorpe and C. P. Martins. Lung tumours with 
distinct p53 mutations display genotype-specific metabolic profiles and differential 
sensitivities to statins. Short ‘poster-taster’ talk and poster presentation - Beatson 
International Cancer Conference, 2nd-5th July 2017.  
 
F. K. Turrell Determining the impact of distinct p53 mutations on lung tumour 
evolution and therapy. Talk - MRC Cancer Unit annual symposium, 2nd December 
2016 
 
F. K. Turrell, M. Gao, E. M. Kerr and C. P. Martins Determining the impact of distinct 
p53 mutations in lung tumours. Poster - MRC Cancer Unit annual symposium, 20th 
November 2015. 
 
F. K. Turrell, M. Gao, E. Gaude, E. M. Kerr, C. Frezza and C. P. Martins. 
Determining the metabolic impact of p53 mutations in lung cancer. Poster - MRC 
Cancer Unit annual symposium, 21st November 2014. 
 
 
 
 iii 
Acknowledgements 
 
Firstly, I would like to thank my supervisor Dr Carla Martins for the opportunity to 
pursue a PhD in her laboratory and her continued guidance. I would also like to thank 
Dr Emma Kerr for all of her scientific input and support over the years, which have 
been instrumental to this work, and for being a great friend during my time here in 
Cambridge. I would like to thank Dr Meiling Gao for providing the samples for the 
microarray analysis and therefore, her work towards initiating the project. 
 
I am also grateful to all members of the Martins and Shields laboratories, past and 
present, who have all helped me in some way over the years. In particular, I would 
like to thank Dr Angela Riedel, Dr Luisa Pedro, Dr Ilya Kotov, Dr Gary Doherty, 
Jennifer Harris, Sarah Davidson and Alyson Speed for their continuous friendship 
and support. I would also like to thank Dr Emma Kerr, Dr Hannah Thorpe, Dr Gary 
Doherty and Jake Cridge for their help addressing reviewer comments. Furthermore, 
I am grateful to Ellie Gregson, who has been pursuing her PhD alongside me from 
interview day until submission, for supporting me through it.  
 
I thank all the staff at the Biological Resources Unit and Cambridge Biomedical 
Services for their help with the in vivo work. In particular, I am grateful to Alyson 
Speed and Mike Mitchell for their invaluable help with the in vivo experiments. In 
addition, I would like to thank Dr Christian Frezza and members of his laboratory, 
particularly Edo Gaude, for running the mass spectrometry and for their advice on the 
metabolism side of the project. I am also grateful to Dr Shamith Samarajiwa and Dr 
David Shorthouse for their work on the microarray data normalisation and advice on 
the analysis, respectively.    
 
Finally, I would like to thank all my family and friends as without their support none of 
this would have been possible.   
 
 
 
 
 
 iv 
Abstract 
 
Lung cancer is the most common cause of cancer-related mortality worldwide with 
current treatments providing limited therapeutic benefit in most cases. TP53 (Trp53, 
p53) mutations occur in approximately 50% of lung adenocarcinoma cases and are 
associated with poor prognosis and so novel therapies that target these p53 mutant 
lung tumours are urgently needed. Despite the high frequency of p53 mutations in 
lung tumours, the impact these mutations have on response to therapy remains 
unclear in this cancer type. The aim of my project is to characterise the gain-of-
function and dominant-negative effects of p53 mutations in lung tumours and to 
identify ways of therapeutically targeting these p53 mutant tumours based on 
dependencies and susceptibilities that our analysis uncovers. 
 
To characterise the gain-of-function and dominant-negative effects of p53 mutations I 
compared p53 mutant murine lung tumour cells that endogenously express either a 
contact (R270H, equivalent to R273H in humans) or conformational (R172H, 
equivalent to R175H in humans) p53 mutant protein and p53 null lung tumour cell 
lines; both in the presence and absence of wild-type p53. Interestingly, transcriptional 
and functional analysis uncovered metabolic gain-of-functions that are specific to the 
type of p53 mutation. Upregulation of mevalonate pathway expression was observed 
only in R270H lung tumours and consequently R172H and R270H lung tumours 
displayed distinct sensitivities to simvastatin, a mevalonate pathway inhibitor widely 
used in the clinic. Furthermore, the transcriptional signature underlying this sensitivity 
to simvastatin was also present in human lung tumours with contact p53 mutations, 
indicating that these findings may be clinically relevant. 
 
On the other hand, our analysis of the potential dominant-negative effects of the p53 
mutants on wild-type p53 demonstrated that wild-type p53 was able to induce typical 
p53 target genes to a similar level in p53 null and mutant cells. Furthermore, wild-
type p53 restoration resulted in comparable tumour suppressive responses in p53 
mutant and null tumours and thus, p53-restoration therapy will likely be of benefit to 
patients with p53 mutations in lung cancer. Hence, I have demonstrated that lung 
tumours harbouring contact and conformational p53 mutations display common and 
distinct therapeutic susceptibilities.  
 v 
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 1 
1. Introduction 
 
1.1. The role of the transcription factor p53 
 
The transcription factor p53 regulates a multitude of genes which impact on 
numerous cellular functions (Bieging et al., 2014). The p53 protein is comprised of 
amino-terminal transactivation domains, a proline-rich domain, a DNA-binding 
domain (DBD), a tetramerisation domain and a carboxy-terminal regulatory domain 
(Figure 1.1; Bullock and Fersht, 2001). The transcription factor functions as a 
homotetramer, binding to two decameric half-sites in the DNA and inducing the 
transcription of its target genes (Figure 1.1; McLure and Lee, 1998).  p53 can also 
function to repress the transcription of genes through interfering with other 
transcription factors or recruiting of histone-modifying enzymes (Ho and Benchimol, 
2003).  
 
1.1.1. ‘Classical’ functions of p53 
 
Under normal conditions, the p53 protein is maintained at low levels by the E3 
ubiquitin ligase mouse double minute 2 (Mdm2; Kubbutat et al., 1997). Various types 
of cellular stress, including DNA damage, oncogenic stress, ribosomal stress, 
hypoxia and nutrient deprivation, can result in p53 activation, often through interfering 
with the Mdm2-p53 interaction (Figure 1.2; Bieging et al., 2014). For example, the 
stress sensor P19ARF stabilises p53 by interacting with Mdm2 and blocking Mdm2-
mediated degradation of p53 in response to stress stimuli such as oncogene 
activation  (Horn and Vousden, 2007; Tao and Levine, 1999). Various 
posttranslational modifications of p53, such as phosphorylation by kinases activated 
in response to DNA damage, also function to stabilise p53 by blocking Mdm2 from 
binding (Xu, 2003). Once activated p53 can elicit many types responses, primarily 
through transcriptional activation of its target genes. These p53-mediated responses 
include, but are not limited to, cell cycle arrest, DNA repair, senescence, apoptosis 
and regulation of cellular metabolism. Mdm2 is a direct transcriptional target of p53 
and so it supports a negative-feedback loop to control the extent of the p53 response 
(Barak et al., 1993; Wu et al., 1993). Importantly, the type and duration of the p53 
mediated response depends on the context and the nature of the cellular stress 
(Horn and Vousden, 2007).  
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The first p53 target gene to be identified was Cdkn1a, a gene which encodes the 
cyclin-dependent kinase inhibitor, p21 (el-Deiry et al., 1993; Harper et al., 1993). 
Loss of p21 has been shown to compromise p53-mediated G1-arrest in mouse 
models following DNA damage (Brugarolas et al., 1995; Deng et al., 1995), 
demonstrating the importance of p21 in the p53-mediated arrest of proliferation. 
However, loss of p21 in these studies did not enhance predisposition to tumours 
(Brugarolas et al., 1995; Deng et al., 1995), although it has been shown result in 
tumorigenic effects in other models (Cole et al., 2010; Jackson et al., 2003; Jones et 
al., 1999). Moreover, p21 has been shown to be involved in another type of 
proliferative arrest, termed senescence, induced again by stress signals such as 
DNA damage and oncogenic stress. Senescent cells differ from quiescent cells, 
displaying a larger, flatter morphology. They also have distinct markers, for example 
β-galactosidase activity, or secrete specific factors such as immune modulators 
(Munoz-Espin and Serrano, 2014; Xue et al.,2007). 
TAD PR DBD Tet Regp53
Figure 1.1. The structure of p53.  
 
Upper, the p53 protein consists of amino-terminal transactivation domains (TAD), a 
proline-rich (PR) domain, a DNA-binding domain (DBD), a tetramerisation domain (Tet) 
and a carboxy-terminal regulatory domain (Reg) (adapted from (Bullock and Fersht, 
2001). Lower, structure of 4 independent ,monomers of the core domain of human 
p53, with the tetrameric p53 binding to the two DNA half-sites (Kitayner et al., 2006). 
The DNA is shown in purple and the four core domains of p53 shown in blue, orange, 
green and red.   
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Importantly, whether p21 mediates senescence or a more transient arrest of 
proliferation depends on the context, the cellular stress and the activity of other 
pathways such as mammalian target of rapamycin (mTOR; (Demidenko and 
Blagosklonny, 2008; Demidenko et al., 2009). In addition, other p53 targets are likely 
required to ensure that these responses are implemented.   
 
Importantly, the findings from studies on the p53-mediated p21 response, in addition 
to investigations into the responses mediated by other p53 target genes, 
demonstrate that the p53-mediated response is dependent on the type, severity and 
duration of the cellular stress and the cellular context (Bieging and Attardi, 2012; 
Bieging et al., 2014). Moreover, specific p53 targets genes can be involved in 
different functions downstream of p53 and which response they help elicit depends 
on the context. A recent study compiled a list of around 350 p53 target genes based 
on evidence that p53 bound and regulated the gene (Fischer, 2017). Furthermore, 
data from chromatin immunoprecipitation sequencing (ChIP-seq) experiments 
Oncogenic
stress
Hypoxia
Ribosomal
stress DNA damage
Telomere
erosion
Metabolic
stress
Cell cycle
arrest
DNA repair
ApoptosisSenescence
Metabolism
WT p53
Figure 1.2. Effector functions of p53 induced in response to cellular 
stresses.  
 
The scheme depicts examples of cellular stresses that can activate p53 
(upper, green) and the responses downstream of p53 that can be 
subsequently engaged (lower, blue). Adapted from Bieging et al., 2014. 
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provide evidence for p53 binding many more genes, which suggests that a multitude 
of additional p53 target genes exist (http://chip-atlas.org). Therefore, the cellular 
responses induced by p53 are very complex and likely involve the regulation of a 
subset of target genes or for particular genes to be induced above a threshold to 
activate a particular response at that precise time.  A summary of some of the known 
p53 target genes and responses that they are primarily involved in is shown in Figure 
1.3.  
 
In addition to p21, many other p53 targets have been shown to contribute to a p53-
induced proliferative arrest. For instance, the p53 target  gene, growth arrest and 
DNA-damage-inducible 45 (Gadd45a), is important for the control of G2/M 
progression, with Gadd45a-/- and p53-/-  cells displaying similar chromosomal defects 
(Hollander et al., 1999; Kastan et al., 1991).  Also, p53 can regulate the expression of 
E2F transcription factor 7 (E2f7; Aksoy et al., 2012; Carvajal et al., 2012) and 
promyelocytic leukemia (Pml) in response to oncogenic-stress which can induce 
cellular senescence (de Stanchina et al., 2004; Ferbeyre et al., 2000; Pearson et al., 
2000). Further examples of p53 targets can be involved in the induction of the anti-
proliferative response of p53 are shown in Figure 1.3.  
 
In the context of DNA damage, the p53-mediated arrest in the cell cycle allows for 
repair of the genome, reducing the propagation of damaged DNA (Kastan et al., 
1992; Williams and Schumacher, 2016). This led to p53 being known as the 
‘Guardian of the genome’ (Lane, 1992).  In addition to mediating the induction of cell 
cycle arrest in response to DNA damage, p53 can induce genes involved in DNA 
repair pathways to help repair the damage to the DNA (Williams and Schumacher, 
2016). Nucleotide excision repair, base excision repair and non-homologous end-
joining can all be induced by p53 depending on the type of DNA damage present via 
the p53-mediated transcriptional regulation of specific DNA repair genes. (Seo et al., 
2002; Tang et al., 1999; Tron et al., 1998). Examples of p53 target genes involved in 
these DNA repair programs are shown in Figure 1.3.  
 
The induction of apoptosis is another well-characterised function of p53, first shown 
in brain choroid plexus epithelial tumours (Symonds et al., 1994). In the same model, 
Bcl-2-associated X protein (Bax) was identified as a p53 target gene required for 
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p53-mediated apoptosis (Yin et al., 1997). However, like other p53-mediated 
functions, apoptosis can be regulated by a number of different p53 target genes. 
Apoptosis can be triggered by p53 via either the intrinsic or extrinsic cell death 
pathway (Bieging and Attardi, 2012). The intrinsic pathway can be induced via p53-
mediated expression of targets such as p53 upregulated modulator of apoptosis 
(Puma) and Noxa, in addition to Bax. For instance, cells which are deficient for Puma 
display an almost complete lack of p53-mediated apoptosis following DNA damage 
Figure 1.3. Examples of genes regulated by p53 and their functional distribution 
across the ‘classical’ p53-mediated responses. 
 
Examples of p53 target genes involved in cell cycle arrest, senescence, DNA repair and 
apoptosis, based on (Aksoy et al., 2012; Bersani et al., 2014; Bieging et al., 2014; Collavin et 
al., 2000; Kannan et al., 2000; Kawase et al., 2009; Zhang et al., 2013b; Zhou et al., 2002). 
14-3-3, tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein sigma, 
Ywhas; Apaf1, apoptotic peptidase activating factor 1; Bax, Bcl-2-associated X protein; Birc5, 
baculoviral inhibitor of apoptosis repeat-containing 5, survivin; Btg2, B cell translocation gene 
2; Ddb2, damage-specific DNA binding protein 2; Dr5, death receptor 5; E2f7, E2F 
transcription factor 7; Ercc5, excision repair cross-complementing rodent repair deficiency, 
complementation group 5; Fas, Fas cell surface death receptor, Gadd45, growth arrest and 
DNA-damage-inducible 45; Gtse1, G2 and S-phase expressed 1, B99; Noxa, otherwise 
known as Pmaip1, phorbol-12-myristate-13-acetate-induced protein 1; p21, also known as 
Cdkn1a, cyclin-dependent kinase inhibitor 1A; Pai1, plasminogen activator inhibitor; Perp, 
p53 apoptosis effector; Phlda3, pleckstrin homology like domain family A member 3; Pig3, 
p53 inducible gene 3; Pml, promyelocytic leukaemia; Polk, DNA polymerase ; Ptprv, protein 
tyrosine phosphatase receptor type V; Puma also known as Bbc3, bcl2 binding component 3; 
Rprm, reprimo TP53 dependent G2 arrest mediator homolog; Xpc, xeroderma pigmentosum, 
complementation group c; Zfp365, zinc-finger protein 365; Zmat3, Zinc finger matrin-type 3. 
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(Jeffers et al., 2003; Villunger et al., 2003), indicating Puma is an essential mediator 
of p53-dependent apoptosis. In contrast, Puma-deficient mice are not prone to 
developing tumours spontaneously, again indicating that the p53-mediated response 
is context-dependent (Jeffers et al., 2003; Villunger et al., 2003). On the other hand, 
the extrinsic cell death pathway can be induced through p53 target genes such as 
Fas and death receptor 5 (Dr5), which encode death receptors on the cell surface 
(Muller et al., 1998; Wu et al., 1997). Additional p53 target genes with roles in 
apoptosis are shown in Figure 1.3.  
 
Together, these p53-dependent transcriptional programmes enable the cell to 
respond to many different cellular stresses. Transient growth arrest and repair of the 
damage, permanent growth arrest or apoptosis can be triggered by p53 depending 
on the extent of the damage and the duration and magnitude of the p53 induction 
(Bieging et al., 2014). The intricacy of the p53-mediated response is key to protecting 
the cells and is achieved primarily through its ability to regulate a multitude of 
different genes.  
  
1.1.2. p53-mediated regulation of metabolism 
 
I have provided an overview of what are considered the ‘classical’ p53 responses. 
However, more recent effector functions of p53 have been identified (Bieging et al., 
2014). One of these is the p53-mediated regulation of cellular metabolism, achieved 
again mainly through regulation of target genes (Berkers et al., 2013; Frezza and 
Martins, 2012).  
 
The metabolic gene expression mediated by p53 generally converges on the 
promotion of mitochondrial oxidative phosphorylation (OXPHOS) and catabolic 
pathways to provide adenosine triphosphate (ATP) and nutrients in conditions of 
stress, while inhibiting the glycolytic pathway and anabolic pathways which are 
conversely used to generate macromolecules (Figure 1.4; Berkers et al., 2013; 
Frezza and Martins, 2012). Transcriptional repression of the glucose transporters 
Glut1 (solute carrier family 2 member 1; Slc2a1) and Glut4 (Slc2a4), inhibits glucose 
uptake into the cell (Schwartzenberg-Bar-Yoseph et al., 2004), while additional steps 
in the glycolysis pathway can also be inhibited through the p53-mediated 
upregulation of TP53-induced glycolysis and apoptosis regulator (Tigar) and Parkin,  
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Figure 1.4. Metabolic regulation by p53. 
 
p53 promotes fatty acid oxidation (FAO), oxidative phosphorylation (OXPHOS), 
glutaminolysis and autophagy while inhibiting glycolysis, the pentose phosphate pathway 
(PPP) and lipid synthesis. p53 promotes OXPHOS through transcriptional activation of 
Sco2, Aif and Rrm2b. p53-mediated transcriptional repression of Glut1 and Glut4 and 
inhibition of the glycolytic enzyme Pgm at the protein level inhibits glycolysis. Glycolysis is 
also repressed by transcriptional activation of Tigar and Parkin. Tigar dephosphorylates 
fructose-2,6-bisphosphate and therefore inhibits phosphofructose kinase 1 (Pfk1) 
activation whereas Parkin can promote activation of pyruvate dehydrogenase (PDH). p53 
downregulates the PPP by interacting directly with glucose-6-phosphate dehydrogenase 
(G6PD) to inhibit its activity.  Through inhibition of mTORC1 and Srebf1c, p53 negatively 
regulates lipid synthesis. p53-mediated inhibition of mTORC1 also promotes autophagy. 
FAO is promoted by p53 by the transcriptional activation of Lpin1, Crot, Cpt1a and Mcd 
and the activation of AMPK via increased expression of Sestrin 1/2. FAO and 
glutaminolysis generate acetyl coA and α-ketoglutarate which feed into the tricarboxylic 
acid (TCA) cycle. Adapted from (Liang, 2013).  
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and the downregulation of phosphoglycerate mutase (Pgm; at the protein level) and 
pyruvate dehydrogenase kinase 2 (Pdk2; Bensaad et al., 2006; Contractor and 
Harris, 2012; Kondoh et al., 2005; Zhang et al., 2013a). Furthermore, p53 can 
promote OXPHOS via induction of synthesis of cytochrome c oxidase 2 (Sco2) and 
apoptosis-inducing factor (Aif), which are required for the assembly of complex IV 
and the maintenance of complex I of the mitochondrial electron transport chain 
(ETC), respectively (Matoba et al., 2006; Stambolsky et al., 2006; Vahsen et al., 
2004). Mitochondrial DNA integrity and mitochondrial function are also promoted by 
p53 via transcriptional activation of the ribonucleotide reductase subunit, p53R2 
(Rrm2b) (Bourdon et al., 2007). 
 
Other aspects of cellular metabolism can also be regulated by p53 such as 
glutaminolysis via the p53-mediated induction of glutaminase 2 (Gls2), and the 
pentose phosphate pathway (PPP), an important pathway in the biosynthesis of 
nucleotides (Hu et al., 2010). The PPP can be negatively regulated by p53 via the 
inhibition of glucose-6-phosphate dehydrogenase (G6PD) activity (Jiang et al., 2011). 
However, the role of p53 in the regulation of the PPP pathway is complex and the 
p53-dependent activation of Tigar can promote flux through the PPP (Bensaad et al., 
2006; Cheung et al., 2012).  
 
The management of reactive oxygen species (ROS) levels is another important role 
of p53 in the regulation of cellular metabolism. The PPP produces NADPH, which 
reduces oxidised (GSSG) to reduced glutathione (GSH, a key anti-oxidant) and so 
p53-mediated upregulation of the PPP is important for the anti-oxidant response 
(Cheung et al., 2012). A p53-mediated anti-oxidant response is also achieved via 
induction of Gls2 (Hu et al., 2010). In addition, p53 can elicit an anti-oxidant response 
in conditions of serine deprivation, channelling the reduced serine stores to the 
synthesis of GSH instead of nucleotide synthesis. p53 promotes the survival of 
cancer cells under conditions of serine depletion via this anti-oxidant response 
(Maddocks et al., 2013). While p53 promotes cell survival when the damage is low or 
transient, if damage within the cells is too high p53 can mediate the transcriptional 
upregulation of pro-oxidant genes, to promote ROS production and cell death 
(Berkers et al., 2013). 
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Catabolic pathways can also be promoted by the p53-mediated regulation of 5'-
adenosine monophosphate-activated protein kinase (AMPK) and mTOR complex 1 
(mTORC1). p53 positively regulates AMPK, via upregulation of Sestrin1 and 
Sestrin2, in conditions which cause ATP depletion such as hypoxia and nutrient 
deprivation (Budanov and Karin, 2008). AMPK can enhance the flux through energy 
producing pathways such as autophagy and fatty acid oxidation (FAO) while 
inhibiting biosynthetic pathways. Conversely, mTORC1 activity enhances cell growth 
and proliferation and is inhibited by p53. p53-mediated mTORC1 inhibition is 
achieved via AMPK activation and upregulation of various other p53 target genes 
which include Tsc2 (tuberous sclerosis complex 2) and Pten (phosphatase and 
tensin homologue) (Feng et al., 2007). The p53-mediated inhibition of mTORC1 also 
promotes autophagy, a pathway that can provide metabolic substrates for the cell via 
the breakdown of cellular components when the cell is under stress (Kim et al., 
2011).  
 
Finally, another branch of cellular metabolism that is regulated by p53 is lipid 
metabolism. p53 regulates both the synthesis and degradation of lipids. Srebf1c is 
transcriptionally repressed by p53. The sterol regulatory element binding transcription 
factor (Srebf2; otherwise known as Srebp) family of transcription factors mediate lipid 
biosynthesis and thus, p53-mediated inhibition of Srebf1c decreases the level of fatty 
acid synthesis (Yahagi et al., 2003). Conversely, p53 increases FAO levels through 
the transcriptional activation of lipin 1 (Lpin1) (Assaily et al., 2011). The transport of 
fatty acids into the mitochondria where they undergo β-oxidation is facilitated by p53-
mediated induction of carnitine acyltransferases, carnitine-O-octanoyltransferase 
(Crot) and carnitine palmitoyltransferase 1A (Cpt1a) (Goldstein et al., 2012). In 
addition, p53 induces malonyl-CoA decarboxylase (Mcd), promoting CPT activity and 
thus FAO (Liu et al., 2014). 
 
1.1.3. Tumour-suppressive functions of p53 
 
As discussed above p53 plays important roles in protecting the cells from various 
cellular stresses and damage. Therefore, it is well-established that p53 is an 
essential tumour suppressor with inactivation of the p53 pathway occurring in the 
majority of cancers (Cancer Genome Atlas Research, 2014). The importance of the 
tumour suppressive role played by p53 was highlighted in early studies, which 
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compared mouse models of p53 deficiency to those with normal wild-type p53.  Mice 
deficient for p53 displayed increased susceptibility to a range of different tumour 
types demonstrating the importance of the p53-mediated tumour suppressive 
functions in many different tissues (Donehower et al., 1992; Jacks et al., 1994). 
These observations were consistent with evidence from human disease where the 
familial Li-Fraumeni syndrome, which pre-disposes individuals to developing tumours 
such as sarcomas and breast tumours, is caused by germline mutations in TP53 (Li 
and Fraumeni, 1969a, b; Malkin et al., 1990; Srivastava et al., 1990). 
 
Despite the importance of p53-mediated cell cycle arrest, DNA repair, senescence 
and apoptosis, mice engineered to carry mutations at three acetylation sites in the 
p53 gene, which render p53 incapable of mediating senescence, apoptosis or cell 
cycle arrest, are not prone to the early-onset tumour formation observed in the p53 
null mice. This study indicates that p53 inhibits tumorigenesis by additional 
mechanisms, which include the p53-mediated regulation of cellular metabolism (Li et 
al., 2012). The role of p53 in regulating metabolic pathways, along with its more 
‘classical’ functions such as cell cycle arrest and induction of apoptosis, likely explain 
why p53 function is lost in the majority of cancers. 
 
1.2. TP53 mutations in cancer 
 
The p53 pathway is disrupted in a large proportion of cancer and importantly, this is 
most commonly achieved by mutation in the p53 gene (Bullock and Fersht, 2001). 
The majority of these p53 mutations are missense mutations which cluster in the 
DNA-binding domain (Figure 1.5). By interfering with the ability of p53 to bind to its 
target genes, p53 mutations are considered to result in a loss of wild-type p53 
function (Joerger and Fersht, 2007). Importantly, p53 mutations frequently result in 
the expression of a stable mutant p53 protein which accumulates in the tumour cells, 
instead of a loss of p53 expression (Iggo et al., 1990). The reason for the selection of 
missense mutations over p53 loss has been the subject of much investigation. In 
particular, it is not yet clear the extent to which p53 mutations exert gain-of-functions 
(GOF) or dominant-negative (DN) effects on remaining wild-type p53, which could 
explain why the mutations are selected for in many cancers (Figure 1.6). 
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1.2.1. Different classes of p53 mutations 
 
The p53 missense mutations can be divided into two classes based on the residues 
they affect and the overall impact on the structure of the p53 mutant protein (Figure 
1.5). The first class is known as the ‘DNA-contact’ or ‘DNA-binding’ class and is 
formed of p53 mutations that affect residues that directly contact the DNA.  The 
second class is known as the ‘conformational’ or ‘structural’ class. In the latter class, 
p53 mutations have significant effect on the overall conformation of the protein 
(Joerger et al., 2006; Joerger and Fersht, 2007). Examples of p53 mutations that 
frequently occur in human cancers are the contact mutations R248 and R273 and 
Figure 1.5. Mutations in the p53 gene in cancer. 
 
Upper, examples of six hotspots for p53 missense mutations are shown (the labelled 
residues show human codons). P53 mutations fall into two classes: the 
conformational class (green) and the contact class (red).  Adapted from (Bullock, 
2001). Lower, structure of the human p53 core DNA-binding domain (DBD; blue) in 
contact with the DNA (grey) based on (Cho et al., 1994). Two frequently mutated 
sites are highlighted; conformational (green) and contact (red).  
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the conformational mutations R175, G245, R249 and R282 (Figure 1.5).  
 
Many studies in which the impact of p53 mutations has been explored did not 
contemplate that there may be functional differences between distinct p53 mutations. 
However, it is feasible that the mutant proteins function distinctly because the 
mutations have different effects on the protein (Joerger et al., 2006; Joerger and 
Fersht, 2007). In addition, conformational mutant proteins are reliant on the heat-
shock protein 40 (Hsp40) family member Dnaja1 for protein stability whereas contact 
mutant proteins are not (Parrales et al., 2016). This implies that tumours with contact 
or conformational mutations could display different susceptibilities. Therefore, 
knowledge of the functional differences between p53 mutations is essential as it may 
Adapted from Brosh and Rotter, 2009
Mutant
p53
Mutant p53
GOF
Invasion/Metastasis,
Proliferation/Growth,
Drug Resistance
Wild-type
p53
Wild-type
p53
Growth suppression,
 Apoptosis, DNA repair,
 Metabolic Regulation
DN
TP53 mutation
Accumulation due to
oncogenic events
LOF
Figure 1.6. Impact of p53 mutations in cancer. 
 
The p53 gene is frequently mutated in cancer and the mutant p53 protein 
accumulates in the cancer cells. Mutations in p53 result in a loss of wild-type 
(WT) p53 function (LOF) and can potential exert dominant-negative (DN) 
effects on WT p53 and/or gain-of-functions. Examples of common functions 
WT p53 and GOFs of mutant p53 are shown (adapted from Brosh and Rotter, 
2009). 
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highlight differences in the therapeutic vulnerabilities of a group of tumours that is 
currently considered as one entity. 
 
1.2.2. Mutant p53 gain-of-functions 
 
The strong selective pressure for the retention of mutant p53 protein expression in 
tumours suggests that mutant p53 can acquire novel, oncogenic functions (gain-of-
functions; GOF), that are advantageous to the cancer cells. Numerous mutant p53 
GOFs have now been reported, which include the promotion of migration, invasion, 
proliferation and drug resistance (Figure 1.6; Muller and Vousden, 2014). Mutant p53 
can increase signalling through growth factor receptors such as epidermal growth 
factor receptor (EGFR), platelet-derived growth factor receptor (PDGFR), hepatocyte 
growth factor receptor (MET) and transforming growth factor receptor β, which 
explains some of the tumour-promoting effects of mutant p53 (Adorno et al., 2009; 
Muller et al., 2009; Muller et al., 2013; Sauer et al., 2010; Weissmueller et al., 2014). 
 
Importantly, p53 mutant tumours have been shown to be more aggressive and 
metastatic than their p53-null counterparts (Lang et al., 2004; Olive et al., 2004). 
Mutations in p53 are also associated with poor prognosis and increased resistance to 
standard cancer therapy (Cancer Genome Atlas Research, 2014; Masciarelli et al., 
2014; Soussi and Beroud, 2001). Therefore, novel targeted therapies aimed at these 
tumours are urgently needed. Several of the oncogenic effects of mutant p53 are 
dependent on the p53 mutant binding and inhibiting p63 or p73, two transcription 
factors that belong to the p53 family (Adorno et al., 2009; Muller et al., 2009; Muller 
et al., 2013; Weissmueller et al., 2014). Therefore, mutant p53 likely exerts its 
oncogenic effects through interacting with other proteins and thereby regulating their 
function. 
 
Interestingly, there is some in vivo evidence which hints that p53 mutations of 
different classes are not functionally equivalent; p53R172H/+ and p53R270H/+ 
(conformational and contact p53 mutations respectively) mice develop a distinct 
spectrum of tumours (Olive et al., 2004). Moreover, Li-Fraumeni patients with R248Q 
p53 mutations (contact) develop cancer earlier than those patients with p53 null or 
G245S mutations (conformational; Hanel et al., 2013). However, it is important to 
note that it may not be as simple as dividing the p53 mutations into classes as p53 
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mutations from within the same class, and even mutations at the same residue 
(depending on the amino acid incorporated), can have different effects on the 
structure or stability of the mutant protein (Joerger et al., 2006; Joerger and Fersht, 
2007). Importantly, whether different p53 mutations can exert distinct GOFs in cancer 
cells and thus exhibit mutant-type specific susceptibilities still remains unclear. 
 
1.2.3. Metabolic impact of p53 mutations 
 
Interestingly, it is now emerging that mutant p53 can also exert its oncogenic effects 
through the manipulation of metabolic pathways. The mevalonate (MVA) pathway 
(Figure 1.7), the pathway of de novo cholesterol biosynthesis, is upregulated by 
mutant p53 in breast cancer and contributes to the invasive phenotype of the breast 
cancer cells (Freed-Pastor et al., 2012). The mutant p53-mediated upregulation of 
the mevalonate pathway and subsequent activation of Rho-GTPases activate the 
Yes Associated Protein 1 (YAP) and transcriptional coactivator with PDZ-binding 
motif (TAZ) oncogenes in breast cancer cells, promoting cell proliferation and self-
renewal (Sorrentino et al., 2014).  Lipid biosynthesis is required for the formation of 
new cellular membranes in proliferating cells and therefore upregulation of the 
cholesterol and fatty acid biosynthesis pathways is often observed in cancer cells 
(Santos and Schulze, 2012). As well as supporting membrane synthesis and cell 
proliferation via he synthesis of cholesterol, the MVA pathway generates 
intermediates such as geranyl geranyl pyrophosphate (GGPP) and farnesyl 
pyrophosphate (FPP) which are important for the lipid modification, membrane 
localisation and activation of the Ras superfamily of GTPases such as Rho and Ras 
(Konstantinopoulos et al., 2007). Therefore, the pathway has also been shown to be 
important for supporting not only the proliferation and growth of the cancer cells, but 
also their invasive potential via modulation of GTPases (Mullen et al., 2016). 
 
The MVA pathway is regulated predominantly by the transcription factor Srebf2, 
although other Srebf family members (1a and 1c) may also play a role (Horton et al., 
2003; Pai et al., 1998). Srebf2 is activated by insulin or when intracellular cholesterol 
levels are low or there is a high demand for cholesterol, for example to support high 
levels of proliferation. Inactive Srebf proteins are located in the endoplasmic 
reticulum (ER) membrane and they are activated by cleavage events which lead to 
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the translocation of the truncated active form to the nucleus where it can bind target 
genes (Ye and DeBose-Boyd, 2011).  
 
Mutant p53 was also shown to drive glycolysis by increasing Glut1 translocation to 
the membrane, an effect mediated by RhoA activation (Zhang et al., 2013a), as well 
as promoting nucleotide biosynthesis to maintain proliferation and invasiveness 
(Kollareddy et al., 2015). An additional metabolic GOF of mutant p53 that has been 
reported is the inhibition of AMPK activation via the direct interaction of mutant p53 
with the AMPKα subunit. Consequently, anabolic metabolism is not inhibited under 
conditions of energy stress, promoting tumour growth (Zhou et al., 2014). 
 
I have previously described the role of wild-type p53 in the regulation of many 
aspects of cellular metabolism, which converge on an inhibition of glycolysis and 
anabolic, biosynthetic pathways and a promotion of catabolic pathways instead. 
These functions of p53 are in keeping with its tumour suppressive role as tumours 
cells frequently re-wire their metabolism to support proliferation and survival by 
increasing glucose uptake, glycolysis and flux through biosynthetic pathways 
(Berkers et al., 2013; Ward and Thompson, 2012). Studies have also shown that p53-
/- cells display enhanced glycolysis and higher levels of synthesis of macromolecules 
such as lipids, relative to cells with wild-type p53 present (Jiang et al., 2011; Ma et 
al., 2007; Sinthupibulyakit et al., 2010). Interestingly, mutant p53 increases this 
metabolic rewiring further, with mutant cells displaying higher levels of glycolysis, 
lipid biosynthesis, MVA pathway upregulation and nucleotide biosynthesis than their 
p53 null counterparts (Freed-Pastor et al., 2012; Kollareddy et al., 2015; Zhang et al., 
2013a; Zhou et al., 2014). It will be important to establish whether distinct p53 
mutations differ in their ability to rewire metabolic pathways in tumours.  
 
1.2.4. Mutant p53 dominant-negative effects  
 
In addition to GOFs, it has been suggested that p53 mutant proteins can exhibit an 
inhibitory, dominant-negative (DN) effect on wild-type p53 function, thereby 
contributing to tumorigenesis (Muller and Vousden, 2014). As mutant p53 proteins 
accumulate in the cancer cells, partly due to a disruption of the Mdm2-mediated 
negative feedback loop, it is feasible that the majority of p53 mutants are able to 
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Figure 1.7. Mevalonate pathway in cancer. 
 
The mevalonate pathway, depicted above, is the pathway of de novo cholesterol 
biosynthesis. Intermediates are also generated which are important for the farnesylation 
and geranylgeranlyation of GTPases such as Rho and Ras. Genes in this pathway are 
upregulated by the transcription factor, Srebf2 (orange). The pathway has been linked to 
cancer, supporting proliferation, cellular signalling and invasive potential of tumour cells. 
Acat2, Acetyl-coA acetyltransferase 2; Cyp51a1, Cytochrome P450 family 51 subfamily 
A member 1; Dhcr7, 7-dehydrocholesterol reductase; Dhcr24, 24-dehydrocholesterol 
reductase; Fdps, Farnesyl diphosphate synthase; Hmgcr, 3-hydroxy-3-methylglutaryl-
CoA Reductase; Hmgcs1, 3-Hydroxy-3-Methylglutaryl-CoA Synthase 1; Idi2, 
Isopentenyl-diphosphate delta isomerase 2; Ldlr, Low density lipoprotein Receptor; 
Lipa, Lipase A, lysosomal acid type; Lss, Lanosterol synthase; Msmol, Methylsterol 
monooxygenase; Mvd, Mevalonate diphosphate decarboxylase; Mvk, Mevalonate 
kinase; Pggt1b, Protein geranylgeranyltransferase type I subunit beta; Pmvk, 
Phosphomevalonate kinase; Rabggta, Rab geranylgeranyltransferase alpha subunit; 
Soat2, Sterol O-acyltransferase 2; Sqle, Squalene epoxidase; Srebf, Sterol regulatory 
element binding transcription factor; Tm7sf2, Transmembrane 7 superfamily member 2.  
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exert DN activity, disrupting wild-type p53 function (Bartek et al., 1991). In 
agreement, p53 mutations have been reported to inhibit wild-type p53 function at 
least partially (Dong et al., 2007; Wang et al., 2011; Willis et al., 2004). As p53 
functions as a tetramer, it is generally thought that mutant p53 proteins prevent the 
formation of functional wild-type tetramers by oligomerising with wild-type p53 
monomers (Chan et al., 2004; Chene, 1998; Milner and Medcalf, 1991). Alternatively, 
the mutant p53 may form aggregates into which the wild-type proteins are 
sequestered and thus, inactivated (Xu et al., 2011). 
 
However, the extent of the DN effects of mutant p53 in tumours is controversial. In 
human tumours, p53 mutations are often accompanied by loss of heterozygosity 
(LOH) at the p53 locus (Baker et al., 1990; Brosh and Rotter, 2009; Liu et al., 2016; 
Mitsudomi et al., 2000; Zienolddiny et al., 2001). This suggests that in many cancers 
the DN effects of p53 mutations on wild-type p53 are at best only partial as there is 
still selective pressure to lose wild-type p53 allele. Further investigation into the 
potential DN effect of p53 mutations is required in specific cancer types to ascertain 
the extent to which p53 mutations inhibit wild-type p53 function. 
 
In summary, mutant p53 proteins may exert multiple effects in the cancer cells in 
addition to loss of wild-type function. Moreover, different p53 mutations may function 
distinctly in cancer cells, which needs to be explored further as any functional 
differences could uncover potential mutation-type specific dependencies and 
susceptibilities of the tumours.  
 
1.3. Lung cancer 
 
Lung cancer is the leading cause of cancer-related mortality. The disease has 
generally a very poor prognosis with only around 15% of patients surviving more than 
five years with the disease (Yang, 2009). There are two main subtypes of lung 
cancer based on the histology of the disease: small cell lung cancer (SCLC) and non-
small cell lung cancer (NSCLC). NSCLC makes up more than 80% of lung cancers 
and can be divided further into different subclasses: adenocarcinomas and 
squamous cell, bronchioalveloar and large cell carcinomas (Chan and Hughes, 
2015). My work will be focussed on the role of TP53 mutations in adenocarcinomas, 
the most common subtype of lung cancer (Parkin et al., 2005). 
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1.3.1. Role of p53 mutations in lung cancer 
 
The TP53 gene (Trp53, mouse; p53) is mutated in almost half of lung 
adenocarcinoma cases (Cancer Genome Atlas Research, 2014). Moreover, p53 
mutations are associated with poor prognosis and reduced survival in NSCLC and so 
novel therapies to target these p53 mutant lung tumours are required (Figure 1.8; 
Figure 1.8. TP53 mutations in human lung adenocarcinoma. 
 
Upper: The frequency of TP53 mutations in lung adenocarcinoma Lower: 
overall survival of patients with p53 mutations versus patients with no p53 
mutation. Data was taken from cBioPortal (Cancer Genome Atlas Research, 
2014). Log-rank (Mantel-Cox) test. 
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Cancer Genome Atlas Research, 2014; Mao, 2001; Mitsudomi et al., 2000). Despite 
this, little is known about the functions of the mutant p53 mutations in this cancer 
type.  
 
The extent of the GOFs that p53 mutations can exert in lung cancer is still unclear. 
Mouse models of lung adenocarcinoma have demonstrated that p53 mutations have 
no effect on lung tumour grade compared to p53 loss (Jackson et al., 2005). In 
contrast, overexpression of p53 mutants in lung tumour cells has been associated 
with oncogenic effects (Zhang et al. 2013; Muller et al., 2009; Muller et al., 2013).  
 
DN effects of p53 mutations on wild-type p53 could also help explain this selection 
for p53 mutations observed in lung cancer. However, similar to mutant p53 GOFs, 
little is known regarding DN effects of p53 mutations in lung tumours. Common p53 
mutations in lung cancer include R158, R175, R248 and R273 (Cancer Genome 
Atlas Research, 2014; Soussi et al., 2006).  R175H and R273H mutant p53 proteins 
are among those which have demonstrated an inhibitory effect on wild-type p53 
when expressed at high levels in vitro in other cancer types (Dong et al., 2007; Willis 
et al., 2004). However, loss-of-heterozygosity (LOH) of p53 has been observed in 
lung cancer suggesting that wild-type p53 is still able to function in the presence of 
the mutant as loss of wild-type p53 is still selected for even in this context (Mitsudomi 
et al., 2000; Zienolddiny et al., 2001). 
 
1.3.2. Therapeutic strategies against p53 mutant lung tumours 
 
Surgery is the standard therapeutic option for patients with early NSCLC (stages I-II), 
with or without adjuvant therapy (chemotherapy or radiotherapy; Hirsch et al., 2017).  
Treatment for advanced stage lung cancer continues to involve platinum-based 
doublet therapy or immunotherapy, unless the molecular alterations present allow the 
tumour to be treated with targeted therapy (for example the tyrosine kinase inhibitor 
erlotinib in EGFR mutant lung cancer or the ALK inhibitor crizotinib in lung cancer 
with ALK gene rearrangements (Hirsch et al., 2017). However, the prognosis is poor 
for those patients that progress after chemotherapy or develop resistance to 
targeted-therapy. Despite the development of drugs to treat some molecular 
subtypes of lung cancer (EGFR mutant positive or ALK gene rearrangement), p53 
mutant lung tumours cannot be directly targeted in the clinic. Therefore, further work 
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is required to identify ways of specifically targeting these p53 mutant lung tumours, 
particularly since they represent nearly 50% of lung adenocarcinomas (Cancer 
Genome Atlas Research, 2014).  
 
One approach to target p53 mutant tumours that is currently being investigated is the 
restoration of wild-type p53 functionality, as wild-type p53 can induce many tumour 
suppressive responses, as discussed earlier. It has been shown that the structural 
changes of some p53 mutations can be reversed by further point mutations, 
demonstrating that the structural changes induced by some p53 mutations are 
reversible (Joerger and Fersht, 2008). Following on from this, various compounds 
have demonstrated an ability to restore wild-type p53 function by stabilising the 
structure and promoting proper folding of the p53 protein (Boeckler et al., 2008; 
Bykov et al., 2002; Demma et al., 2010; Lehmann and Pietenpol, 2012; Soragni et 
al., 2016). One class of such molecules are the PRIMA-1 analogues which have 
reached clinical trials (Lehmann and Pietenpol, 2012). Importantly, one of the main 
strategies of interest for the treatment of p53 null tumours also involves the 
restoration of wild-type p53 activity (Cheok et al., 2011; Frezza and Martins, 2012). 
Therefore, it will be important to determine the extent to which different p53 
mutations can exert DN effects on the wild-type p53. If wild-type p53 function prevails 
over the mutant, restoration of wild-type p53 may show efficacy in tumours even 
when the mutant p53 is still present. 
 
Additional strategies to target p53 mutant tumours have centred around inducing the 
degradation of the mutant p53 proteins mediated by mdm2 and other ubiquitin 
ligases and targeting the heat-shock proteins which are required from stability of the 
mutant p53 proteins (Muller and Vousden, 2014). Moreover, inhibiting pathways 
downstream of mutant p53 in the tumour cells such as metabolic pathways (Freed-
Pastor et al., 2012) and receptor-tyrosine kinase pathways (Weissmueller et al., 
2014) may also be used to target p53 mutant tumours. In lung cancer less is known 
of the pathways downstream of the p53 mutations but if they exist their targeting 
could be of therapeutic benefit to patients with p53 mutant lung tumours.   
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1.3.3. Murine models of lung cancer 
  
Mouse models have developed into an invaluable tool to model tumour evolution and 
response to therapy, in a physiologically relevant system. Mice are a useful species 
in which to model cancer due to their small size, their breeding ability and their 
genetic similarity to humans (Frese and Tuveson, 2007). We are now able to 
conditionally activate or inactivate genes in specific cell-types and also at any given 
time. Driver mutations can be introduced into target cells of interest, enabling the 
development of specific tumour types, for example lung tumours. This enables the 
investigation of how specific driver mutations contribute to the tumour evolution, 
phenotype and response to therapies. Moreover, multiple independent tumours form 
and evolve independently. Therefore, these tumours display distinct mutational 
profiles and so the role of the driver mutations can be examined in the context of 
disease heterogeneity (Frese and Tuveson, 2007).  
 
One of the most well-studied mouse models of lung adenocarcinoma is based on the 
use of a Kras Lox-Stop-Lox(LSL)-G12D mutation (Jackson et al., 2005; Jackson et 
al., 2001). Kirsten Rat Sarcoma Viral Oncogene Homolog (Kras) is a GTPase, which 
is active in its guanosine triphosphate (GTP)-bound form, and can signal through 
multiple pathways such as the mitogen-activated protein kinase (MAPK) and 
phosphoinositide-3 kinase (PI3K) signalling pathways. Thus, Kras plays an important 
role in many cellular processes such as cell proliferation and survival. Mutations in 
KRAS occur in approximately 30% of human lung adenocarcinomas with the 
missense mutations resulting in a constitutively GTP-bound and active Kras protein 
(Cancer Genome Atlas Research, 2014; Gysin et al., 2011). Following Cre-
recombinase administration, recombination and subsequent loss of the stop codon in 
these KrasLSL-G12D mouse models, the mutant KrasG12D is expressed from its 
endogenous promoter. This leads to the sporadic formation of Kras-driven lung 
tumours from the cells which have been in contact with the Cre-recombinase 
(Jackson et al., 2001).  
 
Mice heterozygous for the KrasLSL-G12D allele can be crossed with other genetically 
engineered mice to allow the investigation of other genetic alterations in the context 
of KrasG12D-driven tumours, such as alterations in the p53 gene (e.g. missense 
mutations or p53 loss). Previous models of lung cancer driven by oncogenic Kras fail 
 22 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
to recapitulate the later stages of human lung cancer, with lung tumours resembling 
early-stage human lung adenocarcinoma (Jackson et al., 2001). However, combining 
Kras-mutant with loss of p53 in the lung leads to the formation of lung tumours that 
better recapitulate the human disease, specifically demonstrating features of late-
stage lung adenocarcinoma such as stromal desmoplasia and invasiveness (Jackson 
et al. 2005). Following administration of a viral titre of 106 PFU, Kras-mutant, p53 
deficient mice (KrasLSL-G12D/+;p53Fx/Fx), develop tumours with 100 % penetrance and 
need to be sacrificed due to signs of lung tumour burden at 16 weeks after infection 
with AdenoCre. At this time the mice display multiple low grade, well-differentiated 
(grades 1-2) and high grade (grades 3-5) lung tumours, with the high-grade tumours 
representative of late-stage human lung adenocarcinoma.  
 
The Kras-mutant, p53 deficient mouse model of lung adenocarcinoma (Jackson et 
al., 2005; Jonkers et al., 2001), is a useful way to model this disease type, firstly 
because it incorporates two key genetic alterations that often occur in lung 
Figure 1.9. p53ERTAM mouse model.  
 
The conditional p53ERTAM allele allows wild-type p53 functionality to be toggled 
on and off in the animals or cell cultures depending on the presence or absence 
of 4-hydroxytamoxifen (4OHT), respectively. However, p53 activating signals 
are still required for wild-type p53 activity after 4OHT administration 
(Christophorou et al., 2005; Martins et al., 2006). KI: knock-in. 
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adenocarcinoma (p53 alterations occur in almost half of cases in addition to KRAS 
mutations occurring in almost a third of cases; Cancer Genome Atlas Research, 
2014).  This makes it a relevant model for investigating this disease. In addition, it is 
an endogenous tumour model with the Kras mutation and p53 mutations being 
expressed from their endogenous promoters rather than modelling the disease using 
supraphysiological levels of expression of the Kras and p53 mutant proteins. The 
Cre-recombination system utilised to activate the mutant genes also allows for 
spontaneous recombination events in the target cells in the lung after infection with 
Cre-expressing adenovirus through intranasal administration. This recapitulates the 
spontaneous nature of the mutations in human disease. Importantly, multiple tumours 
develop in each animal, each evolving independently, enabling the simultaneous 
analysis of tumours with distinct evolutionary ‘paths’ and thus, modelling the 
heterogeneity of human cancers (Jackson et al., 2005).  
 
This Kras-mutant; p53-deficient mouse model can be utilised to investigate the 
impact of p53 loss or p53 mutations on tumour progression and response to therapy. 
In addition, incorporation of a conditional p53ERTAM allele into this model enables the 
restoration of wild-type p53 function in the mice in a time-controlled manner through 
administration of tamoxifen (hydroxytamoxifen, 4OHT; Christophorou et al., 2005). In 
the p53ERTAM mouse model the p53ER protein is always expressed but remains non-
functional in the absence of its ligand 4OHT, due to the estrogen receptor (ER) 
domain which is fused to p53. This domain keeps p53 sequestered through 
interaction with heat-shock proteins until its 4OHT ligand binds. On ligand-binding 
p53ER dissociates from the heat-shock proteins, becoming functional (Christophorou 
et al., 2005). Therefore, this p53ERTAM allele enables the study of the effect of wild-
type p53 in tumour models (Figure 1.9).  
 
In summary, there is currently a lack of effective therapies to treat p53 mutant lung 
cancers, which represent a large proportion of lung adenocarcinoma cases. 
Therefore, further assessment of the roles of distinct p53 mutations in lung tumours 
is required to identify potential vulnerabilities in these tumours. Potential mutant p53 
GOFs may highlight pathways downstream of mutant p53 which can be targeted to 
treat these tumours. We may be able to exploit these pathways to target all p53 
mutant lung tumours or tumours with specific p53 mutations, depending on whether 
the GOFs identified are mutation-type specific. Moreover, analysis of the DN effects 
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of different p53 mutations would help us ascertain whether wild-type p53 restoration 
therapy would have efficacy in some or all p53 mutant lung tumours or whether the 
DN functions of the p53 mutations prevail over wild-type p53 function.  
 
1.4. Aims of thesis 
  
The overall objective of my thesis was to define the impact of p53 mutations in lung 
tumours. My research had the following aims: 
 
 
1) To characterise the transcriptional impact of a conformational (R172H) and 
contact (R270H) p53 mutation in lung tumour cells, both in the presence and 
absence of wild-type p53. 
 
2) To identify the gain-of-function effects of distinct p53 mutant classes in lung 
tumours. 
 
3) To assess whether p53 mutants have an inhibitory effect on wild-type p53 
function in lung tumours. 
 
4) To define therapeutic strategies capable of targeting p53 mutant lung tumours. 
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2. Materials and Methods 
 
Methods were adapted from (Turrell et al., 2017). 
 
2.1. In vivo work 
 
In vivo work was performed using mice with all the animal work for my project 
regulated under the Animals (Scientific Procedures) Act 1986 Amendment 
Regulations 2012 following ethical review by the University of Cambridge Animal 
Welfare and Ethical Review Body (AWERB). Animal work was carried out at 
Biological Resources Unit Cambridge Institute and Cambridge Biomedical Services. 
Mice were maintained under specific-pathogen-free (SPF) conditions, housed with no 
more than 5 animals/cage and were kept on an ad libitum diet. All animals were of 
from a mixed background (C57Bl/6/129/Sv). Compound mice were generated of the 
following genotypes: KrasLSL-G12D/+;p53Fx/Fx, KrasLSL-G12D/+;p53LSL-R172H/Fx, KrasLSL-
G12D/+;p53LSLR270H/Fx. KrasG12D/+;p53Fx/ER, KrasG12D/+;p53R172H/ER
 
and 
KrasG12D/+;p53R270H/ER (Jonkers et al. 2001; Christophorou et al. 2005; Jackson et al. 
2005). 
 
2.1.1. Colony management 
 
Breedings were set up with mice 6-8 weeks of age and the females were let to breed 
for typically 6 months. The health and the size of the litters were monitored. The 
presence of two KrasLSL-G12D alleles (absence of Kras) is embryonically lethal and so 
mice heterozygous for the KrasLSL-G12D allele were crossed with Kras+/+ animals. 
Animals from the p53R270H strain were not crossed with animals from p53R172H strain. 
P53R270H and p53R172H animals were not housed together. Examples of typical 
breeding pairs were: KrasG12D/+p53Fx/Fx and Kras+/+p53R270H/Fx; KrasG12D/+p53Fx/ER and 
Kras+/+p53R172H/Fx. Mice were earmarked for identification when weaned (3 weeks of 
age) and the ear biopsies were sent for genotyping. Genotypes (Kras and p53) of the 
mice were determined by a commercial vendor (Transnetyx, Cordova). 
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2.1.2. Induction of endogenous tumours 
 
Mice were infected intransally with AdenoCre (AdCMV; Viral Vector Core, University 
of Iowa, UIowa-5) at 8 weeks of age and with 5x106 plaque-forming units (PFU) 
unless otherwise specified. The virus was thawed and diluted in Eagle’s Minimum 
Essential Media (EMEM; Sigma, M2279) to administer desired amount of 
PFU/mouse in 64 μl.  CaCl2 was added to a final concentration of 12 mM to activate 
the virus and the solution vortexed gently to mix and incubated for 20 minutes at 
room temperature. Meanwhile mice were anesthetised using isoflurane. After 20 
minutes mice were administered with 32 μl of diluted virus to each nostril. After 
recovery from the anaesthesia, animals were kept in quarantine cages for 72 hrs to 
ensure any residual virus was inactive. After Adeno-Cre administration, multiple, 
endogenous lung tumours formed and animals were typically sacrificed 16-18 weeks 
post-infection. 
 
2.1.3. Murine experimental cohorts 
 
Animals were assigned to experimental cohorts (for example vehicle and drug 
treatments) to end up with similar numbers of males and females in each group. A 
minimum of 5 animals was used/cohort unless otherwise stated. We aimed to 
complete experiments using animals from the same infection round but where this 
was not possible we ensured we had comparable vehicle and treatment animals from 
the same infection group. Any animals which had been flagged as receiving the 
Adeno-Cre virus sub-optimally were not used in our experimental cohorts.  
 
2.1.4. Genotyping and sequencing 
 
Tails were collected for all mice in experimental cohorts when the animals were 
sacrificed to confirm the genotype of experimental animals.  Genomic DNA (gDNA) 
was extracted by adding 500 μl of DNA lysis buffer (100 mM Tris.HCl pH 8.5, 5 mM 
EDTA, 0.2% sodium dodecyl sulphate, SDS, 200 mM NaCl) with 100 μg/ml 
Proteinase K (New England Biolabs, P8107S) added fresh. Tails were incubated in 
lysis buffer overnight at 55 C with gentle agitation. Samples were centrifuged to 
remove hair and gDNA was precipitated by adding 500 μl isopropanol to the tube and 
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inverting. Samples were centrifuged at maximum speed for ten minutes to pellet the 
gDNA which was then washed with 70 % ethanol and left to air dry before 
resuspending in ultra-pure water (18.2  filtered). The concentration of gDNA was 
determined using a Nanodrop spectrophotometer (Thermo Scientific) and input for 
the PCRs was 100 ng gDNA.  
 
PCRs were performed as previously described for KrasG12D (https://jacks-
lab.mit.edu/protocols)  and p53Fx (Jonkers et al., 2001). p53ER PCR primers: (1) 5’ 
CCT CCA GCC TAG AGC CTT CCA AGC 3’; (2) 5’ GGT GAG ATT TCA TTG TAG 
GTG CC 3’; (3) 5’ GCA CAC AAA CTC TTC ACC CTG C 3’; WT band: 430bp; KI 
band: 700bp). P53ER PCRs were carried out using the following protocol: 1) 94 C 
for 2 minutes,  2) 94 C for 40 seconds, 3) 66 C for 40 seconds, 4) 72 C for 2 
minutes, 5) go to 2) for 34 times, 6) 72 C for 10 minutes. Mutant p53 sequencing 
was carried our using the following primers: 172: (1) 5’ 
AGGTGTGTTGGCCATCTCTG 3’ (2) 5’ CTCAGGAGGGTGAGGCAAAC 3’; band: 
743 bp; 270: 5’ TTTCTGTTCCACGAGTCCCG 3’, (2) 5’ 
AAAAGACCTGGCAACCTGCT 3’; band: 661 bp.  Mutant p53 PCRs were carried out 
using the following protocol: 1) 95 C for 3 minutes,  2) 95 C for 40 seconds, 3) 66 
C for 30 seconds, 4) 72 C for 1 minute, 5) go to 2) for 31 times, 6) 72 C for 10 
minutes. TakaRa Ex Taq kit (RR001A) was used for all PCR reactions. Samples 
were run on a 1.5% agarose gel and visualised using Ethidium Bromide in a G:BOX 
gel imager (Syngene). Sequencing was performed by the Sanger Sequencing 
Service (Source BioScience) and analysed using 4Peaks software.  
 
2.1.5. Tamoxifen and simvastatin treatments 
 
For p53 restoration studies mice were treated at 15-17 weeks after Adeno-Cre-
administration by intraperitoneal injection, (i.p.) with tamoxifen (1 mg/mouse 
once/day Sigma) or vehicle (Ctrl, peanut oil, Sigma) for 6 days. Simvastatin (200 
mg/kg, EP, S0650000) or vehicle (Ctrl, 1% carboxymethylcellulose (Sigma) in dH2O) 
were administered 15 weeks after Cre, once daily for 6 days (unless otherwise 
stated) by oral gavage. For all in vivo treatments lungs were collected 24 hrs after the 
last treatment and a minimum of three mice/cohort were used (exact values are 
indicated). 
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2.1.6. Transplantation of lung tumour cell lines, imaging and 
survival studies 
 
Transplant studies were carried out using 8- to 12-week-old wild-type mice, one cell 
line/genotype.  Prior to transplantation cells were engineered to express luciferase 
(section 2.3.4). mice were irradiated (4 Gy, caesium source) 6 hrs before they 
received a 100 μl suspension of cells (in PBS) via tail-vein injection (performed by 
members of staff in the animal facility). Recipient mice received either 1x105 
(metastatic potential cohorts) or 1x106 cells (simvastatin/Ctrl cohorts). Tumour growth 
was monitored weekly. Briefly animals were shaved over the chest area, injected 
(intraperitoneal) with D-luciferin (Caliper Life Sciences, 119222; 150 mg/kg), 
anesthetised using isoflurane and bioluminescence was measured ten minutes after 
injection by an IVIS Spectrum Xenogen machine (Caliper Life Sciences). Luciferase 
activity was measured using LivingImage software and normalized to control 
(luciferase-negative animal). Relative luciferase activity is the change from baseline 
(week 1 after transplantation) at indicated time point. All plotted mice developed lung 
lesions and additional thoracic tumors were observed in some mice. Simvastatin or 
control treatment (section 2.1.5) of transplanted models was carried out once/day, 
starting two weeks after transplantation and until endpoint. In all in vivo treatment 
groups lungs were collected 24 hrs after the last treatment and a minimum of three 
mice/cohort were used (exact values are indicated). 
 
2.1.7. Tissue sampling and processing 
 
Hearts were perfused with 5 ml phosphate-buffered saline (PBS) and the lungs were 
inflated with 10 % formalin. Tails were collected on dry ice and kept at -80 C until 
DNA extraction was performed. Lungs were kept in formalin overnight at room 
temperature. The next day the lungs were transferred over to 70 % ethanol and kept 
at 4 C until processing. Individual lobes were placed in tissue cassettes and 
submitted to the Histology core (Cambridge Institute, CRUK) or the Human Research 
Tissue Bank (Addenbrooke’s Hospital) for processing. Lungs were embedded in 
paraffin to expose as many lobes as possible and cut to display a minimum of 4 
lobes/section. H&E staining was performed at the Histology Core or the Human 
Research Tissue Bank. Lung tumour burdern measurements were performed using 
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the H&Es and ImageJ to calculate the total area of the lungs and the area covered by 
lung tumours.  
 
Single tumours that were collected from RNA analysis were isolated from the lungs 
and trimmed to remove any normal tissue. Tumours, or normal lung control tissue, 
were then immediately snap-frozen in liquid nitrogen and stored at -80 C until RNA 
extraction. 
 
2.2. Immunohistochemistry  
 
2.2.1. Ki67 staining and quantification 
 
Histological analysis was carried out on the formalin-fixed, paraffin-embedded lung 
tissue. Sections (5 m) on glass slides were heated for 20 minutes at 55 C and then 
deparaffinised and hydrated by serial passaging through xylene (2x 5 minutes), 100 
% ethanol ( 2x 2 minutes), 95 % ethanol (2x 2 minutes) , 70 % ethanol (2x 2 minutes) 
and water. Staining for Ki67 (Bethyl-Laboratories, IHC-00375) was performed on the 
Leica Bond-Max (Bond Polymer Refine Detection, DS9800). Slides were then 
dehydrated, mounted (DPX mounting media, Sigma) onto coverslips (VWR; 22 x 50 
mm borosilicate glass) and scanned using the Zeiss Axio Scan Z1.  The percentage 
of Ki67-positive cells/tumour was calculated by counting the number of cells 
(hematoxylin) and number of Ki67-positive cells by hand using the counter tool on 
ImageJ or by the automated Halo 2.0 software (Cytonuclear). The number of tumours 
counted are as indicated.  
 
2.2.2. TUNEL staining and quantification 
 
Terminal deoxynucleotidyl transferase dUTP Nick-End Labeling (TUNEL) staining 
was performed on formalin-fixed, paraffin-embedded (5 m) lung tissue. Slides were 
heated for 20 minutes at 55 C and then deparaffinised and hydrated as above. 20 
μg/ml Proteinase K (New England Biolabs, P8107S) in PBS was added (150 μl/slide) 
for 15 minutes at room temperature. The staining was performed as stated by the 
manufacturer’s instructions with the following adaptions: 45 μl equilibration buffer was 
added/slide and then 5 seconds after 30 μl reaction buffer with 10 μl was 
added/slide. Slides with incubated for 1 hr at 37 C before the reaction was stopped 
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with Stop buffer. Slides with then washed with TBS-T (0.1 %) and mounted with 
Everbrite mounting media with DAPI (Biotium, 23004) onto coverslips (VWR; 22 x 50 
mm borosilicate glass). Slides were then scanned using the Zeiss Axio Scan Z1. The 
percentage of TUNEL-positive cells/tumour was calculated by counting the number of 
cells (DAPI) and number of TUNEL-positive cells by hand using the counter tool on 
ImageJ or by the automated Halo 2.0 software (CytonuclearFL). The number of 
tumours counted are as indicated.  
 
2.3. Isolation and maintenance of lung tumour cell lines 
 
2.3.1. Isolation of lung tumour cell lines 
 
KrasG12D/+;p53R270H/ER, KrasG12D/+;p53R172H/ER and KrasG12D/+;p53Fx/ER murine lung 
cancer cell lines were generated prior to the start of this research project. For the 
generation of the KrasG12D/+;p53R270H/Fx, KrasG12D/+;p53R172H/Fx and KrasG12D/+;p53Fx/Fx 
cell lines tumours were harvested from three KrasG12D/+;p53R270H/Fx and two 
KrasG12D/+;p53R172H/Fx mice at 14-15 weeks post-Adeno cre infection with 5x107 PFU 
and from two KrasG12D/+;p53Fx/Fx mice, 15-17 weeks post-Adeno cre infection (5x107 
PFU).  Tumours were collected in Hank’s Balanced Salt Solution (HBSS, with Ca2+ 
and Mg2+), mashed and collected again in fresh HBSS. After centrifugation at 1,000 
rpm at 4C for 5 minutes the pellet was resuspended in HBSS (no Ca2+ and Mg2+) 
with 4 mg/ml collagenase dispase (Roche) and incubated at 37 C for 2.5 hours 
under agitation. HBSS (with Ca2+ and Mg2+) with 10 % fetal calf serum (FCS; Life 
Technologies) and 3.33 l/ml DNase I (Invitrogen; 1 U/μl; 18068-015) was added, 
incubating the cells on ice for 10 minutes. After centrifugation, cells were 
resuspended in Dulbecco’s Modified Eagle Medium (DMEM)/ F-12 (1:1) media (Life 
Technologies), supplemented with 10% FCS, 2mM L-Glutamine (Gibco), 100 U/ml 
penicillin (Sigma), and 0.1 mg/mL streptomycin (Sigma), filtered through a 70 m 
filter and plated. After 1.5 hours the media was re-plated to separate the epithelial 
population.  
 
 
 
 31 
2.3.2. Genotyping of cell lines 
 
Genomic DNA extraction and subsequent genotyping and sequencing of p53 for the 
cell lines was performed in the same way as for the genotyping for the mouse tails 
described above (section 2.1.4). 
 
2.3.3. Maintenance of lung tumour cell lines 
 
All lung tumour cell lines were maintained in DMEM/F-12 media supplemented with 
10% FCS, 2mM L-Glutamine, 100 U/ml penicillin and 0.1 mg/mL streptomycin 
(referred to as complete DMEM/F-12 media), at 37 °C and 5 % CO2.  All cells tested 
negative for mycoplasma and were typically used at passages 10-20 after isolation.  
 
2.3.4. Generation of luciferase-expressing lung tumour cell lines 
 
Bacteria were grown up from bacterial glycerol stocks of the MSCV-luciferase-PGK 
hygromycin retroviral plasmid (Addgene, 18782) in LB broth (10 g Bacto Tryptone/5g 
Bacto Yeast Extract/10 g NaCl/1L dH2O; adjusted to pH 7) with ampicillin (100 
g/ml), overnight at 37 C. A Maxiprep (Qiagen, 12663) was performed to extract 
DNA and DNA was concentrated as required by performing ethanol precipitation (0.3 
M sodium acetate, pH 5.2 and 100 % ethanol).  
 
Phoenix Eco cells were plated at 2.5x106 cells/10 cm plate. The following day when 
the cells with 60-70% confluent they were transfected with 20 g plasmid/plate. For 
lung tumour cell line to be transduced, one plate of Phoenix Eco cells was 
transfected. For each plate to be transfected, 20 g plasmid (maximum volume 10 l) 
was added to 1.5ml Opti-MEM (Gibco, Life Technologies, 31985-062) and 60 l 
Lipofectamine 2000 (Invitrogen, 11668-027) was added to 1.5ml Opti-MEM in a 
second tube. The solutions were then incubated separately for 5 minutes before 
mixing and incubating for a further 20 minutes at room temperature. Complete 
DMEM media (3 ml) was added/plate of cells and then 3 ml of the DNA-
Lipofectamine mix was added drop-wise on top. The next day the cells were rinsed 
with PBS and 5.5 ml complete DMEM/F-12 media was added. The murine lung 
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tumour cell lines were also plated at 1.0x106/10 cm plate. The following day the 
media was collected from the Phoenix Eco cells, which were re-fed with 5.5ml fresh 
media. The viral media was then filtered through a 0.45 l filter, 8 g /ml polybrene 
(Millipore, TR-1003-G) was added and the viral media was then added to the murine 
lung tumour receiver cells. A second round of retroviral transduction was performed 
the following day.  
 
The next day, lung tumour cells (control and transduced plates) were then placed in 
antibiotic selection until the cells on the control plate had all detached (Hygromycin B 
selection, 250-450 g/ml, Invitrogen, 10687010). Luciferase-expressing cells were 
expanded and tested to confirm luciferase activity using a Dual-luciferase reporter kit 
(Promega, E1910), following the manufacturer’s instructions.  
 
2.4. In vitro treatments 
 
Treatments were performed in triplicate and, unless otherwise stated, treatments 
were refreshed daily. For p53 restoration studies, cells were treated with 100 nM 
4OHT (Sigma, H7904) or Ctrl (ethanol) the following day after the cells were plated 
(2D and 3D cultures as indicated). For simvastatin experiments, cells were treated 
with vehicle or simvastatin (Sigma, S6196; 1 M) for 24 hrs (western blots) or 72 hrs 
(3D colony growth). Simvastatin was activated with addition of 125 l ethanol and 
187.5 l NaOH (0.1M)/5 mg drug and incubation at 50 °C for 2 hours. Simvastatin 
was then diluted in water and aliquots of the stock solution were stored at -80 °C. 
Vehicle was made in the same way, without addition of the drug. Fatostatin (Sigma, 
F8932 was used at a working concentration of 10 M in DMSO; Sigma). All 
simvastatin and fatostatin experiments were performed in 3D cultures. Addback 
experiments were performed by addition of Mevalonate (0.3 mM in DMSO; Sigma), 
GGPP (40 M; Sigma, G6025, in methanol:NH4OH, 7:3) or 1 x cholesterol (Sigma, 
S5442). 
 
2.5. 2D proliferation assays 
 
Cells were seeded at 15,000 or 5,000 cells/well in 6 well plates. The next day, where 
relevant, cells were treated with 4OHT/vehicle.  Cells were trypinised and viable cells 
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were counted using trypan blue exclusion in triplicate every 24 hrs at indicated time 
points. Briefly, an equal volume of trypan blue stain (Gibco, Life technologies, 0.4 %) 
was added to the cell suspension and live cells were counted using a 
haemocytometer (blue cells were excluded).   
 
2.6. 3D cultures 
 
For all 3D cultures, cells were seeded around the edge of the wells in a 24-well plate 
in 3:2 Matrigel (Corning, 354234):DMEM/F-12 media unless otherwise stated. The 
plate was incubated at 37 C for 30 minutes to allow the Matrigel to set before the 
addition of media to the wells.  5,000 cells were seeded/well for the colony formation 
assays, with each condition seeded in triplicate. After 72 hours, 3-5 images were 
taken for each well at 20x magnification and the colony size measured using the 
Image J software. For all other 3D growth assays and for microarray sample 
preparation, 50,000 cells were seeded/well. For cell recovery, Matrigel was 
dissociated with Cell Recovery Solution (Corning, 354253) at 4 °C for 45 minutes 
before collection. 
 
2.7. Microarray analysis 
 
Microarray samples were collected by Meiling Gao, prior to the start of my PhD. Four 
independent lung tumour cells lines/genotype (KrasG12D/+p53FxER, 
KrasG12D/+p53R172H/ER and KrasG12D/+p53R270H/ER) were cultured in 3D Matrigel cultures 
for 48 hrs. Cultures were then treated with either vehicle (ethanol) or 4OHT for 2 hrs 
or 8 hrs. The media was then removed, the cultures washed with PBS and the 
Matrigel was dissociated and the cells collected as previously described (section 
2.6). RNA was extracted using the RNeasy Qiagen kit (74106) with on-column 
DNase digestion.  
 
Illumina MouseWG-6 version 2.0 Expression BeadChip (Department of Pathology, 
Cambridge University) was used for the microarray analysis. Standard Illumina 
protocols were used for the scanning of arrays. Data were normalised by Dr Shamith 
Samarajiwa using R (http://www.R-project.org) and Bioconductor (Gentleman et al., 
2004) and spatial artefacts were also removed using BASH (Cairns et al., 2008) and 
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HULK algorithms from the beadarray package (Dunning et al., 2007). Data were then 
log2 transformed and quantile normalised and an average value from each sample 
was calculated from two runs.  
 
Differentially expressed genes were defined as those where there was an average 
fold change between groups >1.4. A cut-off of a standard deviation<0.5 between log2 
expression values within each cohort was also applied to account for intragenotype 
variation. Pathway analysis of differentially expressed genes was performed using 
Ingenuity Pathway Analysis (IPA, Qiagen) software and Fisher’s exact test was used 
to determine statistical significance of canonical pathways (P<0.05). The Multiple 
Experiment Viewer (MeV) software was used for the generation of heatmaps based 
on normalised log2 expression data values.  Principal component analysis was 
performed using R (http://www.R-project.org) with the help of Sarah Davidson. Gene 
Set Enrichment Analysis (GSEA, Broad Institute) was used to generate enrichment 
plots for the Srebf2 target genes. Srebf2 target genes were based on target gene list 
from IPA and ChIPseq datasets (http://chip-atlas.org). p53 “canonical” targets were 
defined based on functional and expression studies (GSEA, Bieging et al., 2014; 
Lehar et al., 1996; Okamoto and Beach, 1994) or ChIP data (http://chip-atlas.org; 
Fischer, 2017).  
 
2.8. qRT-PCR  
 
Cells were pelleted from 10 cm plates (70-80% confluent) or 3D cultures as 
previously described (section 2.6) and RNA was extracted using the RNeasy kit 
(Qiagen, 74106), following the steps for on-column DNase (Qiagen) treatment. RNA 
concentration was measured using a Nanodrop spectrophotometer (Thermo 
Scientific). Complementary (c)DNA synthesis was performed using the iScript cDNA 
synthesis kit (Biorad, 1708891). For each reaction, 4 μl 5X iScript reaction mix, 1 μl 
iScript reverse transcriptase, 2 μl 300 ng/μl RNA and 13 μl nuclease-free water were 
combined and run on a MJ Research Tetrad PTC-225 Thermal Cycler using the 
standard kit protocol (5 min at 25 °C, 30 min at 42 °C, 5 min at 85 °C). The 
quantitative real-time polymerase chain reaction (qRT-PCR) was performed in 5 μl 
reactions using Taqman system (2.5 μl Taqman Universal PCR Master Mix (Applied 
Biosystems, 4304437), 1.25 μl nuclease-free H2O, 0.25 μl probe and 1 μl (7.5 ng) 
cDNA) on 384 well plates.  Plates were sealed with foil, spun at 2,000 rpm for 1 min 
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and loaded onto the LightCycler 480 II (Roche). The samples were analysed using 
standard Taqman hydrolysis programme: 1 pre-amplification step (95 °C, hold 10 
min); 45 amplification cycles (95 °C, hold 10 sec, 60 °C, hold 30 sec, 72 °C, reading, 
hold 1 sec); 1 cooling step (40 °C, hold 30 sec). The following probes were used for 
Taqman analysis: Cdkn1a: Mm00432448_m1; Mdm2: Mm01233136_m1; Bbc3: 
Mm00519268_m1; Mvd: Mm00507014_m1; Pmvk: Mm01212763_m1; Sqle: 
Mm00436772_m1; Srebf2: Mm01306292_m1 Pilra: Mm04211819_m1; Nr2f2: 
Mm00772789_m1; Slc2a9: Mm00455122_m1; Phlda3: Mm00449846_m1; Sesn2: 
Mm00460679_m1; Bax: Mm00432051_m1; Gapdh: Mm99999915_g1; Euk 18S 
rRNA (4352930E) all from Applied Biosystems. 
 
2.9. FACS 
 
2.9.1. EpCAM/PDGFR  
 
Cells were trypsinised and washed twice with cold PBS. Cells were then 
resuspended in 200 l staining buffer (2 % FCS in PBS) with either an 
allophycocyanin (APC)-conjugated antibody against epithelial cell adhesion 
molecule, EpCAM (1:100; Biolegend, 118213) or platelet-derived growth factor 
receptor, PDGFR (1:50; eBioscience, 17-1401-81) and incubated for 1 hr in the 
dark at 4 C. Cells were washed twice in staining buffer and resuspended in staining 
buffer for flow cytometry. Unstained controls for each sample were also collected. In 
addition, negative and positive controls for EpCAM (mouse embryonic fibroblasts and 
an epithelial tumour cell line respectively) and Pdgfra (an epithelial tumour cell line 
and mouse embryonic fibroblasts respectively) were also collected. Samples were 
run on an LSR II flow cytometer (BD Biosciences) and data was analysed using 
FlowJo software (Tree Star). Briefly, FSC-A x SSC-A and FSC-A x FSH-H gating was 
performed to exclude the debris and identify the single cell population and a gate for 
Pdgfra-positivity was generated on a sample which was a mix of the positive and 
negative controls. This gate was then applied to all samples to determine percentage 
Pdgfra-positivity (examples of the gating performed are shown in Appendix 4). 
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2.9.2. BrdU/PI 
 
Cells were seeded in 3D Matrigel cultures at 50,000 cells/well in 24 well plates (3D 
cultures) or onto 6 well plates at 50,000/well (2D cultures). Cells were treated with 
ethanol (vehicle) or 4OHT for the indicated time points. Bromodeoxyuridine (BrdU; 
Thermo Fischer Scientific, 000103; 10 M) was then added 2 hours before collection 
and the treatment was refreshed when the media was changed. After the 2 hours 
incubation at 37 C, cells were washed with PBS and trypsinised. For 3D cultures, 
cells were dissociated and collected as previously described (section 2.6) and 
trypsinised. Cells were washed twice in cold PBS. After the last wash cells ice-cold 
ethanol was added drop-wise under agitation and cells were fixed overnight at 4 C. 
Cells were then washed with cold PBS twice more, spun down, resuspended in 200 
l RNAse A (Qiagen, 0.5 mg/ml in PBS) and incubated at 37 C for 30 minutes. Cells 
were washed again and re-suspended in 200 l HCl/H2O/0.5% Triton X solution and 
incubated for 20 minutes at room temperature. Then 2 ml of 0.1M Na2B4O7 (pH 8.5) 
was added for neutralisation for 5 minutes. Cells were then washed in PBS-T (0.5 
%). Anti-BrdU-FITC (Flow BrdU kit, BD Biosciences) was added to each sample (20 
l antibody and 50 l PBS-T) and cells were incubated for 1 hr at room temperature 
in the dark. Cells were then washed with PBS-T and resuspended in PBS with 20 
g/ml propidium iodide (PI, Sigma, P4170). Samples were run on an LSR II flow 
cytometer (BD Biosciences) with unstained and single-stained controls and data was 
analysed using FlowJo with compensation performed (Tree Star, version 10). Gating 
to exclude cellular debris and identify the single cell population was performed as 
above (section 2.9.1) and the BrdU-positive population was selected to determine the 
percentage of cells in S-phase (an example of the gating performed is shown in 
Appendix 5). 
 
2.10. Cell death analysis  
 
2.10.1. Ethidium homodimer/Calcein AM kit 
 
Cells were seeded at 50,000 cells/100 μl Matrigel (Phenol red free, 356237)/Media 
mix. The following day the 3D cultures were treated with 4OHT/vehicle for 72 hrs in 
triplicate. The percentage dead cells was then measured and calculated using the 
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Ethidium homodimer/Calcein AM-based LIVE/DEAD Viability/Cytotoxicity Kit 
(Molecular Probes, MP03224), following the manufacturer’s instructions for the 
fluorescent microplate protocol.  
 
2.10.2. Cleaved caspase-3 immunofluorescence 
 
For immunofluorescence, cells were seeded at 50,000 cells/100 μl Matrigel (Phenol 
red free, 356237)/Media mix on glass chamber slides and were treated with 
4OHT/Ctrl the next day for 72 hrs. Cultures were then at fixed in 2% 
paraformaldehyde (PFA; 1 hr) followed by 1% Glutaldehyde (1 hr), washed three 
times in wash buffer (PBS/0.15% Triton-X) and blocked in blocking buffer (PBS 
0.15%/Triton-X/3% serum) for 30 mins at room temperature. Incubation with primary 
antibody (anti-Cleaved caspase-3, Cell Signaling, 9664S, 1:200) in blocking buffer 
was performed overnight at 4 C. Cultures were subsequently washed overnight at 4 
C  with wash buffer, with 3 changes, of buffer and incubated with secondary 
antibody (Thermo Scientific A11008; 1:200) in blocking buffer overnight at 4 C, in 
the dark. All subsequent steps after addition of the secondary antibody were also 
performed in the dark. Again the cultures were washed overnight at 4 C with wash 
buffer, with 3 changes in buffer. Following this, cells were incubated with DAPI (1 
μg/ml in PBS) for 20 minutes at room temperature. Cultures were then washed in 
PBS for 3 minutes, fixed again with 4 % PFA for 15 minutes at room temperature and 
washed again in PBS for 10 minutes. PBS was refreshed and the 3D cultures were 
imaged using a Leica SP5 confocal microscope and analysed using Leica imaging 
software.  
 
 
2.11. Senescence assay 
 
The Senescence ß-galactosidase staining kit (Cell Signalling, 9860) was used 
following the treatment of cells in triplicate with 100 nM 4OHT or vehicle (ethanol) for 
72 hours, refreshed daily.  H460 and A549 lung cancer cells were treated with 
Palbociclib (Sigma, PD-0332991, 2 µM) for 72 hours, refreshed daily, as a positive 
control. As instructed by the manufacturers, cells were fixed with the fixative solution 
for 5 minutes and following washing, incubated with ß-galactosidase staining solution 
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(pH 6) overnight at 37˚C no CO2. Images were obtained from 5 random fields of view 
for each cell line in triplicate using an Olympus BX53 brightfield microscope.  
 
2.12. Migration and invasion assays 
 
2.12.1. Scratch assay 
 
40,000 cells were seeded in a 24 well plate (2D). Cells were cultured for 48 hrs 
before each well was scratched twice using a yellow tip and media refreshed. Leica 
live cell microscopy was used to monitor scratch closure, with images acquired every 
hour for 24 hrs (Zeiss Live Cell microscope). Cells were cultured in complete 
DMEM/F-12 media while the closure of the scratch was measured over time. Velocity 
was calculated for each cell line from three measurements per scratch, measuring 
the horizontal distance moved by the cells/hour.  
 
2.12.2. Invasive growth  
 
Inverted invasive growth assays were performed to assay invasion with 40,000 cells 
seeded in each transwell (Costar, 3422; inverted) in 50 l of a growth factor-reduced 
Matrigel (Coring, 356231), and serum free basal DMEM (A14430-001) mix (4:1 
Matrigel: media). The plate was incubated at 37 C for 30 minutes to allow Matrigel to 
set and then 200 l of the diluted Matrigel was added on top of the cells and the plate 
was incubated for a further 30 minutes at 37 C.  120 l of complete DMEM media  
with 20 % FCS was added on top of the Matrigel and 500 l of the serum free basal 
media was added below the transwell. The media were changed daily to maintain the 
gradient. After 8 days the transwells were washed in PBS and stained with 2 mM 
calcein AM (Life Technologies). Z-stack images with slices every 15 m were 
acquired on a Zeiss LSM 510 Meta confocal microscope (3-4 z-stacks for each well) 
and fluorescence intensities were calculated on Image J to assess the numbers of 
invaded cells. 
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2.13. Metabolomics 
 
2.13.1. Metabolite extraction 
 
Cells were seeded at 2.5-4.5 x 106 per well in 6 well plates to achieve 70-80 % 
confluency the next day. Each cell line was seeded in quadruplicate, with one well for 
each to allow determination of cell number. The following day the media was 
refreshed, with media also added to three empty wells to allow for metabolites to be 
collected from the media only as a control. After 8 h the cell number was determined 
using a haemocytometer and the metabolites were extracted. 50 μl of media from the 
remaining three replicates for each condition was collected in 750 μl pre-cooled 
metabolite extraction buffer (50 % methanol, 30 % acetonitrile, 100 ng/ml HEPES 
buffer in water). Samples were agitated on the thermomixer for 15 min at 4 °C and 
then spun at maximum speed for 10 min at 4 °C. The supernatant was transferred to 
mass spectrometry (MS) vials and the samples stored at – 80 °C. The cells were 
washed quickly in PBS, three times on ice. Pre-cooled metabolite extraction buffer 
was added (0.5 ml/ 106 cells) and then collected and processed as before.  
 
2.13.2. Mass spectrometry 
 
Liquid chromatography (LC)-MS analysis was performed by the Frezza lab on a 
Thermo QExactive Orbitrap mass spectrometer using a pHILIC column (150 mm × 
2.1 mm, internal diameter (i.d.) 3.5 µm) with the guard column (20 mm × 2.1 mm i.d. 
3.5 µm) (HiChrom, Reading, UK) and the following settings: flow rate: 180 µL/min; 
mobile phase: A: 20 mM ammonium carbonate plus 0.1% ammonia hydroxide in 
water, B: acetonitrile; gradient: 0 minutes 70% of B, 1 minute 70% of B, 16 minutes 
38% of B, 16.5 minutes 70% of B, 25 minutes 70% of B.  
 
2.13.3. Analysis 
 
The peaks were analysed using the Spectra analysis software XCalibur Qual 
Browser and XCalibur Quan Browser (Thermo Scientific) and the values were 
normalised to the total metabolite levels (the sum of the peak areas) for each 
sample.  MeV software was used for the generation of heatmaps. Principal 
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component analysis was performed using R (http://www.R-project.org; Gaude et al; 
2013) with the help of Edoardo Gaude. 
 
2.14. Extracellular flux assays 
 
2.14.1. Plate preparation 
 
The Seahorse Biosciences XFe24 system was used to assess extracellular flux in 
the previously mentioned murine lung tumour cell lines.  Briefly, cells were plated in 
24 well assay plates (20,000 cells per well) in triplicate and allowed to adhere 
overnight in full culture media, at 37 °C with 5 % CO2. Probe plates were prepared by 
adding 1 ml calibration buffer per well, and incubated overnight at 37 °C, without 
CO2. The following day assay media was prepared by supplementing seahorse 
media (8.3g DMEM (Sigma D5030), 1.85 g NaCl, 0.015g Phenol Red in ultra-pure 
H2O/1L, pH 7.4) with 0.45 % (w/v) glucose, 2 % FCS, 4 mM L-glutamine and sodium 
pyruvate (NaPyr; 0.5 mM) and corrected to pH 7.4. The 24 well assay plate media 
was then replaced with 675 μl per well of freshly prepared assay media, and the plate 
incubated at 37 °C, no CO2 for 30 min. The probe plate was prepared with the 
mitochondrial inhibitors: 75 μl 10 μM Oligomycin in injection port 1, 83 μl 5 μM CCCP 
in injection port 2, and 92 μl 10 μM Rotenone in injection port 3 in assay media.  
 
2.14.2. Running the assay 
 
The probe plate was inserted into the Seahorse XF analyser and then after 15 
minutes of calibration the cell plate was inserted into the analyser. Oxygen 
consumption, extracellular acidification and proton pump rate at each step was 
calculated (basal, injection 1, injection 2 and injection 3), with a 2 minute mix and 1 
minute read cycle repeated three times at each step. After the assay, the media was 
removed and the cells were lysed on ice for 15 minutes in 50 μl 
radioimmunoprecipitation assay (RIPA; 150 mM NaCl/0.1 % Triton X/0.5 % sodium 
deoxycholate/0.1 % SDS; 50 mM Tris-HCl pH 8.0) buffer/well. Protein quantification 
was performed by the bicinchoninic acid (BCA) assay (Thermo Scientific) with bovine 
serum albumin (BSA) standards, and results normalised accordingly. 
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2.15. Measurement of total protein and cell size 
 
The size of trypsinised cells was measured using a Countess (Invitrogen) cell 
counter. To determine protein content, cells were trypsinised and counted using a 
haemocytometer. 10,000 cells were pelleted in triplicate/cell line. Cells were then 
lysed on ice in 30 μl RIPA buffer for 30 minutes. Protein concentration was measured 
using the BCA kit and BSA standards.  
 
2.16. Intracellular lipid measurements  
 
2.16.1. Oil red O staining 
 
Cells were seeded (1x106 cells/well of a 6 well plate) in complete DMEM/F-12 media. 
In total 6 wells were seeded/cell line to perform the Oil Red O staining in triplicate 
and have wells to perform cell counts in order to normalise to cell number. The 
following day working Oil Red O solution was prepared by mixing 3 parts Oil Red O 
stock solution (Sigma, O1391) with 2 parts dH2O. The working solution was left to 
stand for 10 minutes and then filtered through filter paper. Three wells/ cell line were 
washed with PBS and fixed in 10 % formalin (Sigma) for 45 minutes and then 
washed twice in deionised (dH2O). 60 % isopropanol was added to the cells for 5 
minutes. The additional three wells/cell line were trypsinised to determine the cell 
number/well. Working Oil Red O solution was then added to the cells for 10 minutes 
and then the cells were washed four times with dH2O. Fresh dH2O washed added to 
each well and images were taken using a Zeiss bright-field microscope. The wells 
were then dried, the stain was eluted with 100 % isopropanol and the absorbance at 
500 nm was measured using a Tecan microplate reader. The absorbance was then 
normalised to cell number.  
 
2.16.2. Cholesterol staining and quantification 
 
Cells were cultured in glass chamber slides (Nunc, 177402) and then treated with 
Cell Mask Orange Plasma Membrane Stain (Molecular Probes, Life Technologies, 
C10045; 1:1000) for 10 minutes at 37 °C. Cells were then washed in PBS, fixed with 
4 % PFA for 10 minutes and then washed with 0.1 % TBS-T. Cells were stained with 
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filipin (Sigma, 50 μg/ml) in PBS at room temperature for 1 hour in the dark. Cells 
were washed again with 0.1 % TBS-T and mounted onto coverslips using SlowFade 
Gold Antifade (Life Technologies, S36936). Random images were taken (10/cell line) 
using a Zeiss Live Cell microscope. Filipin staining was not assessed quantitatively 
because of its propensity to bleach extremely quickly and instead was used to 
assess cholesterol localisation. 
 
Intracellular cholesterol was measured for cell lines plated in triplicate in 2D cultures. 
Cells were trypsinised and collected. The cholesterol was measured using the 
Amplex Red cholesterol kit (Molecular Probes, A12216), following the manufacturer’s 
instructions. Cholesterol values were normalised to total protein content, measured 
by the BCA kit and BSA standards. 
 
2.17. SDS-PAGE and Western blotting 
 
Cells were harvested from 2D or 3D cultures, as previous described. Pellets were 
lysed on ice for 30 min in lysis buffer (50 mM Tris.HCl pH 7.5/150 mM NaCl/20 mM 
EDTA/0.5 % NP40) with a protease inhibitor tablet added (1 tablet/50 ml lysis buffer; 
Roche, 19543200) and 1 mM phenylmethylsulfonyl fluoride (Thermo Scientific), 1 
mM Dithiothreitol (Melford Laboratories), 1 mM sodium fluoride (Sigma), 1 mM -
glycerophosphate, 1 mM sodium pyrophosphate (Sigma) and 0.2 mM sodium 
orthovanadate (Sigma) added fresh. The cells were spun at 14,000 rpm, 4 °C for 20 
minutes. The protein lysate was retained and quantified using the BCA assay with 
BSA standards. 30 μg of total protein was then prepared with 4x sample buffer (8 % 
SDS/40 % glycerol/0.008% Bromophenol blue/20 % β-mercaptoethanol (added 
fresh)/250 mM Tris pH 6.8). The samples were denatured for 5 min at 95 °C and 
loaded to pre-cast gels 4-12 % Bis Tris (NUPAGE, NP0321BOX) gel, Novex Life 
Technologies).  The gels were resolved at 100V in MOPS (NUPAGE; NP0001) 
running buffer until desired separation had been achieved. 
 
The protein was then transferred from the gel to methanol-activated polyvinylidene 
fluoride membrane (Immobilon-P) using Mini Trans-Blot™ electrophoretic transfer 
cell system (BioRad Laboratories (UK) Ltd.) for 1 hr in Tris-Glycine buffer from 
Biorad, with 20 % methanol. Membranes were blocked for 1 h in 5 % milk in TBS-T 
(0.5 %).  After blocking the membranes were incubated with primary antibodies (in 1 
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% milk in TBS-T for all antibodies other than Cell Signalling antibodies which were 
made up in 5 % BSA in TBS-T) overnight at 4°C with agitation. Membranes were 
then washed for 10 minutes in TBS-T three times and incubated secondary antibody 
(in 1 % milk in TBS-T) for 1 hr at room temperature. Three 15 minute washes in TBS-
T were then performed, followed by 1 minute detection with enhanced 
chemiluminescence (ECL) western blot detection reagent (Amersham, RPN2106). 
Membranes were placed in acetate and exposed to X-ray film before developing 
using the Xograph Compact X4 automatic processor. The band intensities were 
measured using ImageJ software and normalised to the loading control.  
 
 
Table 2.1. List of primary antibodies used for Western blotting. 
 
Target Company Product Host Dilution 
Akt Cell Signalling 4691 Rabbit 1:1,000 
Ampk Cell Signalling 2532 Rabbit 1:1,000 
Beta-actin Sigma A5441 Mouse 1:10,000 
Erk Cell Signalling 9102 Rabbit 1:1,000 
LC3 Cell Signalling 2775 Rabbit 1:1,000 
p53 Vector VP-P956 Rabbit 1:2,000 
Phospho-Akt Cell Signalling 4090 Rabbit 1:1,000 
Phospho-Ampk Cell Signalling 2535 Rabbit 1:1,000 
Phospho-Erk Cell Signalling 4370 Rabbit 1:1,000 
Phospho-S6k Cell Signalling 9205 Rabbit 1:1,000 
S6k Cell Signalling 9202 Rabbit 1:1,000 
Srebf2 
 
 
Abcam 
Santa Cruz 
Santa Cruz 
ab30682 
sc-13552 
sc-5603 
Rabbit 
Mouse 
Rabbit 
1:200 
1:200 
1:200 
Vinculin Santa Cruz sc-73614 Mouse 1:200 
 
 
Secondary antibodies used were HRP-linked-anti-rabbit (1:2000; Cell Signaling, 
7074S) or anti-mouse (1:3000; Invitrogen, 626520). 
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2.18. Immunoprecipitation and binding partner analysis 
 
Cells were scraped and lysed in lysis buffer (20 mM Tris-HCl pH 7.4/0.2% NP-40/150 
mM NaCl/2 mM sodium vanadate; 500 µl/ 15 cm plate), with other proteinase and 
phosphatase inhibitors added as before on ice for 30 minutes, and lysates were 
collected and protein concentration measured as in section 2.17. Samples were pre-
cleared overnight by addition of 30 µl Dynabeads Protein A beads (10002D) to 5.5 
mg (1.5 ml) protein and rotation at 4 ˚C. The supernatant was then transferred to a 
new tube and the lysate was incubated with the antibody against p53 (Cell Signalling, 
2524; 1:500) or mouse IgG (IgG control, 7.5 µl/1.5 ml; Santa Crux, sc-2025) for 3 
hours at 4 °C with rotation. 30 µl beads were then added to the lysates and incubated 
for 1 hour 4 °C with rotation. The supernatant was then removed and the beads were 
washed three times in lysis buffer. The supernatant was removed again and the 
samples were treated as before (section 2.17) to elute and denature protein 
precipitated complexes but with 10 minutes boiling at 95 °C. Samples were run on 
gels as in section 2.17. 
 
The protein-binding partner analysis was performed by staining the gel with 
Coomassie blue R250 (Fischer) overnight at room temperature with shaking. The 
staining solution used was 45 % Methanol/10 % Acetic acid/45 % dH2O/3 g/L R250. 
The gel was then destained with destaining solution (5 % Methanol/7.5 % Acetic acid 
in dH2O) overnight. Bands were identified on the gel in the p53 mutant lanes and 
sent for mass spectrometry analysis and protein identification (Cambridge Centre for 
Proteomics). Protein binding partners of the p53 mutants were identified based on 
whether they were detected in the bands sent for Mass Spectrometry analysis 
(R172H or R270H sample) but not in the IgG control lane, which was analysed in 
parallel.  
 
To confirm pull-down of p53, or to investigate whether Srebf2 was co-precipitated, 
western blotting of gels following immunoprecipitation was also. Western blotting was 
performed and antibodies were used were as in section 2.17. 
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2.19. Srebf2 knockdown 
 
5 g of construct was reconstituted in 100 l ultra-pure H2O. DH5 competent cells 
(New England Biolabs, 50 l) were transformed with 1 l construct for plasmid 
expansion. Briefly, cells were mixed with DNA and incubated on ice for 15 minutes, 
heat-shocked at 42 °C for 2 minutes and then incubated on ice for a further 30 
minutes. Bacteria were grown up in 1 ml LB broth and incubated at 37 °C with 
shaking (300 rpm) for 1 hour. Bacteria were then spun down and resuspended in 100 
l LB broth and spread onto a LB agar + Kanamycin (30 µg/mL) plate. The plate was 
incubated overnight at 37 °C. A single colony was picked the following day and 
grown up in 5 ml LB broth at 37 °C with shaking for 8 hours and then the 5 ml was 
added to 200 ml LB broth with kanamycin and the bacteria were grown up overnight 
at 37 °C. A Maxiprep (Qiagen, 12663) was performed to extract DNA. 
 
Cells were transiently transfected with 10 g green fluorescent protein (GFP)+ 
shRNA plasmids (TG510683A-D), or control non-targeting sequence (TR30013) from 
Origene; transfection as previously described (Section 2.3.4). 48hrs after 
transfection, cells were sorted for GFP positivity by the Flow Cytometry team (CIMR 
and MRC) and 50,000 GFP+ cells seeded in the Matrigel/DMEM-F12 mix. Colony 
size was measured 72 hrs after seeding and cells collected for RNA extraction as 
previously described (section 2.6).  
 
 
2.20. Analysis of publically available datasets 
 
2.20.1. ChIP datasets 
 
ChIP datasets were analysed for the identification of potential Srebf and p53 targets 
from http://chip-atlas.org (Srebf2 and p53) and Fischer et al. 2017 (p53). 
 
2.20.2. TCGA lung adenocarcinoma dataset 
 
Lung adenocarcinoma patient TCGA (Cancer Genome Atlas Research, 2014) data 
was downloaded from cBioportal (http://www.cbioportal.org). Cases which had TP53 
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mutations were selected and these cases were subdivided further based on whether 
the TP53 mutation was a conformational, contact or non-missense mutation, or was 
unclassified. The classification of mutations into conformational or contact classes 
was performed using structural studies on the p53 DNA-binding domain. If the 
mutation occurred in a residue that directly contacted the DNA it was classified as a 
contact mutation, whereas if the mutation did not occur at a residue that directly 
contacted the DNA but instead had more effects on the overall structure of the 
protein it was classified as conformational (Cho et al., 1994; Joerger et al., 2006; 
Joerger and Fersht, 2007).  The expression of MVA pathway genes (RNA Seq V2 
RSEM) was analysed in these samples. Significance was calculated based on 
Significance Analysis for Microarrays (SAM) platform (Tusher et al., 2001), within 
Multiple Experiment Viewer (MeV). 
 
2.21. Statistical analysis 
 
All statistical analyses were performed using Prism 5.0 software (Graph Pad) unless 
otherwise indicated, with P < 0.05 considered statistically significant. P values for 
unpaired comparisons between two groups with comparable variance were 
calculated by two-tailed Student’s t-test. One-way ANOVA (between genotypes) was 
used for analysis between three groups with comparable variance, followed by 
Bonferroni post-test for individual comparisons. Two-way ANOVA (between 
treatments and genotypes) was used for analysis between data with two independent 
variables, followed by Bonferroni post-test for individual comparisons. Kaplan–Meier 
comparison with a Log-rank (Mantel-Cox) test was used for analysis of survival 
cohorts. Significance of altered canonical pathways and molecular functions was 
calculated by Fischer’s Exact test (within IPA) and SAM (Tusher et al., 2001), within 
MeV or a Student’s t-test was used to calculate significance of gene expression data 
as indicated. 
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3. Generation and transcriptional profiling of murine 
lung tumour cells 
 
3.1. Introduction 
 
Mouse models of cancer are frequently utilised to understand the mechanisms of 
tumour development and to assess how the tumours respond to therapy. They 
enable the accurate assessment of the effect of genetic alterations on tumour 
progression as well as the impact of drugs in an in vivo system with a functional 
immune system and a tumour microenvironment (Frese and Tuveson, 2007).  
 
In order to investigate the impact of p53 mutations in lung tumours we used a well-
established mouse model of lung adenocarcinoma (Kraslox-stop-lox(LSL)-G12D), in which 
the formation of the lung tumours is driven by mutant KrasG12D, a frequent driver 
mutation in lung adenocarcinoma (Cancer Genome Atlas Research, 2014; Jackson 
et al., 2001). KrasG12D expression can be induced in the lungs following the 
administration of a recombinant adenovirus expressing Cre recombinase (Adeno-
Cre). Cre expression leads to the removal of the stop codon proceeding the KrasG12D 
gene, thus activating the expression of the mutant allele in the targeted tissue. This 
KrasG12D-driven model of lung adenocarcinoma recapitulates the human disease as 
tumorigenesis is driven by the sporadic activation of mutant Kras which is expressed 
from its endogenous promoter (Jackson et al., 2005; Jackson et al., 2001; Junttila et 
al., 2010; Kerr et al., 2016). In addition, the administration of the Adeno-Cre allows 
for the control of the number of tumours formed and the timing and tissue-specificity 
of tumour initiation (Jackson et al., 2001).  
 
In the model used, the status of p53 can also be manipulated by generating 
compound mice with conditional mutations in Kras and p53 (Jackson et al., 2005). 
These compound mice develop more aggressive lung adenocarcinomas with shorter 
latency, and these lesions are considered to closely recapitulate those seen in 
humans (Jackson et al., 2005). In addition, incorporation of a conditional p53ERTAM 
allele into the compound mice enables the 4-hydroxytamoxifen (4OHT)-controlled 
restoration of wild-type p53 function at will (Christophorou et al., 2005). 
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The aim of this chapter is to utilise the KrasG12D-driven lung adenocarcinoma model 
with different p53 deficiencies to investigate the impact of p53 mutations on 
transcriptional programs. To achieve this, I will compare the transcriptional profiles of 
murine lung tumour cultures generated from independent lung tumours of distinct p53 
genotypes and ascertain whether different p53 mutations (R172H and R270H) have 
gain-of-function (GOF) or dominant-negative (DN) transcriptional effects in lung 
tumour cells. 
 
3.2. Results 
 
3.2.1. Generation of p53 mutant tumours of different p53 
deficiencies 
 
Three distinct compound mice were generated: 1) KrasLSL/G12D/+;p53Fx/Fx,  2) KrasLSL-
G12D/+;p53LSL-R172H/Fx
 
and 3) KrasLSL-G12D/+;p53LSLR270H/Fx. I administered Adeno-Cre 
intranasally to induce the expression of oncogenic Kras in the lungs, which drives the 
formation of the tumours. Adeno-Cre administration also induces recombination of 
the LoxP sites placed within the p53 locus: in 1) the exons 2-10 of the wild-type p53 
allele flanked by two lox sites (p53LoxP) are deleted whereas in 2) and 3) the stop 
codon is removed, leading to the endogenous expression of the conformational p53 
mutant R172H or the contact mutant R270H (corresponding to codons 175 and 273 
in human cancers, Figure 3.1), respectively (Jackson et al., 2005; Jonkers et al., 
2001). Therefore the final genotypes of the lung tumours formed in this Fx model are 
KrasG12D/+;p53-/-, KrasG12D/+;p53R172H/-
 
and KrasG12D/+;p53R270H/- which will be referred 
to as Null, R172H and R270H for simplicity.  This model, referred to as the ‘Fx model’ 
in the text, was used to investigate the GOF effects of different p53 mutations in lung 
tumours: R172H and R270H compared to Null. 
 
Furthermore, another variation of this murine lung adenocarcinoma model was also 
generated. In this second model, instead of a p53Fx allele, the mice also express a 
switchable p53 allele (p53ER) that enables the restoration of wild-type p53 function in 
a time-controlled manner, following the administration 4OHT. The p53ER protein is 
always expressed in the tumour cells but whether it is functionally active or not  
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Figure 3.1. p53ER and p53Fx lung tumour models. 
 
Mice of the above genotypes were administered Adeno-Cre (Cre) intranasally to drive 
the Cre-induced recombination of the Kras and p53 alleles in the lungs. KrasG12D;p53-
null, -R172H and -R270H tumours were generated in either the p53Fx (upper) or p53ER 
(lower) model.  Lung tumours or cultures generated from lung tumours were analysed in 
vitro and in vivo. Wild-type p53 function can be restored in the ER model via 
administration of 4OHT (see Figure 1.9). 
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depends on the administration or removal of 4OHT respectively (Figure 1.9, 3.1; 
Christophorou et al., 2005). Therefore, the final genotypes of the lung tumours 
formed in these mice are KrasG12D/+;p53-/ER, KrasG12D/+;p53R172H/ER
 
and 
KrasG12D/+;p53R270H/ER and these will also be referred to as Null, R172H and R270H. 
Whether these terms refer to the ‘ER model’ or the ‘Fx model’ will be indicated.  This 
ER model will enable me to simultaneously investigate both the GOF (absence of 
4OHT) and DN effects (presence of 4OHT) of different p53 mutations in lung 
tumours.  
 
In my study lung tumours (from the Fx and ER models) were collected for analysis of 
the different p53 genotypes at endpoint, when the animals displayed visible signs of 
tumour burden (reduced activity, laboured breathing, hunched posture), with the 
latency period being 16-18 weeks post-Adenocre infection. Each animal develops 
multiple, independent lung tumours which can be analysed (Figure 3.2). All animals 
in our experimental cohorts were re-genotyped; PCRs were run on genomic DNA 
extracted from the tails of the mice for the p53mutant, p53ER and p53Fx alleles and the 
p53 gene was also sequenced. Figure 3.3A,B shows examples of the PCR and 
sequencing results obtained from the tails of the animals with different p53 
genotypes. 
 
3.2.2. Isolation and characterisation of p53 mutant and null lung 
tumour cell lines 
In order to profile the transcriptional effects of p53 mutations we generated multiple 
lung tumour cell lines from independent, late-stage lung tumours. We hypothesised 
that the utilisation of multiple, independent cell lines that endogenously express 
mutant p53, or that are p53 null, would be a robust way to analyse the transcriptional 
and functional effects of p53 mutations in lung tumour cells.  
 
KrasG12D/+;p53-/ER (Null),  KrasG12D/+;p53R172H/ER (R172H) and KrasG12D/+;p53R270H/ER 
(R270H) lung tumour cell lines were generated prior to the start of my research 
project. In addition to these cell lines, I also generated KrasG12D/+;p53-/- (Null),  
KrasG12D/+;p53R172H/- (R172H) and KrasG12D/+;p53R270H/- (R270H) lung tumour cells 
lines from the ‘Fx model’ to further investigate and validate the GOF phenotypes 
identified.  
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Figure 3.2. Lung tumour burden 
 
Representative H&E images of p53 null, R172H and R270H lung 
sections. Multiple independent lung tumours are formed/animal. Scale 
bar: 2 mm.  
 
Null
R172H
R270H
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Figure 3.3. Validation of genotypes of lung tumour mice. 
 
A. PCRs were performed to test for the presence of the p53Fx (upper), p53ER 
(middle) and p53WT/Mut (lower) alleles in the experimental animals (unrecombined). 
B. Sequencing of the p53 locus confirms the presence of the corresponding p53 
mutation in the R172H and R270H animals. Negative control: -ve; positive control: 
+ve; non-template control: NTC. 
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When generating the cell lines from the tumours, epithelial lung tumour cells were 
separated from tumour-associated fibroblasts by exploiting their differential 
attachment rates. I assessed expression of epithelial cell adhesion molecule 
(EpCAM; epithelial marker) and platelet-derived growth factor (Pdgfr; fibroblast 
marker) by flow cytometry to confirm epithelial populations based on a low 
percentage of Pdgfr-positive cells (<8%; Figure 3.4A,B). I also confirmed the 
genotypes of the murine lung tumour cell lines by PCR analysis and sequencing for 
presence of the p53 mutation Figure 3.4C,D). Immunoblot analysis also confirmed 
the expression of the mutant p53 protein in the R172H and R270H cell lines (Fx and 
ER). The expression of p53ER was at lower levels than that of the mutant p53 (Figure 
3.4E). 
 
Next, I measured the proliferation rates of the lung tumour cell lines generated to 
ensure the cell lines were all growing efficiently after isolation.  The cell lines all grew 
well in 2D culture, with some cell lines growing faster than others but no overall 
genotype-specific difference in growth rates in either the ER or Fx model (Figure 
3.5A). However, for transcriptional and functional analysis we decided to 
predominately utilise a Matrigel-based 3D culture system. 3D cultures are considered 
to better recapitulate the in vivo environment as cells are grown on a more 
physiologically relevant structure with cell-matrix interactions  (Pampaloni et al., 
2007). All lung tumour cells grew well in Matrigel when seeded at 50,000 cells in 100 
l of a 3:2 Matrigel/media mix, forming spheroid colonies. Again I observed no 
genotype-specific difference in growth in these 3D cultures using cells from both Fx 
and ER models (Figure 3.5B). 
 
3.2.3. Transcriptional impact of p53 mutations in lung tumour 
cultures 
 
Transcriptome (microarray) analysis on four independent cell lines/genotype (p53 
null, R172H and R270H; ER model), cultured in 3D Matrigel was performed by the 
lab prior to my arrival. Utilisation of the ER model enabled the investigation of the 
transcriptional effects induced by the R172H conformational and R270H contact p53 
mutations in the presence (4OHT, p53 On; DN) and absence (vehicle, p53 Off; GOF) 
of wild-type p53.  
 54 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4. Generation and characterisation of lung tumour cell lines. 
 
A. Representative data showing EpCAM (epithelial marker; left) and Pdgfra (fibroblast 
marker; right) expression in murine lung tumour cell lines (Epithelial) and mouse 
embryonic fibroblasts (MEFs; Fibroblasts) based on FACS analysis. B. Percentage of 
Pdgrfa-positive cells for the lung tumour cell lines (Fx model). Epithelial cells were used 
as a negative (-ve) and MEFs as a positive (+ve) control. A,B. Two independent repeats 
were performed/cell line.  C. PCRs were performed to test for the presence of the p53Fx 
(upper), p53ER (middle) and p53WT/Mut (lower) alleles in the Fx and ER cell lines 
(recombined). Negative control: -ve; positive control: +ve; non-template control: NTC. D. 
Sequencing of the p53 locus confirms the presence of the corresponding p53 mutation 
in the R172H and R270H ER and Fx cell lines. E. Expression of mutant p53 and p53ER 
proteins in p53 null, R172H and R270H ER cell lines (upper) and the mutant p53 in Fx 
cell lines (lower), assessed by immunoblot analysis. Beta-actin (Actb) was used as 
loading control. Two independent repeats were performed/cell line.  
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Figure 3.5. Characterisation of the growth of lung tumour cell lines. 
 
A. Cells were seeded in 2D and the viable cell growth was assessed over time 
by trypan blue exclusion; left, ER cells; right, Fx cells. Representative data is 
shown for two independent cell lines of the indicated genotypes from the ER 
model (of n=4 cell lines assessed/genotype) and the Fx model (of n=3 cell lines 
analysed/genotype). Symbols depict average cell number for a cell line SD of 
triplicates. B. Upper, Representative images of p53 null and mutant cell lines 
grown in 3D Matrigel culture. Lower, viable cell number of p53 mutant and null 
cell lines seeded at 50,000 cells/well in Matrigel, assessed by trypan blue 
exclusion after 72 hrs. Cell number values relative to the null average are 
shown. Symbols represent independent cell lines of the indicated genotypes 
(Fx, squares; ER circles) and genotype average is shown SEM. P>0.05, One-
way ANOVA. A minimum of two independent repeats were performed/cell line, 
with each cell line performed in triplicate in each experiment. 
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First, to establish if there are general mutant p53 transcriptional GOFs we compared 
the expression profiles of the p53 null (n=4) and p53 mutant (conformational and 
contact mutants combined, n=8) cell lines in the basal setting (vehicle) to identify 
whether there were transcriptional effects of the p53 mutants. The expression of 
anumber of genes was altered in p53 mutant cells compared to p53 null (Figure 
3.6A). We applied a cut-off of a 1.4 average fold-change (FC) in expression and a 
standard deviation of <0.5 between expression values of cell lines of a single 
genotype to account for intragenotype variation observed for some genes.  Using this 
analysis, we found 465 genes altered in p53 mutant cells compared to p53 null cells, 
indicative of p53 mutant GOF at a transcriptional level. Moreover, after further 
analysis of our transcriptome data, what struck me as particularly interesting and 
unexpected were the differences in the transcriptional profiles of lung tumour cells 
expressing the contact or the conformational mutant p53. We observed that the 
expression of many gene (n=972) was altered between lung tumour cell lines of 
distinct p53 mutational status (R172H and R270H; >1.4 average FC and <0.5 SD 
between samples in each group), indicating that individual p53 mutants have different 
functions in lung tumour cells (Figure 3.6B). 
 
Finally, we analysed the transcriptional impact of the p53 mutations in the presence 
of wild-type p53 to establish whether wild-type p53 was still able to function in the 
presence of p53 mutations. We compared the transcriptional profiles of our p53 null 
cells and p53 R172H and R270H cells after wild-type p53 restoration (2 hrs and 8 
hrs). Two time points of wild-type p53 restoration were used to help distinguish 
between direct (2 hrs) or indirect (8 hrs) wild-type p53 targets. As with our previous 
analysis we applied a 1.4FC cut-off between control and p53 restoration expression 
values with a standard deviation limit of 0.5 to exclude intra-genotype variability. 
Subsequently, we identified a subset of genes that were similarly induced or 
repressed in p53 null and p53 mutant lung tumour cells after wild-type p53 
restoration. Eleven of these genes were altered 2 hrs after p53 restoration (Figure 
3.7, upper) and 87 (including the 2 hrs subset) after 8 hrs restoration (Figure 3.7, 
lower). Importantly, many of these similarly regulated genes are known p53 targets 
(based on literature searches; (Bieging et al., 2014; Fischer, 2017a; Lehar et al., 
1996; Lo et al., 2001; Okamoto and Beach, 1994; Quintens et al., 2015; Utrera et al., 
1998); www.chip-atlas.org) including all the genes in the 2 hrs subset, which are 
likely to represent direct p53 targets. 
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Figure 3.6. p53 mutations display transcriptional GOF when 
compared to p53 null and also p53 mutant-specific effects. 
 
A. Genes that are differentially expressed in p53 mutant (n=8) and 
p53 null (n=4) lung tumour cell lines are displayed in the heatmap. 
B. Genes differentially expressed between lung tumour cells with a 
R172H or a R270H mutation are shown. A,B. Each individual 
square in each row corresponds to an independent cell line. The 
microarray analysis was performed on one sample/cell line but n=4 
cell lines were analysed/genotype.  MeV was used to generate the 
heatmaps and the software normalised genes/row: Value=[(Value)-
Mean(Row)]/SD(Row). The minimum and maximum normalised 
expression values and their corresponding colours are shown in 
the scale bars. 
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However, despite a large subset of genes being similarly regulated by wild-type p53 
in p53 null and mutant cells, upon further analysis of our transcriptome data some 
genotype-specific transcriptional effects induced by WT p53 in lung tumours cultures 
were identified. By performing comparative analysis of the genes altered by wild-type 
p53 across the different genotypes we concluded that after 2 hrs wild-type p53 
restoration there are 27, 1 and 11 genes uniquely altered in p53 null, R172H and 
R270H cells respectively. At the 8 hrs time point this is increased to 213, 46 and 257 
genes for the respective genotypes (Figure 3.8A). This indicates that there are 
genotype-specific effects following WT p53 restoration which include potential DN 
effects of p53 mutations on wild-type p53. 
 
Taking the subset of genes that are not altered after 8 hrs of wild-type p53 restoration 
in R172H cultures (213+90) and R270H cultures (213+27) I assessed the DN effect 
of the p53 mutants. I classified these genes further based on whether a similar trend 
the (>1.2FC) was observed for the genes in the p53 mutant cells compared to the 
p53 null cells after restoration (decreased ability) or whether there was complete 
failure (<1.2FC) of the induction or repression of these genes. In some cases, the 
reason for the decreased ability or complete failure for the wild-type p53 to induce or 
repress the genes in the mutant cells was because the basal levels of expression in 
the p53 mutant cells were similar to those in the p53 null cells after restoration 
(<1.4FC between mutant p53 Off and Null p53 On; wild-type-like). In all cases a 
standard deviation limit of 0.5 was imposed as before and a small number of genes 
were excluded based on this. As a result, we observed DN effects for both mutants, 
Figure 3.7. Wild-type p53 restoration similarly induces or represses a subset of 
genes in p53 mutant and null cells. 
 
Microarray analysis was performed on p53 mutant and null cell lines after Ctrl treatment 
(p53 Off) or 2 hrs or 8 hrs wild-type p53 restoration (p53 On). Genes that are similarly 
induced or repressed by WT p53 in mutant p53 and null cells at 2 hrs (n=11, upper) or 8 
hrs (n=87, lower) are depicted in the heatmap. Genes identified as known p53 targets are 
highlighted in blue (see sections 2.7.4 and 2.19.1). Each individual square in each row 
corresponds to an independent cell line. MeV was used to generate the heatmaps and 
the software normalised genes/row: Value=[(Value)-Mean(Row)]/SD(Row). The relative 
minimum and maximum expression values are the limits of the scale bars which are 
shown. 
The microarray analysis was performed on one sample/cell line/condition but n=4 cell 
lines were analysed/genotype for each condition. Work on the analysis of commonly 
regulated genes was performed with the help of Emma Kerr and David Shorthouse. 
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some common and some mutant-type specific, as well as interestingly some wild-
type-like function of p53 mutants (Figure 3.8B-D).  
 
In conclusion, we have utilised genetically modified mice to model KrasG12D-driven 
lung tumorigenesis in the background of various p53 deficiencies. Multiple lung 
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Figure 3.8. p53 mutants display DN effects on wild-type p53 transcriptional 
function. 
 
A. Venn diagrams depict the number of genes altered after 2 hrs (left) or 8 hrs (right) of 
wild-type p53 restoration for the cell lines of different p53 status. Shaded regions 
represent genes changed in the null but not in R172H (green), R270H (red) or both 
mutants (yellow) after 8 hrs p53 restoration. B. Classification of genes altered in the p53 
null cells but not in the R172H or R270H cells (A) following 8 hrs wild-type p53 
restoration to assess DN functions. C. Heatmaps depict examples of DN (left) and wild-
type-like (right) effects of mutant p53 for the R172H mutant and the R270H mutant. 
Previously identified targets are shown in blue (see sections 2.7.4 and 2.19.1). MeV was 
used to generate the heatmaps and the software normalised genes/row: 
Value=[(Value)-Mean(Row)]/SD(Row). The minimum and maximum normalised 
expression values are the limits of the scale bars which are shown. 
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tumour cell lines were generated from independent, advanced lung tumours of 
different p53 genotypes which enabled us to characterise the transcriptional impact 
of p53 mutations in vitro, both in the presence and absence of wild-type p53.  
 
Based on our initial transcriptome analysis we devised a model of the impact of p53 
mutations in lung cancer to test (Figure 3.9). We hypothesised that: 
 
1) R172H and R270H mutations exhibit common GOFs in lung tumour 
development culminating in different phenotypes of p53 mutant and null 
tumours. 
2) p53 mutations may exert inhibitory effects on wild-type p53 (DN), which may 
also influence the mutant p53 lung tumour phenotype.  
3) R172H and R270H mutants may function distinctly in lung tumours. 
 
We further hypothesised that by characterising the impact of p53 mutants in lung 
tumour cell cultures and ultimately advanced lung tumours, we may uncover novel 
therapeutic vulnerabilities of p53 mutant lung tumours. 
 
3.3. Discussion 
 
Previous studies have identified oncogenic effects of p53 mutants, covering a range 
of cancer types (Adorno et al., 2009; Freed-Pastor et al., 2012; Muller et al., 2009; 
Muller et al., 2013; Sauer et al., 2010; Sorrentino et al., 2014; Weissmueller et al., 
2014; Zhang et al., 2013a). However, the majority of these studies were based on 
investigation into the effect of mutant p53 in cell lines by either over-expressing 
mutant p53 in p53 null cell lines or knocking down mutant p53 in p53 mutant cell 
lines. In contrast, we wanted to avoid using non-physiological conditions such as 
over-expression. In addition, mutant p53 knock-down in cells may have detrimental 
effects on the growth of the cells if they evolved in tumours which were addicted to 
the mutant p53. Therefore, we focussed our investigations on comparing multiple, 
independently evolved cell lines which endogenously expressed mutant p53 or were 
p53 null. By using multiple independent cell lines/genotype that exhibited an array of 
other different mutations and alterations we hypothesised that any p53 genotype- 
dependent phenotypes that were identified would be robust and more likely to 
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translate into similar phenotypes in vivo. Moreover, our model enabled us to 
investigate the effects of p53 mutations in the presence and absence of wild-type 
p53, enabling us to extend our investigations to include the DN effects as well as 
GOFs of mutant p53. Through use of these models we aimed to provide the first 
comprehensive analysis of the impact of distinct p53 mutations in this cancer type. 
 
Importantly, our transcriptome data also highlighted potential differences in the 
function of distinct p53 mutations. Such differences have been largely overlooked so 
far, with both types of p53 mutation considered to result in a loss-of-wild-type function 
(Joerger and Fersht, 2007) and with the majority of GOFs described as general 
functions of mutant p53 (Adorno et al., 2009; Freed-Pastor et al., 2012; Muller et al., 
2009; Muller et al., 2013; Sorrentino et al., 2014; Weissmueller et al., 2014; Zhang et 
p53mut
p53null
p53WT
p53R172H
p53R270H
Accelerated lung
tumour progression
GOF?
DN?
=?
Therapeutic vulnerabilities?
Figure 3.9. Model predicting the effects of p53 mutations in lung tumours 
based on transcriptional data.  
 
The schematic depicts the hypothesised effects of p53 mutations in lung tumours 
based on transcriptional data. p53 mutants may exert gain-of-function (GOF) or 
dominant-negative (DN) effects to promote tumorigenesis. Mutant-specific effects 
may also exist.  
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al., 2013). Characterisation of the potential functional distinctions between p53 
mutations is required as they may highlight mutant-specific therapeutic vulnerabilities 
in a class of tumours which are currently considered as one entity in the clinic.  
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4. Defining mutant p53 gain-of-functions in lung 
tumours 
 
4.1. Introduction 
 
As discussed in Chapter 1.2.2, gain-of-functions (GOFs) of mutant p53 that have 
been previously described often involve mutant p53 manipulating growth factor 
signalling pathways (Adorno et al., 2009; Muller et al., 2009; Muller et al., 2013; 
Sauer et al., 2010; Weissmueller et al., 2014) and generally result in a more 
aggressive phenotype relative to p53 loss. Further work into characterising the 
oncogenic effects of p53 mutations in lung cancer is required as it may provide 
insight into how to target these p53 mutant lung tumours. 
 
Previously, it was shown that KrasG12D-p53 mutant lung tumours were a similar grade 
to their p53 null counterparts, arguing against additional oncogenic functions of 
mutant p53 in lung tumours (Jackson et al., 2005). However, the authors report that 
KrasLSL-G12D-p53LSL-mutant/Fx animals had an increased mortality following Adeno-Cre 
infection compared to KrasLSL-G12D-p53Fx/Fx animals. This was not due to differences 
in the lung tumours formed but instead was explained by an enhanced susceptibility 
to forming adenocarcinomas in the upper respiratory tract.  These findings suggest 
that there are additional, oncogenic functions of p53 mutants. Our initial 
transcriptome analysis of multiple p53 mutant and null lung tumour cultures indicates 
that p53 mutants can exert additional effects in lung tumour cells (Figure 3.5A). 
 
Therefore, the aim of this chapter was to compare our p53 null, R172H and R270H 
murine lung tumour cell lines and endogenous lung tumours to investigate the 
potential GOF effects of p53 mutations in lung cancer. 
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4.2. Results 
 
4.2.1. Functional profiling of p53 mutant and p53 null lung 
tumour cells 
 
As described in Chapter 3, our transcriptome analysis lead to the identification of 465 
genes that were differentially expressed between p53 mutant (conformational and 
contact, n=8 cell lines) and p53 null (n=4 cell lines) 3D cultures (Figure 3.5A). Next, I 
sought to analyse which pathways may be altered by the presence of p53 mutations 
by performing pathway analysis on the differentially expressed genes.  Through 
ingenuity pathway Analysis (IPA), the top significant molecular functions altered were 
cellular survival, movement and proliferation and cell cycle regulation. More 
specifically, when I analysed the canonical pathways it was various growth factor 
signalling pathways that were the top significantly altered pathways in p53 mutant 
cells, such as phosphoinositide-3-kinase/Akt, 14-3-3 and nerve growth factor (NGF) 
signalling (Figure 4.1A).  
 
Next, I proceeded to assess whether there was a functional difference between the 
p53 mutant and null lung tumour cells. I assessed levels of phospho(p)-Akt, a read-
out of PI3K/Akt pathway activity, but observed no difference in p-Akt levels between 
cells of the different p53 genotypes (Figure 4.1B). This result suggested that activity 
of this pathway is not altered between p53 null and mutant cells despite genes 
involved in these pathways being differently expressed. At the same time, I assessed 
p-Erk levels, which is downstream of many growth factor signalling pathways but 
similarly observed no genotype-specific difference (Figure 4.1B). As previously 
shown, we found no difference in the growth of p53 mutant and null cells in 2D or 3D 
cultures (Figure 3.4).  
 
An oncogenic function of mutant p53 that has been frequently reported is an 
enhanced invasive potential of mutant p53 tumour cells, relative to p53 null cells 
(Adorno et al., 2009; Freed-Pastor et al., 2012; Muller et al., 2009; Muller et al., 2013; 
Weissmueller et al., 2014). Therefore, next I assessed the ability of the lung tumour 
cells to form colonies in the 3D Matrigel culture when seeded at a low density (5,000 
cells/100l Matrigel/Media mix). I hypothesised that the presence of the mutant may 
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Figure 4.1. Analysis of growth-factor signalling in p53 mutant cells (ER model). 
 
A. Pathway analysis was performed on genes that were differentially regulated 
(>1.4FC and <0.5 SD cut-off between samples in each group) between the p53 mutant 
and p53 null lung tumour cell lines. Top molecular functions (left) and canonical 
pathways (right) significantly altered in p53 mutant cells compared to p53 null cells. 
Statistical significance was determined by Fisher’s exact test. B. Expression of p-Akt 
and p-Erk, and their corresponding total proteins, was analysed in lung tumour cell 
lines of indicated p53 genotypes (ER cells shown). -actin (Actb) and vinculin were 
used as a loading controls.  
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increase the cells’ ability to survive and form colonies, indicative of their colonisation 
potential in vivo.  Using multiple independent cell lines from both ER and Fx models 
we did notobserve a significant increase in the size or number of p53 mutant colonies 
compared to p53 null, demonstrating that the mutant p53 was providing no extra 
growth advantage in 3D cultures, nor did we observe a difference in the morphology 
of the colonies (Figure 4.2A).  
 
In addition, we performed scratch assays to assess the migratory capacity of the cell 
lines (done in collaboration with Emma Kerr). We observed a trend towards 
enhanced movement of the p53 mutant lung tumour cells across a 2D surface 
compared to p53 null cells but no significant difference (Figure 4.2B). I proceeded to 
assess the invasive potential of the lung tumour cell lines in 3D cultures by 
performing invasive growth assays, using a similar Matrigel-based culture to that 
used for the transcriptome analysis. However, p53 null and mutant lung tumour cells 
were similarly invasive through Matrigel (Figure 4.2C).  
 
Finally, we transplanted p53 null, R172H and R270H cell lines that I engineered to 
express luciferase into wild-type mice to assess their ability to survive, colonise the 
lung and form lung tumours. I measured the impact of mutant p53 on the location and 
burden of the tumours, and subsequent survival of the mice that formed lung 
tumours. I  observed no difference in any of these parameters when comparing 
animals that were transplanted with lung tumours cells expressing a conformational 
or contact mutant p53 or p53 null cells (Figure 4.3).  
 
4.2.2. p53 null, R172H and R270H lung tumours are similarly 
aggressive 
 
Data from our cell lines indicate that p53 mutant and null lung tumour cells are 
similarly aggressive. To assess whether there were any differences in the 
endogenous p53 mutant and null lung tumours, I infected ‘Fx’ mice with AdenoCre, 
sacrificed the animals 16 weeks post-infection and compared the murine p53Mutant/Fx 
and p53Fx/Fx  lung tumours. The time point of 16 weeks was chosen as the end point 
as the animals were displaying moderate signs of lung tumour burden. Animals 
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Figure 4.2. p53 mutant cells do not exhibit increased invasiveness compared to p53 
null cells. 
 
A. Average size of colonies (left) and number of colonies (right) formed when cells were 
seeded at low density (5,000/ well). Values are relative to a randomly picked reference. 
Colony size was measured after 72 hrs using ImageJ software. and genotype average is 
shown SEM. Ns: non-significant, P>0.05, One-way ANOVA. B. Migrational potential of p53 
mutant and null lung tumour cell lines was assessed by measuring the distance travelled in 
one direction/time over 24 hrs after an initial scratch was made in the cell monolayer. Left, 
representative images of p53 null and mutant cell lines migrating over time to close the 
scratch. Scale bar: 300 m. Right, velocity of p53 mutant and null cell lines with the average 
value shown/genotype SEM. A,B. Symbols represent independent cell lines of the 
indicated genotypes (Fx, squares; ER circles). C. Invasive growth assays were performed on 
p53 mutant and null colonies in Matrigel (ER cells shown). Left, representative images of z-
stack slices used to assess the ability of the colonies to invade through Matrigel. Scale bar: 
200 m. Right, percentage of colonies that invaded >120m through the Matrigel was 
calculated. Representative data shows one cell line/genotype with the average of replicates 
SD shown. Ns: non-significant, P>0.05, One-way ANOVA. 
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Figure 4.3. Transplantation of p53 mutant cells, compared to p53 null, did not 
reduce host survival 
 
Mice were transplanted with luciferase-expressing p53 null and mutant lung tumour 
cells (a minimum of 5 animals/cohort). A. Tumour growth was monitored by in vivo 
bioluminescence imaging with example images of lung tumour burden shown. B. 
Average luciferase activity/genotype 7 (left) and 14 days (right) after transplantation 
SEM. C. Percentage lung tumour burden at endpoint with the average value 
shown/genotype SEM D. Survival (upper) and tumour location (lower) after 
transplantation with null or mutant lung tumour cells. All animals shown had lung 
tumours at endpoint (one cell line/genotype). Additional tumours were occasionally 
found on the rib cage and in the chest cavity (thoracic tumours). Log-rank (Mantel-Cox) 
test. B,C. Ns: non-significant, P>0.05, One-way ANOVA. 
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showed similar signs of disease at this stage regardless of the p53 genotype, 
indicating a similar tumour latency of p53 mutant and null lung tumours.  Consistent 
with this I observed comparable lung tumour burden in p53 mutant and null lung 
tumours, measured by percentage tumour coverage and number of lung tumours 
(Figure 4.4A,B). In addition, p53 mutant and null lung tumours displayed similar 
levels of proliferation as measured by Ki67 staining (Figure 4.4C).  
 
In summary, I performed extensive analysis of the impact of different p53 mutations 
(conformational and contact) on cancer-associated phenotypes in lung tumour cells 
but observed no significant genotype-specific difference across multiple independent 
p53 mutant and null cells. Moreover, endogenous R172H or R270H p53 mutant 
expression does not affect the aggressiveness of the lung tumours, as p53 null, 
R172H and R270H show comparable lung tumour burden at endpoint as well as 
latency and proliferation levels in the tumours.  
 
4.3. Discussion 
 
Our data on the comparison of p53 null and mutant lung tumours and corresponding 
cell lines is inconsistent with the effect of p53 mutations in other cancers where the 
mutant p53 was shown to increase the growth and invasiveness of tumour cells 
(Freed-Pastor et al., 2012; Muller et al., 2009; Muller et al., 2013; Weissmueller et al., 
2014), and tumours (Lang et al., 2004; Olive et al., 2004). As mentioned earlier, the 
discrepancy between the phenotypes of the tumour cell lines is probably explained 
by the use of endogenous p53 mutant and null cell lines compared to using mutant 
p53 over-expression or knock-down. Previous studies which have demonstrated a 
GOF effect of p53 mutations in vivo have compared p53 null mice with mice that 
express mutant p53 throughout the body (Lang et al., 2004; Olive et al., 2004). The 
mutant p53 animals have a predisposition to develop a different spectrum of tumours 
relative to p53 null. Therefore, it is likely that the p53 mutations have tissue specific 
effects. Instead our data, along with previously published data, indicates that there is 
no difference in the aggressiveness of p53 mutant and lung null lung tumours 
(Jackson et al. 2005). However, Jackson et al. report an increased mortality of 
KrasLSL-G12D- p53LSL-mutant/Fx animals compared to KrasLSL-G12D-p53Fx/Fx due to the 
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Figure 4.4. Endogenous p53 mutant and null lung tumours display 
comparable tumour burden and proliferation. 
 
A. Representative H&E images of the lung for p53 null, R172H and R270H 
tumour-bearing mice. B. Assessment of lung tumour burden in Null, R172H 
and R270H tumour-bearing animals. Left, The percentage tumour coverage of 
the lung shown as an average percentage coverage/genotype SEM. Right, 
average number of lung tumours/animal. Symbols represent independent 
animals. A minimum of 5 animals/genotype was analysed. C. Quantification of 
% Ki67-positive cells/tumour. The average percentage/genotype is shown with 
symbols representing individual tumours. A minimum of 4 animals and 25 
tumours were analysed/genotype, B,C. ns: non-significant, P>0.05, One-way 
ANOVA.  
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development of sinonasal adenocarcinomas, a difference in mortality that we do not 
observe. This is likely explained by the lower AdenoCre titre used in the other study 
(5x105 plaque-forming units; PFU). Our mice, which receive a higher titre (5x106 
PFU), are culled due to primary lung tumour burden across all genotypes and likely 
before other respiratory-tract tumours present.  
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5. Distinct transcriptional and metabolic profiles in 
p53 R172H and p53 R270H mutant lung tumour cells 
 
5.1. Introduction 
 
There are many different p53 mutations found in lung adenocarcinoma cases 
(Cancer Genome Atlas Research, 2014). As described in detail in Chapter 1.2.1, p53 
mutations fall into two classes, conformational (R172H) and contact (R270H), based 
on the residues they affect. It is feasible that, because of the different effects they 
have on the structure of the protein, the p53 mutants may exert distinct functions 
within the cancer cells. However, the distinct of effects of different p53 mutations in 
tumorigenesis have not been well-characterised. 
 
Surprisingly, the number of genes differentially expressed between p53 R172H and 
R270H lung tumour cells was considerably larger than the number whose expression 
was differentially altered between p53 null and mutant (R172H and R270H) cells 
(Figure 3.5B). Therefore, my initial analysis of the transcriptome data indicated that 
the different p53 mutations may indeed function distinctly in lung tumour cells. 
Despite these differences, comparison of KrasG12D-driven lung tumours, and 
corresponding cell lines, by myself and others (Jackson et al., 2005), has 
demonstrated that there is no difference in the aggressiveness of the p53 R172H and 
R270H mutant lung tumours, at least from a gain-of-function (GOF) perspective.  
However, I hypothesise that p53 null, R172H and R270H tumours may be dependent 
on different cellular pathways in tumorigenesis to reach a comparable, aggressive 
end-point. Delineation of these pathways has the potential to highlight unique 
therapeutic vulnerabilities of p53 mutant lung tumours, as has been described in 
other cancer types (Freed-Pastor et al., 2012; Weissmueller et al., 2014) 
 
Consequently, the aim of this chapter is to further explore the transcriptional 
differences between R172H and R270H lung tumour cultures and to establish 
whether p53 mutants of different classes can exhibit distinct phenotypes in the cells. 
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5.2. Results 
5.2.1. Mutant-type specific transcriptional and metabolic profiles 
 
R172H and R270H p53 mutant lung tumour cells displayed distinct transcriptional 
profiles, as reported in Chapter 3. In agreement, when the expression of all gene was 
analysed by principal component analysis, the cell lines separated based on the p53 
mutation present (Figure 5.1A). To explore these transcriptional differences further I 
performed pathway analysis (IPA). This analysis indicated that it was the cholesterol 
biosynthesis pathway and related pathways that were the most significantly altered in 
the R270H lung tumour cells compared to those that express the R172H mutation 
(Figure 5.1B, left). Furthermore, multiple areas of metabolism were significantly 
altered between the two types of p53 mutant lung tumour cells, notably lipid and 
vitamin and mineral metabolism, and protein synthesis when I performed molecular 
function analysis on IPA (Figure 5.1B, right). 
 
Next, I looked specifically at the expression of the genes involved in these three 
metabolic functions (Figure 5.2A). There was some overlap between genes involved 
in lipid metabolism and vitamin and mineral metabolism and these included many 
genes involved in cholesterol biosynthesis. For the genes involved in these two 
metabolic areas there were GOFs that were specific to R172H, that is where the 
R172H cells were different from the null and R270H cells, and some that appeared to 
be R270H-specific GOFs. In both cases these were true GOF effects of the specific 
p53 mutant as expression in the mutant cells was altered compared to both p53 null 
and p53 ‘wild-type’ cells (null cells with wild-type p53 restored; with 8 hrs 4OHT). On 
the other hand, the genes involved in protein synthesis that were differently 
expressed in lung tumour cells expressing distinct mutations, were predominantly 
R172H-specific GOF effects. Finally, using a compiled list of all known metabolic 
genes (compiled by Edoardo Gaude), IPA comparison analysis confirmed that the 
most significant difference in expression of metabolic genes existed between the 
cells expressing different p53 mutations (Figure 5.2B). As before areas of lipid and 
protein metabolism were significantly altered but also mitochondrial metabolism was 
highlighted as significantly different in the R172H cells.  
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Subsequently, to further investigate the metabolic differences between R172H and 
R270H mutant cells we performed metabolomic analysis on the independent lung 
tumour cell lines to confirm whether conformational and contact p53 mutations 
regulate metabolic pathways distinctly. Cellular metabolite levels were measured by 
mass spectrometry in collaboration with the Frezza lab. Principal component analysis 
on the metabolites measured for four independent cell lines of each genotype was 
performed with the help of Edoardo Gaude. The principal component analysis 
revealed that the R172H cells separated away from the R270H cells apart from one 
R172H cell line which was an outlier and displayed very different cellular metabolite 
levels to all other cell lines (Figure 5.3A). Nonetheless the metabolomics data 
supports the idea that lung tumour cells expressing distinct p53 mutations have 
different metabolic profiles with three independent R172H cell lines displaying altered 
levels of metabolites compared to four R270H cell lines. 
 
I further analysed the metabolites that were altered between the lung tumour cells 
expressing a R172H mutation or a R270H mutation. To do this I excluded the R172H 
outlier from the analysis and focussed on the metabolic differences between the 
remaining p53 mutant cell lines. Encouragingly, the metabolites that were different 
between the R172H and R270H cell lines were fatty acids, amino acids and TCA 
cycle intermediates (Figure 5.3B), which supports the conclusion from our 
transcriptome analysis that lipid metabolism, protein synthesis and mitochondrial 
metabolism were altered between the cells expressing the different p53 mutations. 
However, it is important to note that the metabolites involved in lipid metabolism that 
were identified for the mass spectrometry analysis were fatty acids and their 
derivatives. We were unable to detect any metabolites in the MVA pathway, likely 
due to the hydrophilic metabolite extraction used which prevents the detection of 
sterols.  
 
Both the transcriptome and metabolomics analysis indicated that R172H and R270H 
cells may have different levels of mitochondrial respiration; genes involved in 
mitochondrial dysfunction and the TCA cycle were highlighted by the transcriptome 
pathway analysis and TCA cycle intermediates were present at different levels in the 
metabolomics analysis. Therefore, I performed mitochondrial stress test extracellular 
flux assays to assess whether there were any differences in the levels of 
mitochondrial respiration in the R172H and R270H cells (Figure 5.4). 
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Figure 5.1. Metabolic genes are differentially expressed in p53 R172H and 
R270H cells.  
 
A. Principal component analysis on total gene expression data separated p53 
R172H and R270H mutant cells. 61.1% of the total variance is covered. Each 
symbol represents an individual cell line. B. Pathway analysis was performed on 
genes that were differentially regulated (>1.4FC and <0.5 SD cut-off between 
samples in each group) between the R172H mutant and R270H mutant lung tumour 
cell lines. Left, top canonical pathways significantly altered in R270H cells 
compared to R172H cells. Right, metabolic functions that are significantly altered in 
cells expressing distinct p53 mutations. Statistical significance was determined by 
Fisher’s exact test. 
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Figure 5.2. Altered expression of genes involved in lipid, protein and 
mitochondrial respiration in p53 R172H and R270H cells. 
 
A. Expression of the genes involved in the most significantly altered metabolic 
functions between R172H and R270H cells are shown in heatmaps. Expression 
values were normalised/row and the scale bar shows the minimum and 
maximum values. Each individual square in each row represents an 
independent cell line of the indicated genotype. Expression in the p53 R172H 
and R270H cells is compared to p53 null and p53 WT (p53 null with p53 On 
(+4OHT)) cells. B. Ingenuity comparison analysis of a list of total metabolic 
genes highlighted the extent of the differences in metabolic gene expression 
between p53 null, R172H and R270H cells. Top significantly altered functions 
(left) and canonical pathways (right) are shown. The likelihood of the overlap 
between a set of differentially expressed genes and a canonical pathway being 
significant was determined by Fisher’s exact test with Benjamini-Hochberg 
multiple testing correction within the IPA software, P<0.05 was considered 
significant. 
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Figure 5.3. p53 R172H and R270H cells display altered metabolic profiles. 
 
Metabolite levels in p53 null, R172H and R270H were measured by mass 
spectrometry analysis for four independent cell lines/genotype (ER model). A. 
Principal component analysis was performed in collaboration with the Frezza 
group using the R. A total of 47.5% of the variance is covered by the analysis. 
Symbols show triplicates values for each cell line for the four cell 
lines/genotype. B. Heatmap displaying cellular metabolite levels in R172H and 
R270H lung tumour cell lines. Each square represents a triplicate average for 
an independent cell line (n=3 R172H cell lines, n=4 R270H cell lines). Heatmap 
was generated by MeV in which metabolite values were normalised/row. The 
scale bar limits depict the colour corresponding to the minimum and maximum 
normalised values.  Metabolites shown have a greater than 1.3 average fold 
change between the two genotypes.  
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Using a Seahorse Extracellular Flux analyser, I measured the oxygen consumption 
rate (OCR) and the extracellular acidification rate (ECAR) of the media, which 
provide a read-out of mitochondrial respiration (OXPHOS) and glycolysis, 
respectively. Levels of OCR and ECAR were measured in basal conditions as well as 
upom administration of various mitochondrial stressors: oligomycin, which inhibits 
ATP synthase, was used to obtain levels of mitochondrial respiration associated with 
ATP production; CCCP, which is an electron transport chain (ETC) uncoupler and 
results in uninhibited electron flow through the ETC, was used to measure the 
maximal respiration levels; and Rotenone was used to inhibit all mitochondrial 
respiration. There was no difference in the basal levels of mitochondrial respiration 
between the R172H and R270H lung tumour cells but a trend was observed for a 
higher spare respiratory capacity (maximal respiration achieved after CCCP injection 
minus basal respiratory level) in the R270H cells compared to the R172H cells with 
three out of four R270H cell lines displaying higher levels (Figure 5.4B, left and 
centre) This suggests altered mitochondrial metabolism and ability to compensate 
under stress conditions in the R270H p53 mutant cells relative to R172H cells. In 
addition, higher levels of glycolysis were observed in the R270H cells compared to 
the R172H cells (Figure 5.4B, right).   
 
Genes involved in protein metabolism and amino acids were significantly altered 
between R172H and R270H mutant cells, as shown by our transcriptome and 
metabolomics analysis respectively. Therefore, next I sought to investigate the 
potential differences in protein metabolism between cells expressing the contact or 
conformational p53 mutant.  First, I measured protein levels in our p53 null, R172H 
and R270H cell lines to establish whether there were any differences in the overall 
protein levels. However, we observed no genotype-specific differences with only one 
R172H cell line displaying higher protein levels which could be explained by its larger 
cell size (Figure 5.5A). We also assessed ribosomal S6-kinase (S6K) 
phosphorylation which is downstream of the mTOR pathway and promotes protein 
synthesis. Once S6K is phosphorylated and activated it phosphorylates the ribosomal 
protein S6 which upregulates protein synthesis (Hay and Sonenberg, 2004). 
However, we observe no genotype-specific difference in P-S6K levels (Figure 5.5B). 
Finally, the different levels of amino acids we observed in R172H and R270H cells 
may be a result of altered levels of autophagy, the breakdown of macromolecules.  
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Figure 5.4. p53 R270H cells display higher levels of glycolysis and a trend 
for increased mitochondrial respiratory capacity.  
 
Mitochondrial stress test extracellular flux assays were performed on p53 null, 
R172H and R270H cell lines (ER model) by measuring OCR and ECAR in 
response to mitochondrial inhibitors. A. Representative mitochondrial stress test 
profile showing two cell lines/genotype. Measurement over time (1-12) refers to 
the measurements the machine takes as the assay is running. B. Average basal 
respiration levels (OCR) for p53 mutant relative to p53 null cells (left). Average 
spare respiratory capacity (Maximal OCR-basal OCR) for p53 mutant relative to 
p53 null cells (middle). Average basal glycolysis levels (ECAR) p53 mutant 
relative to p53 null cells (right), n=4 cell lines assessed/genotype with symbols 
depicting average values for independent cell lines. The average level/genotype 
is shown SEM. *P<0.05, t-test. 
 
 
 81 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
2
4
9.8 9.3 9.3 9.9Diameter (μm) 12.2 9.5 9.5 8.6 8.9 9.4 8.4 9.4
Null R172H R270H
μ
g
 p
ro
te
in
/ 
1
0
5
 c
e
lls
A
B
Null R172H R270H
p-S6k
S6k
p-Ampk
LC3I
Vinculin
Actb
LC3II
Ampk
Figure 5.5. Analysis of protein levels and expression of metabolic 
regulators in p53 mutant and null cells. 
 
A. Cellular protein content was assessed by BCA protein quantification and 
normalised to cell number, with n=3 independent repeats performed/ cell line, 
n=4 independent cell lines analysed (ER). The average amount of 
protein/10,000 cells is shown for each cell line SD of the triplicates. Cell 
diameter was also measured using a Countess cell counter. B. Expression of p-
S6K and p-AMPK and their corresponding total proteins, as well as LC3 levels 
were analysed in lung tumour cell lines of indicated p53 genotypes (ER cells 
shown). -actin (Actb) and vinculin were used as loading controls. 
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However, after assessment of cleaved LC3 levels (LC3II) we again find no genotype-
specific difference in autophagy (Figure 5.5B). 
 
Finally, lipid metabolism was also highlighted as an area of metabolism differently 
regulated by R172H and R270H cells in our transcriptome (cholesterol biosynthesis) 
and metabolomics (fatty acids levels) analysis. AMP-activated protein kinase (AMPK) 
is one of the key metabolic sensors involved in the regulation of lipid metabolism, 
promoting fatty acid oxidation (the breakdown of lipids) in conditions of low energy, 
while opposing the synthesis of lipids (Long and Zierath, 2006).  Also, a previous 
metabolic GOF that has been attributed to mutant p53 is an inhibition of AMPK 
signalling (Zhou et al., 2014). Therefore, we assessed levels of AMPK activation 
measured by its phosphorylation and observed a trend for decreased activity in the 
p53 R270H mutant cells although one R172H cell line had lower AMPK activation too 
(Figure 5.5B). Next, I assessed lipid levels in the lung tumour cell lines by oil red o 
staining and although I observed a trend for higher lipid levels in the R270H cells 
compared to the R172H when I solubilised and quantified the stain, the difference 
was not significant (Figure 5.6A).  
 
A type of lipid that is predicted to be present at different levels between cells 
expressing the two types of p53 mutation based on our transcriptome analysis is 
cholesterol, a sterol and an essential component of cellular membranes. Therefore, I 
assessed both the localisation and total amount of intracellular cholesterol in the 
R172H and R270H lung tumour cell lines and found that cholesterol was present at 
significantly higher levels in the R270H cells compared to the cells expressing the 
R172H mutation (Figure 5.6B).  
 
Overall, we observed metabolic differences between the lung tumour cells 
expressing different classes of p53 mutation, particularly in levels of glycolysis and 
intracellular cholesterol as well as a considerable number of other metabolites. 
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Figure 5.6. R270H mutant cells display higher levels of intracellular cholesterol 
than R172H cells. 
 
A. Oil red O was used to stain lipids in the p53 null and mutant cells. Left, 
representative images of staining of lipid droplets in the lung tumour cells. Scale bar: 
20 m.  Right, quantification of the Oil red O stain was performed by measuring 
absorbance after the stain was resuspended and values were normalised to protein 
content. Representative data (from n=2 cell lines/genotype, ER model) is shown. 
Average values of staining/genotype are shown relative to p53 null average SEM. 
Each symbol represents an independent cell line (n=4 analysed/genotype, ER cells). 
B. Left, filipin (cholesterol) and cell mask orange (plasma, membrane, PM) staining 
were performed to assess cholesterol levels and localisation in p53 null, R172H and 
R270H cells. Scale bar: 60 m. Right, cellular cholesterol levels were quantified using 
a fluorescence-based Amplex red kit, and fluorescence values were normalised to 
total protein content and are shown relative to average null.  Representative data 
shows two cell lines/genotype with experimental repeats of n=4 cell lines tested (Fx 
and ER model). Symbols represent individual cell lines with the average/genotype 
shown SD. ns: non-significant, P>0.05, ***P<0.001, One-way ANOVA P>0.05, One-
way Anova. 
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5.2.2. Mevalonate pathway gene upregulation is a gain-of-
function specific to p53
R270H
 lung tumours 
 
After observing the difference in cholesterol levels between the R172H and R270H 
lung tumour cells I proceeded to analyse the cholesterol biosynthesis genes that 
were differentially expressed. 
 
The pathway responsible for the de novo synthesis of cholesterol is known as the 
mevalonate (MVA) pathway and it is a pathway which has been implicated in 
tumorigenesis by supporting cancer cell growth and invasion (Mullen et al 2016). We 
observed that upregulation of MVA pathway gene expression is a GOF of the p53 
R270H mutant in lung tumour cells as MVA pathway genes are upregulated 
compared to p53 null cells. In addition, it is a true GOF phenotype rather than a 
retention of wild-type p53 activity by the mutant protein as the genes are upregulated 
compared to p53WT cells (p53 null + 4OHT) as well. However, what is most 
interesting is MVA pathway gene upregulation appears to be a mutant-type specific 
GOF, as it is not observed in the R172H p53 mutant cells.  (Figure 5.7A,B).  I 
confirmed that these MVA pathway genes were upregulated in the R270H mutant 
cells by qRT-PCR (Figure 5.7C).  
 
To establish whether we observe this R270H mutant-specific function in vivo I 
assessed the expression of MVA pathway genes in lung tumours. To do this, I used 
tumours from animals from our Fx lung adenocarcinoma model. I collected 
independent late-stage lung tumours from multiple animals/genotype and snap-froze 
the tissue in liquid nitrogen immediately after isolation. I also collected normal lung 
from non-tumour animals as a control. I lysed the tissue and isolated the RNA for 
qRT-PCR analysis. Encouragingly, I observed higher expression of MVA pathway 
genes in R270H tumours compared to p53 null and R172H tumours and the normal 
lung (Figure 5.7D). 
 
The Srebf (also known as Srebp) family of transcription factors controls the 
expression of genes involved in lipid and cholesterol biosynthesis and Srebf2 in 
particular is the main regulator of the cholesterol biosynthesis genes (Pai et al. 1998;  
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Figure 5.7. Higher MVA pathway gene expression in p53 R270H cells and lung 
tumours. 
 
A. Expression of mevalonate (MVA) pathway genes in p53 null, R172H and R270H cells 
are displayed in the heatmap (based on microarray data). MeV was used to generate the 
heatmaps and the software normalised genes/row: Value=[(Value)-
Mean(Row)]/SD(Row). The minimum and maximum normalised expression values and 
their corresponding colours are shown in the scale bars. Null cells are shown in the 
presence (WT) and absence (Null) of WT p53 restoration (4OHT treatment; 8 hrs) to 
compare gene expression in mutant cells relative to p53 WT and null conditions. B. 
Schematic representation of the MVA pathway with genes significantly altered in R172H 
and R270H shown in red (t.test, P<0.05). C. Expression levels of indicated MVA pathway 
genes in the p53 null, R172H and R270H lung tumour cells grown in 3D cultures (qPCR). 
Expression values were normalised to Gapdh. Representative data (of n=3 cell lines/ 
genotype) show average expression of one cell line/genotype SD of triplicates. 
***P<0.001, One-way ANOVA. D. Expression of indicated MVA pathway genes (qPCR) 
in normal lung tissue and lung tumours of the indicated p53 genotypes (Fx model). 
Values were normalised to 18S expression. Average expression values for each group 
are shown relative to the average expression of p53 null lung tumours SEM/genotype 
(n=10 normal tissue, n=15 tumours/genotype; a minimum of 4 animals 
analysed/genotype). **P<0.01, * P<0.05, t. test. 
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Horton et al. 2003). Interestingly, the expression of Srebf2 is also upregulated in the 
R270H lung tumour cells compared to the cells of other p53 deficiencies (Figure 
5.7A-C). Therefore, I. hypothesised that Srebf2 was responsible for the upregulation 
of these genes in the R270H mutant lung tumour cells. 
 
To investigate this hypothesis, I compiled a list of genes considered to be 
transcriptional targets of Srebf2 based on IPA data of known Srebf2 targets and 
genes that Srebf2 had been shown to bind in ChIP-seq datasets (www.chip-
atlas.org). A number of these targets were significantly upregulated in R270H cells 
compared to R172H cells (Figure 5.8A, left), which includes many other genes in 
addition to the MVA genes that I identified earlier. Furthermore, based on the target 
genes of Srebf2, GSEA identifies Srebf2 function as enriched in the R270H cells 
compared to the R172H cells (Figure 5.8A, right). This strengthens the hypothesis 
that it is Srebf2 activity that is altered in the R270H cells, resulting in upregulation of 
its target genes which includes genes in the MVA pathway.   
 
To establish whether the increased MVA pathway gene expression in the R270H 
cells was Srebf2-mediated I used an inhibitor of Srebf activation, fatostatin (Kamisuki 
et al., 2009), on the p53 null, R172H and R270H 3D cultures and examined the effect 
on the expression of the MVA pathway genes. Fatostatin reduced the expression of 
the MVA pathway genes to similar levels across all cell lines demonstrating that 
Srebf transcription factors regulate the expression of these genes in the lung tumour 
cell lines (Figure 5.8B). To confirm it was the Srebf2 isoform, and not other Srebf 
proteins, that was regulating the expression of these genes, Srebf2 knockdown was 
independently performed (by Emma Kerr) in R270H tumour cell cultures. Knockdown 
of Srebf2 was confirmed by analysing expression of Srebf2 by qRT-PCR (Figure 5.8, 
upper left). Srebp2 protein levels following knockdown could not be assessed due to 
a lack of available Srebp2 antibody that reliably detects inactive and active forms.  
Srebf2 knockdown also resulted in a decrease of MVA pathway gene expression 
demonstrating that Srebf2 is largely responsible for regulating the expression of MVA 
pathway genes in R270h lung tumour cells (Figure 5.8C).  However, even though 
Srebf2 knockdown results in a decrease in target gene expression, the correlation 
between Srebf2 and target gene RNA levels is not always strong. This likely reflects 
the variability of the qRT-PCR analysis. Targets that are expressed at lower levels 
following knockdown of Srebf2 may be subject to more variability in the analysis. In 
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Figure 5.8. Srebf2 regulates MVA pathway gene expression in the lung tumour cells. 
 
A. Left, heatmap depicting Srebf2 targets which are differently expressed in the R172H and 
R270H lung tumour cultures (genes are significantly altered by SAM statistical package 
within MeV). Expression values were normalised/row and the scale bar shows the minimum 
and maximum values. Right, enrichment plot for Srebf2 target genes in R172H and R270H 
cultures (GSEA). B. Expression of indicated genes analysed by qRT-PCR in p53 null, 
R172H and R270H cultures in the presence or absence (Ctrl) of the Srebf inhibitor, 
fatostatin. Representative data of n=3 independent runs shows one cell line/genotype SD 
of triplicates. Two-way ANOVA, ns: non-significant, *** P<0.001. C. Expression of genes 
analysed by qRT-PCR in p53 null, R172H and R270H cultures with or without short-hairpin 
(sh) Srebf2 knockdown. Four constructs (1-4) and a pool of all constructs were analysed. 
Representative data of n=2 independent runs shows one cell line/genotype SD of 
triplicates, relative to non-targeting control (NTC). t-test, ns: non-significant, * P<0.05, 
**P<0.01, *** P<0.001. 
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addition, levels of active Srebf2 protein remaining in the samples following 
knockdown may be subject to some deviation because of slight variations in the cell 
sorting of different shRNA cultures or the separate 3D cultures influencing the 
stability of the protein. On finding a suitable antibody, it will be important to analyse 
remaining active/nuclear Srebf2 protein levels following knockdown.   
 
Both p53 mutants were expressed at high levels compared to the p53ER (wild-type) 
protein, which is in keeping with the accumulation of mutant p53 that is frequently 
observed in cancer cells (Figure 3.3E) (Bartek et al., 1991). We observed a tendency 
for higher expression of the R270H mutant over the R172H mutant but this was not 
significant across all lung tumour cell lines. Moreover, the R172H mutant cells did not  
display an intermediate phenotype between the null and R270H cell lines for R270H-
specific GOFs, such as the higher MVA pathway expression. This indicates that 
these mutant-type specific GOFs are not due to a difference in the expression of the 
p53 mutants. In addition, previous data from our lab indicates that it is not a 
difference in localisation of the p53 mutant that explains the distinct mutant p53-
specific transcriptional profiles as both displayed a similar cytosolic and nuclear 
localisation. 
 
Instead, the mutant-specific functions are likely to involve differences in their ability to 
bind other proteins. In line this this, mutant p53 proteins have been shown to exert 
their GOFs via binding to other proteins, such as the transcription factors p63 and 
p73 (Adorno et al., 2009; Muller et al., 2009; Muller et al., 2013; Weissmueller et al., 
2014), in the cancer cells. Moreover, mutant p53 was previously shown to bind 
Srebf2 and the mutant p53 that the authors analysed in this study was the R273H 
contact mutant (Freed-Pastor et al., 2012). Therefore, I hypothesised that the 
difference in the Srebf2-mediated genes expression observed between R172H and 
R270H lung tumour cells may not only be due to higher Srebf2 expression in the 
R270H cells, and that there may also be differential binding of the distinct p53 
mutants to Srebf2, influencing its activity. However, despite trying different Srebf2 
antibodies, I could not find one that reliably detected the active form of Srebf2 to 
assess binding of the p53 mutants to Srebf2. 
 
Together, these data demonstrate that Srebf2-dependent MVA pathway gene 
upregulation is a GOF of mutant p53 that is relevant in lung tumours although 
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importantly it is specific to the p53 contact mutant, highlighting that distinct p53 
mutations have different functions and may exploit different pathways during 
tumorigenesis.  
 
5.3. Discussion 
 
Mutant p53 proteins have been shown to exert GOFs through manipulation of 
metabolic pathways, in addition to growth factor signalling pathways, as was 
discussed in detail in Chapter 1.3.4. Loss of wild-type p53 has been shown to alter 
metabolism due to the loss of the p53-mediated metabolic regulation. For instance, 
p53 null cells are more reliant on glycolysis than p53 wild-type cells (Ma et al., 2007; 
Sinthupibulyakit et al., 2010). However, the mutant p53 appears to alter metabolism 
further, as p53 mutant cells have been shown to be more glycolytic than p53 null, 
enhancing the glycolytic changes further to support tumorigenesis (Zhang et al, 
2013). In contrast, our data imply that metabolic differences between the cells 
expressing distinct p53 mutations are more pronounced than between p53 mutant 
cells as a single entity compared to p53 null cells. Therefore, it is important to assess 
the metabolic impact of different p53 mutations.  
 
Importantly, the upregulation of MVA pathway gene expression (via Srebf2) has been 
described as a function associated with mutant p53 in breast cancer. Interestingly, 
the authors analysed p53 R273H and R280K mutant breast cancer cell lines, two p53 
mutations that belong to the contact mutant subgroup (Freed-Pastor et al., 2012).  
Our data demonstrate that while it is a GOF of the contact R270H mutation relevant 
to lung cancer, it is not the case for all p53 mutations. Under physiological conditions, 
MVA pathway activity is inhibited by high intracellular sterol concentrations or when 
there is less demand for cholesterol such as when cell growth ceases. However, the 
MVA pathway is frequently deregulated in cancer cells to provide increased 
cholesterol synthesis and production of other MVA pathway intermediates to support 
tumorigenesis (Mullen et al., 2016). Therefore, we propose the higher cholesterol 
levels we observe in R270H mutant lung tumour cells are indicative of aberrant 
regulation of Srebf2 and a higher requirement for MVA pathway activity in these cells.   
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6. Characterisation of the dominant-negative effects 
of p53 mutants in lung tumour cells 
 
6.1 Introduction 
 
Mutations in the p53 gene are selected for in many human cancers, including lung 
adenocarcinoma (Cancer Genome Atlas Research, 2014) and are more common 
than p53 loss. Therefore, it is considered that the mutant p53 proteins exert effects in 
the tumour cells that are additional to just loss of wild-type p53 function. I have 
analysed and discussed the GOF effects of two p53 mutations in lung tumours, with 
the GOFs representing one potential reason for the selection for p53 mutations. This 
chapter will instead focus on the potential dominant negative (DN) effects of mutant 
p53.  
 
As discussed in detail in chapter 3, there is evidence for p53 mutations interfering 
with the activity of the wild-type p53 protein. However, the extent of this DN activity 
remains unclear with loss-of-heterozygosity (LOH) occurring in many cancers 
including lung cancer, suggesting that p53 mutants do not completely inhibit wild-type 
p53 (Baker et al., 1990; Brosh and Rotter, 2009; Liu et al., 2016; Mitsudomi et al., 
2000; Zienolddiny et al., 2001). It will be important to characterise the extent of the 
DN effects of the p53 mutants on WT p53 to establish whether p53-restoration 
therapy could have potential efficacy in p53 mutant lung tumours. Moreover, as I 
reported earlier, different p53 mutations are not functionally equivalent and therefore 
the extent of wild-type p53 inhibition may vary depending on the type of mutation 
present.   
 
In this chapter, I aim to identify and compare the DN activity of the R172H and 
R270H p53 mutations with the help of the p53ER model. 
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6.2 Results 
6.2.1 Transcriptional analysis of wild-type p53 activity in p53 
mutant lung tumour cells 
As reported in Chapter 3, a substantial subset of genes was similarly induced or 
repressed by wild-type p53 restoration (4OHT treatment) in p53 null, R172H and 
R270H lung tumour cultures. Many of these genes were typical p53 targets, identified 
based on evidence of a functional effect of wild-type p53 on target gene expression 
or on evidence of p53 binding the target gene from the literature (Figure 3.6; (Bieging 
et al., 2014; Fischer, 2017a; Lehar et al., 1996; Lo et al., 2001; Okamoto and Beach, 
1994; Quintens et al., 2015; Utrera et al., 1998); www.chip-atlas.org). In support of 
this, the most altered canonical pathway following wild-type p53 restoration was p53 
signalling (Figure 6.1A). The cellular functions that some of these identified p53 
target genes are involved in regulating was identified by performing further literature 
searches (Aksoy et al., 2012; Barak et al., 1993; Bersani et al., 2014; Bieging et al., 
2014; Collavin et al., 2000; Jerga et al., 2007; Kannan et al., 2000; Kawase et al., 
2009; Lehar et al., 1996; Lo et al., 2001; Nithipatikom et al., 2014; Okamoto and 
Beach, 1994; Tanikawa et al., 2017; Watanabe et al., 1995; Zhang et al., 2013b; 
Zhao et al., 2012; Zhou et al., 2002), http://chip-atlas.org).  Interestingly, this subset 
of commonly-regulated genes includes p53 targets involved in a range of different 
p53 functions (Figure 6.1B).  This suggests that various tumour suppressive 
responses may still be induced by wild-type p53, at least to some extent, in p53 
mutant cells.  
 
Next, I validated the expression of the well-established, ‘canonical’ p53 target genes 
Mdm2, p21 (Cdkn1a), Puma (Bbc3), Sesn2, Phlda3 and Bax in the lung tumour cell 
lines. Firstly, I analysed the expression of three of these genes in the basal setting 
and I observed no genotype-specific expression difference for these genes (Figure 
6.2A). To confirm that these genes were similarly regulated by wild-type p53 across 
all genotypes, I performed qRT-PCR on four cell lines/genotype following 2hrs and 8 
hrs 4OHT treatment (p53 On). All genes were induced by p53 restoration which 
supports our transcriptome data; no genotype-specific differences in the levels of  
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Figure 6.1. Wild-type p53 restoration altered the expression of 
genes involved in various tumour suppressive functions of p53. 
 
A. Ingenuity pathway analysis was performed on the genes similarly 
altered by p53 restoration across p53 mutant and null cells (8 hrs 
cohort).  The top six canonical pathways associated with these gene 
expression changes are displayed. Significance was determined by 
Fischer’s exact test. B. Diagram showing examples of p53 targets genes 
that are commonly regulated in all genotypes, grouped according to their 
cellular functions. Ccng1, cyclin G1; Ei24, autophagy associated 
transmembrane protein; Ddit4, DNA damage inducible transcript 4; 
Dgka, Diacylglycerol kinase alpha; Ephx1, Epoxide hydrolase 1; 
Slc19a2, solute carrier family 19 member 2; Trp53inp1, transformation 
related protein 53 inducible nuclear protein 1; Upp1, uridine 
phosphorylase 1. Other genes as described previously. 
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Figure 6.2. Typical p53 targets are similarly induced by wild-type p53 in p53 mutant 
and null cells. 
 
A,B. Expression of p53 indicated target genes was assessed by qPCR analysis in p53 
mutant and lung tumour cells (2D). A. Expression values shown were normalised to 18S 
expression and are relative to a randomly chosen p53 null cell line. Bars depict expression 
levels for independent cell lines as indicated SD of triplicates. B. Expression of p53 
indicated target genes was assessed following 2 hrs or 8 hrs WT p53 restoration (p53 
On). Expression values shown were normalised to 18S expression and are relative to Ctrl 
(p53 Off) values for a null cell line. Representative data of two independent runs is shown. 
Bars depict average fold-change in expression for an independent cell line SD of 
triplicates. 
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induction of these p53 target genes were observed in the lung tumour cells (Figure 
6.2B). The transcriptome and qRT-PCR data were intriguing as they indicated that 
wild-type p53 was able to induce expression of several of its canonical genes when a 
p53 mutantprotein was present and to levels similar to those achieved by p53 
restoration in p53 null cells.  
 
I also performed time-course experiments to assess the impact of wild-type p53 
restoration across a longer period of time and thus determine whether these 
expression changes were sustained in the cells. Encouragingly, the p53 targets were 
still upregulated 24-72 hrs after p53 restoration was initiated, although there was a 
trend observed for higher levels of induction in the p53 null cells at the 72 hrs time 
point (Figure 6.3).  
 
Together, these data argue towards limited or lack of DN effects of the p53 mutants 
on wild-type p53 function because multiple canonical p53 target genes are similarly 
induced or repressed in p53 mutant (both R172H and R270H) and p53 null cells. 
However, as reported in Chapter 3, we also observed genotype-specific 
transcriptional effects following wild-type p53 restoration (Figure 3.7). These 
transcriptional differences included genes that were altered in the p53 null cells but 
not in one or both of the p53 mutant cells (DN or ‘wild-type-like’ effects). Examples 
were also validated by qRT-PCR (Figure 6.4A). To identify which wild-type p53 
functions the DN effects may be impacting in the p53 mutant cells I investigated the 
pathways that these genes are involved in. The most significant molecular functions 
highlighted by the DN effects of both p53 mutants were proliferation and the cell 
cycle (Figure 6.4B). Therefore, we predicted that p53-mediated cell cycle arrest may 
be hindered in the p53 mutant cells. 
 
6.2.2. Effect of p53 mutant on wild-type p53 tumour-
suppressive functions 
 
Next we aimed to assess the functional impact of these wild-type p53-induced gene 
expression changes in the p53 mutant lung tumour cells. The investigation of these 
functional effects was a collaborative effort between myself and other members of 
the Martins’ group.  
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Figure 6.3. p53 target genes are upregulated at later time points in p53 null 
and mutant cells.  
 
Expression of the indicated target genes was assessed by qPCR analysis in p53 
mutant and null lung tumour cells (2D, 2 cell lines/genotype) following 24, 48 or 72 
hrs of wild-type p53 restoration (p53 On). Expression values shown were 
normalised to 18S expression and are shown relative to Ctrl (p53 Off) values. 
Representative data of two independent runs is shown. Bars depict average fold-
change in expression for each cell line SD of triplicates. 
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Figure 6.4. Validation of DN and wild-type-like transcriptional 
effects. 
 
A. Expression of the indicated p53 target genes was assessed by qPCR 
analysis in p53 mutant and null lung tumour cells (2D; 2 cell 
lines/genotype) following 8 hrs of wild-type p53 restoration (p53 On). 
Expression values shown were normalised to 18S expression and are 
relative to average Ctrl (p53 Off) values for null. Representative data of 
two independent runs is shown. Bars depict average fold-change in 
expression for an independent cell line SD of triplicates. B. Top two 
molecular functions following pathway analysis of the DN transcriptional 
effects of the R172H and R270H mutants. The significance was 
determined by Fischer’s exact test.  
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First, we measured the impact of p53 restoration on the live cell number in p53 null, 
R172H and R270H cells. Cells were treated with vehicle or 4OHT and viability was 
determined by trypan blue exclusion at specific time points post-restoration. 
Importantly, we observed no significant difference in the response to p53 restoration 
across the p53 genotypes, demonstrating that wild-type p53 results in a similar 
reduction in viable cells in p53 mutant and null cultures (Figure 6.5A,B). We also 
assessed the effect of 4OHT treatment on the number of live cells in p53-/- cells (Fx 
model) of found no effect of 4OHT on cell viabiity. Thus, we were able to confirm that 
the impact of 4OHT treatment on the p53 null and mutant cells (ER model) was due 
to wild-type p53 restoration and not another effect of the 4OHT treatment (Figure 
6.5C). 
 
To determine what was responsible for this reduction in live cell number following 
wild-type p53 restoration in these cells we performed BrdU and PI staining and 
subsequent FACS analysis, to assess whether wild-type p53 induced cell cycle 
arrest. We observed a similar induction of cell-cycle arrest (lower percentage of cells 
in S-phase) following wild-type p53 restoration in p53 mutant and null cells (Figure 
6.5D). Importantly, this result was recapitulated in 3D cultures which were the model 
used for transcriptome analysis (Figure 6.5E).  
 
Wild-type p53 can also induce apoptosis and senescence (Bieging et al., 2014), 
which may also be partly responsible for the p53-mediated reduction in live cell 
number observed in the lung tumour cells. We observed a small induction of 
apoptosis following p53 restoration in the p53 mutant and null 3D cultures (Figure 
6.6A,B) but interestingly not in 2D cultures (data not shown). In addition, we 
observed no induction of senescence in the p53 null and mutant lung tumour cells 
(Figure 6.6C).  
 
To summarise, despite some evidence of transcriptional DN effects of the p53 
mutants on WT p53 function, the tumour suppressive activity of the wild-type protein 
(cell cycle arrest and apoptosis) prevailed over mutant p53, and independently of the 
type of p53 mutation present. Therefore, the DN effects of the p53 mutants in these 
lung tumour cells are limited and the subset of similarly-regulated p53 target genes 
are sufficient to induce significant and long-lasting tumour-suppressive responses in 
p53 mutant cells.  
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Figure 6.5. Similar reduction in proliferation observed in p53 null and mutant cell 
lines after wild-type p53 restoration. 
 
A. Growth of p53 null and mutant cell lines (1 cell line/genotype shown of 4 analysed) 
following wild-type p53 restoration (p53 On) or vehicle treatment (p53 Off). The number 
of viable cells, measured by trypan blue exclusion, at indicated time points is shown. 
Symbols show triplicate average SD  B. Percentage viability of p53 null and mutant 
cell lines after 72 hrs of wild-type p53 restoration (4OHT treatment), measured by 
trypan blue exclusion. Four independent cell lines/genotype are shown SEM. C. 
Number of live cells following 72 hrs of Ctrl or 4OHT treatment in a p53Fx/Fx cell line. 
Triplicate mean is shown SD. Representative data of n=3 cell lines analysed. D. 
Representative images of FACS plots showing the change in the percentage S-phase 
cells (BrdU-positive) following p53 restoration (24 hrs, 2D). E. Percentage of BrdU-
positive cells in p53 null, R172H and R270H 3D cultures following 72 hrs p53 
restoration (4OHT treatment), relative to Ctrl analysed by FACS. Symbols represent 
independent cell lines and SEM of average percentage/genotype is shown. C,E, ns: 
non-significant P>0.05, One-way ANOVA. BrdU analysis was performed by Meiling 
Gao and myself.  
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Figure 6.6. p53 restoration induces apoptosis, but not senescence, in p53 mutant 
and null cell cultures. 
 
A. Percentage of dead cells 72 hrs after vehicle or p53 restoration (4OHT treatment). 
Representative data is shown, displaying one cell line/genotype of three cell lines 
analysed. The triplicate mean is shown SD. B. Representative immunofluorescence 
images of cleaved caspase 3 staining 72 hrs after p53 restoration in p53 null and mutant 
cell lines (3D cultures). Examples of positive staining are shown by arrows. Scale bar: 100 
m. C. Images show representative -galactosidase staining in p53 null, R172H and 
R270H lung tumour cells following 72 hrs p53 restoration (p53 On). One cell line/genotype 
is shown of two cell lines analysed. Palbociclib treatment of wild-type p53 human cancer 
cells was used as a positive control. Scale bar: 40 m. Cell death analysis was performed 
by Emma Kerr and the senescence assay was performed by Hannah Thorpe. The image 
analysis of the senescence assay was performed by myself.  
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6.3 Discussion 
 
 
Our data argue against there being significant DN effects of the p53 mutations which 
can impact on the well-established tumour-suppressive functions of p53 (cell cycle 
arrest and apoptosis). This is despite previous evidence for DN effects of mutant p53 
(including R175H and R273H) on wild-type p53 (Aurelio et al., 2000; Dong et al., 
2007; Wang et al., 2011; Willis et al., 2004). Instead our data may explain the LOH 
phenotype observed in many tumours (Baker et al; Brosh and Rotter et al 2009, 
Mitsudomi et al. 2000; Zienolddiny et al. 2001; Liu et al. 2016). In other words, even if 
the p53 mutation occurs first tumour cells still profit significantly from counter-
selection of the wild-type p53.  
 
The functional impact of the DN transcriptional effects observed for the p53 mutants 
is unclear. It may be that these DN effects manifest at other levels not covered by our 
analysis. Moreover, although we did not observe any difference in the DN effects of 
R172H and R270H mutants in vitro, it has been demonstrated that these different 
mutants can affect wild-type p53 distinctly in vivo (Jackson et al., 2005; Olive et al., 
2004, Wang et al., 2011). Next, it will be important to assess the impact of p53 
restoration in the lung tumours to establish whether the presence of R172H and 
R270H mutants can affect the p53-mediated tumour suppressive responses in vivo.  
 
The wild-type-like transcriptional effects of the two mutants that we observed are also 
intriguing, as they suggest that p53 mutants can retain at least some wild-type 
functions. According to published ChIP datasets (www.chip-atlas.org;(Fischer, 
2017a)), there is direct-binding evidence for p53 binding to promoter regions of the 
majority (~70%) of these ‘wild-type-like’ genes. These data indicate that p53 mutants 
retain some transcriptional functions of wild-type p53, contrary to the view that these 
p53 mutations lose all wild-type DNA-binding ability (Joerger and Fersht, 2007). It will 
be important to investigate further these ‘wild-type-like’ transcriptional effects will be 
important to investigate further as it is possible that the mutants may retain parts of 
wild-type p53 activity that they can exploit in tumorigenesis.   
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7. Targeting p53 mutant lung tumours 
 
7.1. Introduction 
 
Lung tumours with p53 mutations are associated with poor overall survival and 
comprise almost half of lung adenocarcinoma cases, as described in chapter 3 
(Cancer Genome Atlas Research, 2014). Importantly, there is currently a lack of 
targeted therapies against mutant p53 and so novel therapies which target p53 
mutant lung tumours are urgently needed.  
 
The overall aim of this chapter is to investigate whether we can uncover any 
therapeutic susceptibility of p53 mutant tumours based on our transcriptional and 
functional profiling of p53 null, R172H and R270H lung tumour cells. I will establish 
whether wild-type p53 restoration can be beneficial in p53 mutant lung tumours.  This 
will allow us to determine the potential impact of p53-targeted therapies (i.e. restoring 
wild-type function) in p53 mutant lung tumours. I will also determine whether R270H 
p53 mutant tumours are dependent on the MVA pathway and whether by inhibiting 
this pathway downstream of the R270H mutant we can uncover a way of targeting 
these R270H mutant lung tumours.   
 
7.2. Results 
 
7.2.1. Similar tumour-suppressive responses are induced by 
wild-type p53 restoration in p53 mutant and null tumours 
 
Previously, it was shown that wild-type p53 restoration successfully targeted p53 null 
lung tumours (Feldser et al., 2010; Junttila et al., 2010), and we aimed to determine 
to what extent wild-type p53-mediated tumour-suppressive could be effective in p53 
mutant lung tumours. To address this, we restored wild-type p53 in advanced p53 
mutant and null lung tumours and assessed the resulting levels of proliferation and 
apoptosis in these tumours. To restore wild-type p53, tamoxifen (which is 
metabolised into 4OHT in the liver (Crewe et al., 1997)) was administered daily to the 
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animals. The in vivo work involving p53 restoration was initiated by Meiling Gao and 
completed by myself and Emma Kerr.  
 
After 6 days of wild-type p53 restoration or control treatment we harvested the lungs 
and stained the sections with Ki67, a proliferation marker. Importantly, we observed a 
statistically significant and comparable decrease in proliferation in p53 null and p53 
mutant lung tumours (Figure 7.1A). To confirm that this anti-proliferative effect was 
specific to wild-type p53, and not another effect of the 4OHT treatment, I treated 
KrasG12Dp53Fx/Fx animals with 4OHT. As was the case in vitro, no cytostatic response 
was observed in this model, demonstrating that the effect was specific to the p53ER 
model and thus, to p53 restoration (Figure 7.1B).  
 
A different cohort of ER mice was treated with tamoxifen or vehicle for 24 hours to 
identify immediate effects of p53 restoration. We observed an induction of apoptosis 
in p53 null, R172H and R270H tumours, following wild-type p53 restoration, which we 
measured by TUNEL staining (Figure 7.2A). Quantification of the staining revealed 
that apoptosis was significantly induced across all genotypes (Figure 7.2B). In 
addition, as with the cytostatic response, the 4OHT-induced cytotoxic response was 
not observed in KrasG12Dp53Fx/Fx animals and so was again due to p53 restoration 
(Figure 7.2C). 
 
Taken together these results demonstrate that wild-type p53 tumour suppressive 
functions prevail even in the presence of the mutant p53 protein. Thus, any DN 
effects of the mutant p53 are limited in vivo, as responses to wild-type p53 
restoration are comparable in p53 mutant and null lung tumours. This highlights the 
potential of using p53-targeted therapies for the treatment of p53 mutant and null 
lung tumours. 
 
7.2.2 p53
R270H
 lung tumours display enhanced sensitivity to 
mevalonate pathway inhibition 
 
Next, I sought to determine whether we could use our knowledge of the 
transcriptional differences between p53 null, R172H and R270H lung tumour cells to 
identify genotype-specific susceptibilities. To achieve this, I explored the sensitivity of 
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Figure 7.1. Similar anti-proliferative effects in p53 null and mutant lung 
tumours following wild-type p53 restoration. 
 
A. Percentage Ki67-positive cells/tumour in p53 null, R172H or R270H 
animals treated with Ctrl (p53 Off) or Tamoxifen (p53 On) for 6 days. A 
minimum of 3 animals were analysed/cohort and the number of tumours 
analysed is indicated. Average positivity/cohort SEM is shown. Treatment 
of this cohort of mice and subsequent analysis was a collaborative effort 
between Emma Kerr, Meiling Gao and myself. B. Percentage Ki67-positive 
cells/tumour in p53Fx/Fx animals treated with Ctrl or Tamoxifen (Tam) for 6 
days. A minimum of 3 animals were analysed/cohort and the number of 
tumours analysed is indicated. Average positivity/cohort SEM is shown. 
ns: non-significant, P>0.05 ** P<0.01 ***P<0.001, t.test.  
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Figure 7.2. Wild-type p53 restoration induces similar apoptotic responses 
in p53 null and mutant lung tumours 
 
A. Representative images of TUNEL staining (arrows) in p53 null, R172H and 
R270H tumours. Scale bar: 60 m. B. Percentage TUNEL cells/tumour in p53 
null, R172H and R270H animals following p53 restoration (p53 On, 24 hrs) or 
vehicle treatment (p53 Off). Average positivity/cohort is shown SEM. A 
minimum of 3 animals were used/cohort with the number of tumours analysed 
indicated. A,B. Treatment of this cohort of mice and subsequent analysis was a 
collaborative effort between Emma Kerr, Meiling Gao and myself. C. 
Percentage TUNEL-positive cells/tumour in p53Fx/Fx animals treated with vehicle 
or Tamoxifen (Tam) for 6 days. A minimum of 3 animals were analysed/cohort 
and the number of tumours analysed is indicated. Average positivity/cohort 
SEM is shown. ns: non-significant, P>0.05, **P<0.01, t.test. 
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each genotype to MVA pathway inhibition. Inhibition of the MVA pathway can be 
achieved via statins which inhibit Hmgcr, an enzyme that catalyses an early step in 
the MVA pathway cascade (Figure 7.3A; (Istvan and Deisenhofer, 2001)). Therefore, 
I treated p53 null, R172H and R270H 3D cultures (using both Fx and ER models) 
with simvastatin for 72 hours to assess whether statins impacted colony growth of 
cells expressing a particular subclass of p53 mutation. I observed an inhibition of 
colony growth after statin treatment in all cell lines but importantly, R270H lung 
tumour cells displayed higher sensitivity to the treatment (Figure 7.3B). Importantly, 
this statin-induced inhibition of cell growth was rescued by addition of mevalonate 
(MVA), the metabolite downstream of Hmgcr, demonstrating the growth inhibitory 
effect of statins is due to inhibition of MVA pathway activity (Figure 7.3C). 
 
Subsequently, I aimed to investigate the mechanism for the increased sensitivity to 
statin treatment that we observed in the R270H contact mutant cell lines. It was 
reported that statins could induce a reduction in mutant p53 stability, which rendered 
the cells sensitive to statin treatment (Parrales et al., 2016). Therefore, I investigated 
the impact of statin treatment on mutant p53 expression in our p53 R172H 
conformational mutant and R270H contact mutant lung tumour cultures. I observed 
statin-induced mutant p53 degradation in our lung tumour cells that ranges from a 10 
to 55% reduction in mutant p53 levels but this reduction does not correlate with 
sensitivity to statin treatment (Figure 7.4A) 
 
Furthermore, we previously concluded that MVA pathway gene expression was 
regulated by the transcription factor Srebf2. Therefore, to confirm that R270H lung 
tumour cells were dependent on the upregulation of the genes in this pathway, we 
assessed the impact of the Srebf inhibitor (Fatostatin) on 3D cultures. While 
fatostatin treatment reduced the expression of the MVA genes to similar levels 
across all genotypes (Figure 5.8), R270H cells were more sensitive to this inhibitor. 
(Figure 7.4B). We also confirmed that this growth-inhibitory phenotype was specific 
to Srebf2 inhibition by assessing the impact on 3D growth after Srebf2 knockdown 
(Figure 7.4C), knock-down performed by Emma Kerr). These findings demonstrated 
that R270H mutant cells are more dependent on MVA pathway gene expression, as 
well as pathway activity shown by their sensitivity to statin treatment Figure 7.3B).  
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Figure 7.3. p53 R270H cells display increased sensitivity to treatment with 
simvastatin compared to p53 null and R172H cells. 
 
A. Schematic representation of the MVA pathway shows the step at which 
statins inhibit the pathway. B. Percentage live cells relative to vehicle after 72 hrs 
of simvastatin (Stn) treatment (ER and Fx cells, 3D culture). Average percentage 
live cells/genotype is shown SEM, with symbols representing independent cell 
lines. Data is representative of n=2 independent repeats. * P<0.05, One-way 
ANOVA. C. Mevalonate (MVA) addition to Stn-treated 3D cultures on live cell 
number for three cell lines/genotype performed at independent times (Fx model, 
one cell line/genotype shown in each graph). Bars shown triplicate average for a 
cell line SD. ns, * P<0.05, t.test.  
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Following this, I sought to investigate why the R270H cells were dependent on this 
higher MVA pathway gene expression. The MVA supports multiple cellular functions. 
On one hand, it provides cholesterol to the cell, which supports the synthesis of new 
membranes and therefore cell proliferation. In addition, the MVA pathway produces 
many intermediates that are important for the modification and activity of the Ras-
superfamily of GTPases. These GTPases require prenylation in the form of 
farnesylation or geranylgeranylation for their localisation to the plasma membrane 
and subsequent activation (Mullen et al., 2016) 
 
Therefore, I assessed the impact of the addition of downstream intermediates to 
establish which branch of the pathway the R270H cells depended on. Addition of the 
intermediate GGPP to the statin-treated cells partially rescued the growth inhibitory 
effect of the statins in the R270H tumour cells (Figure 7.4, left). These data suggest 
that the R270H cells may rely more on the activity of a Rho-family GTPase member 
which requires geranylgeranylation and that its activity is supported through 
increased MVA pathway expression. However, addition of exogenous cholesterol 
also partially rescued the growth inhibitory effect of statin treatment, implying that the 
cells are at least to some extent dependent on cholesterol generated by the MVA 
pathway (Figure 7.4, right). Thus, it appears that the R270H cells are not solely 
dependent on one branch of the MVA pathway. Further analysis of the effects of 
these downstream intermediated in p53 null and R172H cells will provide more 
information as to which branch of the pathway R270H cells are more reliant on, 
compared to the other genotypes. 
 
After demonstrating that p53 R270H mutant lung tumour cells displayed higher 
sensitivity to MVA pathway inhibition than p53 R172H or null cells, the main question 
we sought to ask next was whether we could use statins to target R270H p53 mutant 
lung tumours. For that purpose, I treated our endogenous KrasG12D/+;p53Fx/Fx, 
KrasG12D/+;p53R172H/Fx and KrasG12D/+;p53R270H/Fx (Fx model) advanced lung tumours 
for 6 days with simvastatin. We observed a significant decrease in the percentage of 
proliferating cells measured by Ki67-positivity in the R270H tumours treated with 
simvastatin but not the R172H or p53 null tumours (Figure 7.5A). In addition, the 
statin-treated R270H tumours displayed an induction of apoptosis as assessed by 
TUNEL staining (Figure 7.5B). Following statin treatment there was a significant 
increase in the percentage TUNEL-positive cells/tumour but no induction of apoptosis 
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Figure 7.4. Determining why p53 R270H cells are more sensitive to simvastatin. 
 
A. Left, expression levels of mutant p53 and Actb (loading control), assessed by 
immunoblotting, in p53 null, R172H and R270H lung tumour cell lines (Fx model, 3D) 
24 hrs after simvastatin (Stn) treatment. Right, correlation between % mutant p53 
protein levels following Stn treatment (relative to Ctrl), measured by band densitometry 
plotted against the % live cells after Stn treatment (relative to Ctrl). B. Live cell number 
following 72 hrs fatostatin (Srebf inhibitor) or Ctrl treatment of 3D cultures of p53 null, 
R172H and R270H cells. Representative data of n=3 independent runs shows one cell 
line/genotype SD of triplicates. Two-way ANOVA, ns: non-significant, ** P<0.01. C. 
Average colony size of R270H cells grown in 3D cultures with and without shSrebf2 
knockdown. Four constructs and a pool of the constructs were analysed. 
Representative data of n=2 independent runs shows one cell line/genotype SD of 
triplicates, relative to non-targeting control (NTC). t-test, ns: non-significant, *** 
P<0.001. D. Percentage live cells relative to Ctrl shown for indicated treatments (72 
hrs). Representative data showing one cell line of two analysed (Fx model).  Triplicate 
mean is shown SD. 
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in p53 null or R172H tumours (Figure 7.5C). Therefore, our data demonstrate that 
simvastatin treatment can selectively target p53 R270H mutant, but not p53 R172H 
or null, lung tumours. 
 
To better examine the impact of simvastatin treatment on tumour growth over time, I 
used an orthotopic model of p53 R270H mutant lung cancer by transplanting 
luciferase-expressing R270H cells into recipient mice. I imaged the animals weekly to 
assess tumour burden and found that after 2 weeks of daily statin treatment the 
tumour burden, measured by luciferase activity, was significantly reduced compared 
to the control-treated animals (Figure 7.6A). Furthermore, simvastatin treatment 
resulted in improved host survival but these results were not significantly significant 
(Figure 7.6B). 
 
Finally, I asked the relevance of these findings to human cancer. To assess this 
question I utilised publically available data for human lung adenocarcinoma cases  
(Cancer Genome Atlas Research, 2014). First, I classified p53 mutations into the two 
classes of p53 mutant, conformational and contact, based on evidence of the location 
of the mutations in the DNA-binding domain and overall impact on the structure of the 
protein (Table 6.1; (Cho et al., 1994; Joerger et al., 2006; Joerger and Fersht, 2007). 
Then I analysed the expression data for these tumours and excitingly I found a 
similar upregulation of MVA pathway genes in the R273 and other contact mutant 
tumours compared to the R175 and other conformational mutant tumours (Figure 
7.7). Hence, the transcriptional signatures that underlie the sensitivity to simvastatin 
were also observed in these human samples, suggesting that use of statins to treat 
these tumours may be clinically relevant. 
 
To summarise, I have shown that lung tumours expressing a R270H p53 mutation 
can be successfully targeted by treatment with statins and that the anti-proliferative 
and apoptotic effects of statin treatment are only observed in the R270H lung 
tumours and not in p53 null or R172H tumours. 
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Figure 7.5. Statin treatment induces a cytostatic and cytotoxic response in p53 
R270H lung tumours but not in R172H and null tumours. 
 
A. Percentage Ki67-positive cells/tumour in p53 null, R172H or R270H animals (Fx model) 
treated with Ctrl or simvastatin (Stn) for 6 days. A minimum of 47 tumours from 5 animals 
were analysed/cohort. Average positivity/cohort SEM is shown. B. Representative TUNEL 
staining (arrows) in p53 null, R172H and R270H (Fx model) lung tumour sections from Ctrl 
or statin (Stn)-treated mice (6 days). Scale bar: 50 m. C. Percentage TUNEL cells/tumour 
in p53 null, R172H or R270H animals (Fx model) treated with Ctrl or simvastatin (Stn) for 6 
days. Average positivity/cohort is shown SEM. A minimum of 93 tumours (n=5 mice) was 
analysed/cohort. A,C ***P<0.001, t-test. 
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A 
B 
Figure 7.6. Simvastatin treatment reduces lung tumour 
burden and may improve host survival in p53 R270H lung 
tumour model. 
 
A. Lung tumour burden (luciferase activity) in animals 
transplanted with luciferase-expressing R270H lung tumours 
cells (i.v.) following vehicle (ctrl) or simvastatin (Stn) treatment. 
The luciferase activity shown is relative to the start of treatment 
(week 0). Symbols represent animals (n≥5 mice/cohort) and the 
average relative luciferase activity is shown/cohort SEM 
***P<0.001, t-test. B. Survival of recipient mice transplanted 
with R270H lung tumor cells and treated with Ctrl or Stn. Log-
rank (Mantel-Cox) Test. A,B. Daily treatments were started 14 
days after transplantation (week 0). 
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7.3 Discussion  
 
We have explored two avenues of targeting p53 mutant lung tumours in this chapter. 
We have demonstrated that restoration of wild-type p53 induces similar tumour-
suppressive responses in p53 mutant (conformational and contact) and p53 null lung 
tumours. A number of therapies based on restoring wild-type p53 function in p53 null 
tumours have been investigated (Cheok et al., 2011; Frezza and Martins, 2012). 
Importantly, our findings imply that wild-type p53 restoration therapies may show 
efficacy in the clinic in p53 mutant as well as p53 null tumours. Our data also confirm 
a lack of DN function of the p53 mutants in vivo, at least when considering the 
cytostatic and cytotoxic functions of p53, similar to what we observed previously in 
vitro. As discussion in Chapter 6.3, these results may help explain the LOH of p53 
that is observed frequently in tumours (Baker et al., 1990; Jackson et al., 2005; Liu et 
al., 2016; Mitsudomi et al., 2000; Zienolddiny et al., 2001).  
 
Furthermore, in this chapter we showed that p53 R270H mutant lung tumours are 
sensitive to treatment with statins, a class of clinically available drugs. This finding 
importantly highlights that tumours expressing different p53 mutations can display 
distinct responses to therapy, a concept that has been under-explored previously, as 
p53 mutant tumours are generally considered as a single entity. In contrast to our 
findings, it was reported by one group that p53 conformational mutations were more 
sensitive to statin treatment (Parrales et al., 2016). Our findings are instead in line 
with what has been observed in breast cancer, where breast cancer cells expressing 
R273H and R280K p53 mutations were reported to be sensitive to simvastatin 
treatment (Freed-Pastor et al., 2012). Therefore, it may be that the effect of statin 
treatment is tissue-specific. The response to statin treatment may also differ 
depending on the in vitro system used: 2D (Parrales et al., 2016) or 3D (Freed-Pastor 
et al., 2012) cultures. Importantly, our in vitro data translates into comparable 
responses following simvastatin treatment in endogenous lung tumours. 
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Table 7.1. Classification of TP53 mutations in lung 
adenocarcinoma cases (TCGA, Nature 2014). 
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The anti-cancer impact of statins in the clinic has so far been somewhat controversial 
(Mullen et al., 2016), but the use of statins has been correlated with improved 
survival of lung cancer patients (Cardwell et al., 2015; Lin et al., 2016). Treating a 
subset of lung tumours that have specific molecular alterations (such as contact p53 
mutations that result in increased dependence on the MVA pathway may improve the 
efficacy of statin-based anti-cancer therapy in the clinic.  
 
 
 
-1.5         1.5        -2.0                  4.5 
Figure 7.7. Increased MVA gene expression occurs in human lung 
tumours that express a contact p53 mutation compared to a 
conformational p53 mutation. 
 
MVA pathway gene expression in lung adenocarcinoma patient 
samples (TCGA, Nature 2014) with a R175 or R273 mutation (left) or 
conformational or contact mutation (right) shown in heatmaps. 
Expression values were normalised/row and the scale bar shows the 
minimum and maximum values. Genes significantly upregulated in 
R273/contact groups following SAM (Significance Analysis for 
Microarrays) analysis are displayed. * denotes a sample with a R175H 
and a C277F (contact) mutation. 
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8. Discussion 
 
8.1. Summary 
 
In this dissertation I have provided the first comprehensive transcriptional analysis of 
the effect of two common p53 mutations (R172H and R270H) in lung tumour cells, 
both in the presence and absence of wild-type p53. The transcriptional and functional 
profiling of the lung tumour cells led us to identify a p53 genotype-independent 
response of Kras mutant lung tumours to wild-type p53 restoration but a p53 
mutation-type specific sensitivity of lung tumours to simvastatin treatment. 
Importantly, p53 mutant tumours can no longer be considered as a single entity as 
they do not always function similarly, particularly in their regulation of cellular 
metabolism, and can therefore display distinct responses to therapeutic agents.  
 
8.2. Impact of p53 mutations in lung cancer  
 
Although p53 mutations were established as an important oncogenic event around 
30 years ago (Weisz et al., 2007), the impact of p53 mutations in tumorigenesis has 
not been fully delineated. Mutations in p53 are considerably more common than p53 
loss in human lung adenocarcinoma cases, with p53 mutations occurring in almost 
50% of cases and only three cases of p53 loss reported in TCGA (Cancer Genome 
Atlas Research, 2014). The presence of a p53 mutation is associated with poor 
survival in human lung adenocarcinoma when compared to cases without a p53 
mutations, and the same is true in mice (Cancer Genome Atlas Research, 2014; 
Jackson et al., 2005; Jackson et al., 2001). 
 
Our analysis has defined the impact of R172H (conformational) and R270H (contact) 
p53 mutations in KrasG12D-driven lung tumours. When expressed throughout the 
mouse, p53 mutations cause a predisposition to a different spectrum of tumours, 
including more invasive carcinomas, compared to p53 null animals (Lang et al., 2004; 
Olive et al., 2004). However, as we observed no difference in aggressiveness 
between p53 null and p53 mutant (R172H and R270H) lung tumours, it is likely that 
mutant p53 has different effects in the lung tumours compared to other tissues.  
We have established how distinct p53 mutations differ from each other functionally, 
an area of investigation which has been so far largely overlooked. Mutant p53 has 
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previously been associated with enhanced glycolysis, lipid synthesis, and 
mevalonate (MVA) pathway upregulation as well as AMPK inhibition in cancer cells 
(Freed-Pastor et al., 2012; Zhang et al., 2013a; Zhou et al., 2014). Interestingly, in 
our lung tumour cells these metabolic gain-of-function phenotypes were associated 
with the R270H contact and not the R172H conformational mutant protein. These 
discrepancies are likely due to tissue-specific effects of the p53 mutants or the 
method used to investigate the impact of mutant p53: p53 knockdown or 
overexpression compared to our analysis which investigated mutant p53 in a 
physiologically relevant setting.  
 
However, the metabolic impact of the R172H mutant still remains to be elucidated. 
The majority of the R172H-specific metabolic effects centred around protein and 
amino acid metabolism. One possibility is that specific amino acid biosynthesis or 
degradation pathways are altered in the R172H cells. For instance, the serine 
biosynthesis pathway, a pathway emerging with important roles in tumorigenesis 
(Amelio et al., 2014), may be differently regulated in the R172H cells. Amino acid 
depletion experiments would help ascertain whether the R172H cells are more reliant 
on the exogenous supply of particular amino acids. 
 
The mutant-specific functions likely occur due to the p53 mutants binding different 
proteins. Mutant p53 has been reported to bind Srebf2 in R273H breast cancer cells 
(Freed-Pastor et al., 2012). It is possible that R172H and R270H differ in their ability 
to bind to Srebf2 or that both mutant proteins bind but only the Srebf2-R273H p53 
complex is recruited to the Srebf2-response elements. This can be addressed by 
performing ChIP-seq analysis of the R172H and R270H proteins, to identify if only 
the R270H mutant binds to Srebf2 target genes. Interestingly, a preliminary, 
unbiased investigation into the binding partners of the R172H and R270H mutants by 
mass spectrometry analysis indicated that these mutants bind different proteins in 
lung tumour cells. Of the binding partners identified 15% were common to both 
mutants, 32% were bound to the R172H mutant and 53% were bound by the R270H 
mutant protein (data not shown). Further analysis into the binding partners will be key 
to improving our understanding of the distinct functions of p53 mutant. 
 
We show that wild-type p53 function prevails over mutant p53 in lung tumours, 
providing an explanation for the frequent loss-of-heterozygosity (LOH) observed in 
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tumours, including lung tumours (Baker et al., 1990; Jackson et al., 2005; Liu et al., 
2016; Mitsudomi et al., 2000; Zienolddiny et al., 2001). Mutant p53 is more highly 
expressed in our lung tumour cells that the p53ER (wild-type) protein but quantification 
of the western blots indicates that the mutant is on average only 2.1 fold more highly 
expressed than the wild-type protein.  Interestingly, it has been shown that for p53 
mutants at least three mutant subunits are required to inhibit the activity of the 
tetramer (Chan et al. 2004). Therefore, it is likely that the mutants, which are 
expressed at endogenous levels, are not expressed at a sufficient level to form these 
predominately mutant tetramers. This provides a potential explanation for the 
discrepancy with previous studies, which demonstrate that the mutant p53 inhibits 
wild-type p53 function (Chan et al., 2004; Dong et al., 2007; Milner and Medcalf, 
1991; Willis et al., 2004; Xu et al., 2011). In vivo, the R172H mutation was previously 
shown to have DN effects on a hypomorphic wild-type p53. Importantly, the mutant 
could not fully inhibit the wild-type p53 when it was expressed at normal levels, again 
indicating that the mutant p53 needs to be present at much higher levels than the 
wild-type to exert an inhibitory effect on wild-type p53 function (Wang et al., 2011). 
 
It has previously been reported that lung tumours from KrasG12D;p53R270H/+ mice 
displayed a higher tumour grade than those from KrasG12D;p53R172H/+ and 
KrasG12D;p53-/+ mice. KrasG12D;p53R270H/+ mice also exhibited a higher tumour 
burden/animal (Jackson 2005). These differences were not due to GOF effects of the 
R270H mutant as KrasG12D;p53-/-, KrasG12D;p53R172H/- and KrasG12D;p53R270H/- lung 
tumours were similar. Importantly, LOH occurred at similar frequencies in 
KrasG12D;p53R270H/+ and KrasG12D;p53R172H/+ lung tumours demonstrating that wild-type 
p53 still retained some function in the presence of either mutant as its loss was still 
selected for in all cases (Jackson, 2005). Instead, these data suggest that the R270H 
mutant displayed DN functions but that this effect was partial. Of note, in our model 
wild-type p53 was only restored for a short duration in advanced tumours, potentially 
explaining the lack of an obvious DN phenotype and indicating that the DN effect of 
the R270H mutant observed previously occurred earlier in tumorigenesis (Jackson et 
al., 2005). Indeed, we did not observe any decrease in tumour burden after either 1 
or 6 days of p53 restoration in all cases (data not shown). Importantly, we utilised this 
duration of p53 restoration as we aimed to model the DN effects of the p53 mutants 
as well as the therapeutic impact of wild-type p53 restoration in these advanced p53 
mutant lung tumours, using a similar approach to what was used previously in p53 
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null lung tumours (Feldser et al., 2010; Junttila et al., 2010). These studies 
demonstrated that wild-type p53 only becomes activated in advanced p53 null lung 
tumours following p53 restoration when there are sufficient levels of oncogenic stress 
and activating signals (p19ARF) present. However, it could be that the presence of a 
p53 mutation provides activating signals earlier on in tumorigenesis to explain the DN 
effect of the R270H mutant when it is present from tumour initiation (Jackson et al. 
2005). Alternatively, it may be explained by transient activation of p53 earlier on in 
tumorigenesis or if p53 is functioning downstream of stress mediators other than 
oncogenic stress and p19ARF activation.  
 
It is important to note that we observed some DN effects of the R172H and R270H 
mutants on the transcriptional function of wild-type p53 that need to be considered. 
Interesting, the R172H mutant appeared to exert stronger, ‘complete-failure’ DN 
effects than the R270H mutant, even though it is the R270H mutant cells that appear 
more resistant to a p53-mediated proliferative arrest in vitro. We established that 
R172H and R270H potentially bind multiple different proteins. Therefore, it is feasible 
that the p53 mutants bind the promoters of genes distinctly due to the mutations 
causing different structural effects in the mutant proteins. It may be that the R172H 
forms tetramers with wild-type p53 that prevent the complex binding to some 
promoter regions whereas the R270H-wild-type complexes may retain transcriptional 
activity at these sites. On the other hand, it is interesting that it is also the R172H that 
retains more ‘wild-type-like’ transcriptional functions and it could alternatively be that 
the wild-type genes expressed in the R172H create redundancy for certain genes or 
negative-feedback regulation on wild-type p53 function, thus limiting the transcription 
of some p53 targets when wild-type p53 function is restored in these cells. It is 
important to note that the majority of these ‘wild-type-like’ genes were found in ChIP-
seq datasets (http://chip-atlas.org) and so they likely represent direct wild-type p53 
target genes. This finding indicates that the p53 mutants, and particularly the R172H 
mutant, retain some aspect of wild-type p53 transcriptional activity. 
 
The functional impact of these DN and ‘wild-type-like’ effects remains to be 
elucidated and they likely manifest at other levels not covered by our analysis. It will 
be important to investigate these further, particularly on whether they translate into 
any difference in phenotype in vivo. The ‘wild-type-like’ transcriptional effects are 
particularly intriguing. It may be that p53 mutants are able to utilise some activity of 
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wild-type p53 in tumorigenesis.  For instance, the regulation of metabolism by wild-
type p53 could potentially be exploited in tumour cells.  Tumours cells that reside in 
hypoxic or nutrient-deprived regions, or are metastasising to other sites may be more 
dependent on catabolic pathways (such as FAO and autophagy which can be 
promoted by wild-type p53) for cell survival in low-nutrient or matrix-detached 
conditions, respectively. Therefore, there may be some benefit in certain contexts for 
p53 mutant tumour cells retaining some aspects of wild-type p53 activity.  
 
As discussed it is likely that the distinct transcriptional effects observed by the R172H 
and R270H mutants are explained by the formation of heterotetramers with wild-type 
p53 that exhibit differential cooperativity and distinct promoter affinities (Schlereth et 
al., 2013). As well as providing insight into the mechanism underlying the GOF 
effects of the different p53 mutants, ChIP-seq analysis could increase our 
understanding of the DN effects of the mutants. Performing ChIP-seq experiments to 
analyse the DNA bound by p53 in p53Fx/ER (p53 off; control), p53Fx/ER (p53 On), 
p53R172H/ER (p53 On) and p53R270H/ER (p53 On) samples would provide information 
regarding which genes are bound by mutant p53-wild-type p53 complexes. 
 
8.3. Clinical Implications 
 
By exploiting the most altered pathway between the R172H and R270H mutant lung 
tumours, the MVA pathway, we were able to therapeutically target R270H mutant 
tumours but not R172H tumours using simvastatin. Therefore, we argue that in the 
future, when considering therapeutic strategies against these mutant tumours, the 
responses of tumours with of distinct p53 mutations are explored. Moreover, the 
expression signature that underlies this sensitivity to statins was also found in p53 
contact mutant human lung adenocarcinomas, suggesting this R270H-specific 
susceptibility is clinically relevant. Statin-use has been associated with improved 
survival of lung cancer patients (Cardwell et al., 2015; Lin et al., 2016). Identification 
of molecular subsets of lung tumours that display enhanced sensitivity to statin 
treatment, such as the p53R273H-positive subset proposed in this study, will likely 
improve the anti-tumorigenic impact of statins. 
 
The MVA pathway expression signature observed in humans suggests the statin-
sensitivity phenotype may be applicable to other contact mutant proteins. However, it 
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will be important to establish whether this is true for lungs tumours expressing other 
p53 contact mutants as it is important to determine the percentage of p53 mutant-
lung adenocarcinoma this susceptibility could be applicable to. Indeed, the most 
common p53 mutation is the R248 contact mutation (Soussi et al., 2006). However, it 
is not clear whether this p53 mutation would have the same functional effects as the 
R273H mutation. Even though both mutations affect a residue that directly contacts 
the DNA, these mutations still exert different effects on the structure of the DNA-
binding face and thus, its potential DNA-binding ability (Joerger and Fersht, 2007). 
Importantly, our study has highlighted numerous transcriptional differences unique to 
the R172H lung tumour cells.  Future identification of the pathways that the R172H 
mutant lung tumour cells depend on may uncover therapeutic susceptibilities unique 
to lung tumours of this p53 mutation type. 
 
Our data has also highlighted the effectiveness of using 3D cultures as an in vitro 
system for the investigation of therapeutic responses.  We found that the phenotypes 
we observed in 3D Matrigel culture translated better in vivo than 2D responses. 
Indeed, wild-type p53 induced apoptosis in 3D cultures and in tumours but not in 2D 
cultures and the MVA pathway phenotype (expression and sensitivity to statin) was 
more pronounced in 3D cultures than 2D cultures. The differences between 2D and 
3D cultures may also explain why we and others found contact p53 mutant tumour 
cells are sensitive to MVA pathway inhibition by statins (Freed-Pastor et al., 2012; 
Turrell et al., 2017) but others have not (Parrales et al., 2016).  A potential reason for 
the p53-mediated induction of an apoptotic response in 3D cultures but not in 2D 
cultures could be explained by differences in the stress signals in the cells cultured in 
these environments.  If the stress signals (p53-activating signals) are higher in cells 
in 3D cultures it could support the induction of cell death in a proportion of the cells 
following restoration of wild-type p53. In addition, it has been shown that 3D cultures 
represent an intermediate transcriptional and metabolic phenotype between that of 
2D cells and tumours (Smith et al., 2012). Metabolic phenotypes may differ between 
2D and 3D cultures because culturing cells in 3D results in oxygen and nutrient 
gradients, with the cells at the centre of the spheroid having a more limited nutrient or 
oxygen supply. Specifically, the MVA pathway phenotype may differ in 3D and 2D 
cultures because of these gradients but also potentially because the interactions to 
cells form between themselves (2D and 3D) and the matrix (3D) differ. The MVA 
pathway is important for cellular membrane integrity as it generates cholesterol but 
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also is important for the activity of GTPases of the Ras superfamily, such as Rho and 
Ras. Signalling downstream of these GTPases is directly regulated by integrin-matrix 
interactions and so the dependency on these pathways is likely altered in 3D cultures 
(Legate et al., 2009).  
 
Restoration of wild-type p53 function has previously been shown to therapeutically 
target mutant Kras, p53 null lung tumours (Feldser et al., 2010; Junttila et al., 2010). 
We have now demonstrated that wild-type p53 restoration similarly targets p53 
mutant lung tumours, a cohort much more relevant to human lung adenocarcinoma 
(Cancer Genome Atlas Research, 2014). However, the efficacy of p53 restoration is 
limited to advanced lung tumours, which display high levels of oncogenic stress and 
p19ARF, thereby providing the activating signals required for wild-type p53 function 
(Feldser et al., 2010; Junttila et al., 2010). We have also shown that this is the case 
for at least the p53-mediated proliferative arrest response in p53 mutant lung 
tumours (Turrell et al., 2017). However, as the majority of lung cancer patient 
typically present at late-stages (Scheff and Schneider, 2013), p53-targeted therapies 
may still be of benefit against a large proportion of human lung cancers.  
 
Future analysis of the different binding partners of the p53 mutants may uncover 
additional ways to target a group of lung tumours with a specific mutation. However, 
we have identified almost 500 genes that are similarly regulated by both p53 mutants 
but have distinct expression in both p53 null and wild-type cells. Therefore, it may be 
more useful from a therapeutic perspective to explore these differences further. Even 
though we did not identify a cancer-associated phenotype common to both mutants 
(enhanced proliferation or invasiveness), further analysis of these genes may 
uncover a pathway similarly exploited by both mutants in tumorigenesis and 
subsequently, common vulnerabilities. Ultimately, these insights may lead to the 
identification of other generic susceptibilities of p53 mutant lung tumours which, if 
clinically relevant in humans, would be applicable to a larger proportion of lung 
adenocarcinoma cases.  
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Appendix 2: Microarray data accession number 
 
Microarray data were deposited in Gene Expression Omnibus (accession number: 
GSE94758). 
 
 
Appendix 3: R scripts 
 
1.Microarray principal component analysis 
 
#load in data 
data <- read.delim("~/Desktop/FT data.txt", row.names=1, stringsAsFactors=FALSE) 
#extracting groups 
groups <- as.data.frame(data[1,]) 
#remove group names and transpose 
data.t <- as.matrix(t(data[-1,])) 
#perform PCA 
pc=prcomp(data.t, center = T, scale =T) 
#Variances 
summary(pc) 
 
#defining groups: group1 = RT172H (green), group2 = R270H (brown) 
groupColours_all <- as.factor(as.character(groups[1,])) 
levels(groupColours_all) <- c("forestgreen", "brown3") # These must be in the correct 
order 
cols <- groupColours_all 
 
#plotting graph 
install.packages("scatterplot3d") 
library(scatterplot3d) 
 
pdf("PCA.plot.pdf", width=6, height = 7) 
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scatterplot3d(pc$x[, 1], pc$x[, 2], pc$x[,3], main = "PCA", xlab = "PC1", ylab = "PC2", 
zlab = "PC3", color=cols, xlim = c(-100, 150), zlim = c(-150, 150), ylim = c(-150,150), 
scale.y=0.5, angle = 110, pch = 19, grid=F, box=T ) 
dev.off() 
 
 
2. Metabolomics data principal component analysis 
 
Principal component analysis was performed using the muma R package (Gaude et 
al, 2013).  
 
 
Appendix 4: Gating for Pdgfa FACS analysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Examples of gating performed for Pdgfra FACS analysis. 
 
Upper, gating performed on a sample that was a mix of the negative (epithelial cell line) and 
positive (mouse embryonic fibroblasts) controls for Pdgfra expression. The gate for Pdgfra 
positivity was set for this sample and applied to subsequent samples. Lower, gating 
performed on a lung tumour cell line to identify the % Pdgfra-positivity. See Figure 3.4. 
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Appendix 5: Gating for BrdU/PI FACS analysis 
 
Example of gating performed for BrdU/PI FACS analysis. 
 
Gating performed on a lung tumour cell line following vehicle treatment to assess 
percentage BrdU-positivity. See Figure 6.5. 
